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Abstract	  
 Cancer and infectious diseases are huge threats to human beings. With the rapid rise in 
drug resistance, there is a need for new drugs, and isoprenoid biosynthesis is an attractive target 
for drug discovery. In chapter 1, I briefly introduce the isoprenoid biosynthesis pathway and 
two important drug targets: a trans-prenyl transferase farnesyl diphosphate synthase (FPPS), 
and a cis-prenyl transferase undecaprenyl diphosphate synthase (UPPS). 
 In chapter 2, I report the discovery and x-ray crystallographic structures of 10 
structurally diverse compounds (benzoic/diketo/phosphonic acids, bisamidines and bisamines) 
that inhibit UPPS, an essential enzyme involved in cell wall biosynthesis. The inhibitors bind to 
one or more of the four inhibitor-binding sites with the most active leads binding to site-4, not 
the substrate-binding site. The most potent lead is active against Staphylococcus aureus and 
potently synergizes with methicillin. These results provide numerous new leads for anti-
bacterial development.  
 In chapter 3, I report the mechanisms of action and inhibition of antibacterial leads, keto 
and diketo acids, targeting dehydrosqualene synthase (CrtM) as well as UPPS. The X-ray 
structures of CrtM and UPPS with inhibitors bound are also reported. In all cases, the inhibitors 
bind to a farnesyl diphosphate substrate-binding site. Some of the compounds have potent 
activity against a variety of bacteria but very little activity against human cell lines.   
 In chapter 4, I report the additional targets of bisamidine inhibitors, in addition to UPPS. 
The enzyme inhibition results show that bisamidines also inhibit FPPS. In addition, the 
differential scanning calorimetry (DSC) results show that these compounds bind to DNA, 
shifting the melting temperature (Tm) by more than 10 degrees. And a crystallographic 
investigation reveals that the inhibitor binds to the central AATT site located in the minor 
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groove of the DNA dodecamer d(CGCGAATTCGCG)2 duplex. These results provide new leads 
for antibacterial development based on a poly-pharmaceutical approach targeting DNA and 
isoprenoid biosynthesis. 
 In chapter 5, I report the investigation of bisphosphonates as chemo-immunotherapeutic 
anti-malarials, acting by killing malaria parasites directly via FPPS/GGPPS enzyme inhibition, 
as well as indirectly via activation of human γδ T cells. 
 In chapter 6, I report the synthesis and characterization of novel Mo, W or V-containing 
polyoxometalate (POM) bisphosphonate complexes with metal nuclearities and their potent 
activities against human cell lines, opening up the possibility of the development of novel drug 
leads based on polyoxometalate-bisphosphonate clusters.   
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Chapter	  1	  	  
Introduction	  
	  
1.1	   Isoprenoid	  Biosynthesis	  
Isoprenoids are a large collection of natural products produced by living organisms. Their 
functions include structural constituents (e.g. cholesterol in cell membranes) and functional 
elements (e.g. carotenoids in photosynthesis, retinal in vision, quinones in electron transfer) [1]. 
Despite their structural diversity, all isoprenoid compounds originate from two C5 precursors: 
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), which can be made in 
two different pathways: the mevalonate pathway (MVA, also known as HMG-CoA reductase 
pathway) [2] in most eukaryotes and Achaea, and methylerythritol phosphate (MEP) pathway [3] 
in chloroplasts, green algae, cyanobacteria, eubacteria, etc.  
  The sequential condensation of IPP with different chain-length isoprenoid diphosphates 
are catalyze by enzymes known as prenyl transferases. They can be classified into two 
categories: cis-prenyl transferases that condense in a “head-to-tail” fashion and trans-prenyl 
transferases that condense in a “head-to-head” fashion [4]. The condensation starts with DMAPP 
and one or more IPP molecules to form GPP, FPP and GGPP, catalyzed by three trans-prenyl 
transferases: geranyl diphosphate synthase (GPPS), farnesyl diphosphate synthase (FPPS), and 
geranylgeranyl diphosphate synthase (GGPPS), respectively [5]. Starting from FPP and GGPP, a 
variety of products with different chain lengths are made.  
 Many prenyl transferases are of great pharmaceutical interest since they are important 
drug targets due to their roles in biosynthesis [6]. In this work, however, I will focus two 
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enzymes for the development of antibacterial, anti-infective or anti-cancer drug leads: a trans-
prenyl transferase farnesyl diphosphate synthase (FPPS), and a cis-prenyl transferase 
undecaprenyl diphosphate synthase (UPPS).  
	  
1.2	   Farnesyl	  Diphosphate	  Synthase	  (FPPS)	  
FPPS catalyzes the condensation of geranyl diphosphate (GPP) and isopentenyl diphosphate 
(IPP) to form farnesyl diphosphate (FPP) via a trans double-bond addition. FPP can be further 
condensed to form geranylgeranyl diphosphate (GGPP). FPP and GGPP can then condense to 
form a variety of isoprenoids such as squalene, phytoene (precursors of carotenoids), cholesterol, 
etc. FPP and GPP can also be used to post-translationally modify proteins such as Ras, Rho, Rac, 
and Rap, etc. in the processes known as prenylation and geranylgeranylation [7-9]. In these 
processes, the farnesyl or geranylgeranyl moieties are transferred to target proteins to facilitate 
attachment to cell membranes [10]. The structure of FPPS was solved long time ago [11] and it 
consists mostly α-helices that surround a large hydrophobic cavity where FPP synthesis occurs. 
Like other trans prenyl transferases, FPPS has two highly conserved “DDXXD” motifs (D, 
aspartic acid; X, any amino acid), which are used to chelate 3 Mg2+ that are involved in the 
catalysis [12, 13].  
  FPPS is an important drug target. Bisphosphonates, which are used to treat bone diseases 
such as Zoledronate, inhibit FPPS and block subsequent prenylation, resulting in tumor cell 
killing [12-14]. The inhibition of FPPS also results in the accumulation of IPP, which activate 
γδ T cells, enhancing tumor cell killing [15]. 
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1.3	   Undecaprenyl	  Diphosphate	  Synthase	  (UPPS)	  
UPPS catalyzes elongation of farnesyl diphosphate (FPP) with eight isopentenyl diphosphate 
(IPP) molecules via cis double-bond addition to generate a C55 product UPP [16, 17]. UPP is 
then hydrolyzed to the monophosphate, which is converted to Lipid I and Lipid II, leading to the 
production of cell wall peptidoglycan (Figure 1.1) [18]. Drugs such as penicillin, methicillin and 
vancomycin act in the latter stages of peptidoglycan formation. The homologue of bacterial 
UPPS in eukaryotes dehydrodolichyl diphosphate synthase (DHDDPPS) is responsible for 
making C55-100 dolichols for glycoprotein biosynthesis, a pathway similar to that of bacterial 
peptidoglycan synthesis [4]. In this work, I focus on the development of UPPS inhibitors since 
UPPS is an essential gene [19] not present in humans and UPPS inhibitors might synergize with 
the more conventional cell wall biosynthesis inhibitors, reducing e.g. the toxicity of drugs such 
as vancomycin (by decreasing dosage), or restoring sensitivity (e.g. with MRSA, methicillin 
resistant S. aureus). 
  UPPS contains an FPP substrate-binding site in which the FPP diphosphate (PPi) group 
binds via Mg2+ to a highly conserved Asp (D26), adjacent to an IPP site, Figure 1.2a, b. The UPP 
product (55 carbons) is much larger than the FPP/IPP substrate (20 carbons total) so there must 
be many other possibilities for ligand binding sites and indeed in previous work [20] we found 
that the bisphosphonate inhibitor BPH-629 could occupy up to 4 different binding sites (sites 1-
4), as illustrated in Figure 1.2c, d. Sites 1-3 occupy the top of a “funnel” region, Figure 1.2c, 
whereas the fourth site is located at the bottom of the funnel and it is clear that site 1 corresponds 
to the FPP (or FsPP, Figure 1.2a, c) substrate-binding site, as shown in the superposition of BPH-
629 (PDB ID code 2E98) and FPP/IPP/Mg2+ from several reported crystal structures (PDB ID 
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codes 1X06; 1X08; 1X09 in Figure 1.2e, f). However, 3 other inhibitor sites can also be seen in 
this superposition.  
  UPPS is essential for cell survival and there are no existing commercial drugs that inhibit 
it, so resistance will not be acquired due to gene transfer. The inhibition of UPPS will result in 
prevention of bacterial cell wall biosynthesis, a well-established antibacterial mechanism. In 
addition, the uppS gene is the most up-regulated isoprenoid biosynthesis gene in S. aureus on 
mevalonate pathway inhibition [21], and in E. coli on non-mevalonate pathway inhibition [22], 
indicating that UPPS is particularly important for cell survival. Overall, UPPS is an attractive 
drug target and a completely new drug lead that targeting UPPS will be exceptionally significant.  
	  
1.4	   Inhibitors	  of	  UPPS	  
Bisphosphonates. Bisphosphonates are analogs of inorganic diphosphate, in which a central 
carbon atom replaces the phosphor-ether bond between the two phosphate groups. Nitrogen-
containing bisphosphonates such as 
zoledronate (Novartis), are bone resorption 
drugs, acting by inhibiting FPPS to block 
the formation of FPP and GGPPS, which are required for prenylation of GTPases, essential for 
anti-resorptive activity [23-26]. Nitrogen-containing bisphosphonates have a second remarkable 
activity in killing tumor cells by γδ T cell activation, via IPP and DMAPP accumulation resulting 
from the inhibition of FPPS [15]. In previous work, our collaborator Dr. Andrew H.-J Wang 
showed that bisphosphonates could also inhibit bacterial UPPS and they obtained a crystal 
structure of E. coli UPPS with 4 bisphosphonate BPH-629 bound [20]. This opens up 
possibilities for synergistic effect of bisphosphonates resulting from multi-target inhibition. 
P
P
O
O
OH
OH
OH
OH
OH
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P
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O
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OH
OH
OH
OH
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N
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However, the bisphosphonate class of drugs bind very tightly to bone mineral [27] – a desirable 
feature for a bone drug, but not an anti-infective, since these drugs are rapidly removed from the 
circulation. Therefore, there has been considerable interest in developing non-bisphosphonate 
prenyl transferase inhibitors that are less hydrophilic and do not bind to bone.  
 
Diketoacids. The initial diketoacid inhibitors, designed by Merck as HIV-1 integrase (IN) 
inhibitors [28], act by binding at or near the Mg2+/Asp motif [29] in the IN to form an IN-Mg2+-
DNA-diketoacid complex. Coincidently, most 
prenyl transferases also contain a similar 
Mg2+/Asp motif and thus could be targeted by 
diketoaicd inhibitors.  Our group thus developed a 
series of diketoacid analogs and I tested them 
against different prenyl transferases of interest, finding that they had good activity against E. coli 
UPPS (best IC50 ∼ 0.5 µM), and S. aureus UPPS (best IC50 ∼ 0.7 µM) [30].  
 
Benzoic acids. We recently reported [31] that a dicarboxylic acid, BPH-1100, inhibited UPPS 
with IC50 values of 3.2 µM (EcUPPS) and 6.9 µM (SaUPPS). BPH-1100 was obtained by high-
throughput virtual screening of the NCI diversity library 
using a MD-simulated structure of E. coli UPPS as the 
ligand receptor. The advantage of using MD-structure 
based methods to carry out in silico high throughput screening (HTS), rather than simply using 
an X-ray structure- is that a large conformational space can be investigated. What was 
remarkable about the MD simulation results, Figures 1.3a, b, carried out on the UPPS/BPH-629 
H
OH
OH
O
O
O
BPH-987
O
O OH
OH
O
BPH-1330
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SaUPPS  0.73
EcUPPS  0.5
SaUPPS  2.0
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structure (2E98), was that after the original ligand-binding volume collapsed (the ligand-binding 
pocket volume decreased from ~1100 Å3 to ~400 Å3), this volume remained constant through 
almost all of the trajectory and was the same as found in the apo-enzyme [32]. However, there 
was a very large fluctuation (at ~12 nsec) in which a (potential) ligand-binding pocket opened 
up, Figure 1.3a and when using several such “open” structures in Glide [33] docking 
investigations with a series of known UPPS inhibitors we found much better accord between 
Glide docking scores and enzyme inhibition pIC50 (= -log10 IC50) values.  
	  
1.5	   Research	  Strategies	  
 My ultimate goal is to design or discover anti-tumor, anti-infective or anti-bacterial drug 
leads that target isoprenoid biosynthesis (FPPS and/or UPPS, to be specifically). Generally 
speaking, there are two approaches to realize my goal.  
 The first approach is to screen existing compound libraries to discover new hits. Over the 
last decade, our lab has accumulated more than a thousand compounds with a variety of 
scaffolds. Many of them have been proved to be active against one or more drug targets. It is 
highly possible that they may have activity against others. And indeed in our previous work [31, 
34], we found that bisphosphonates that inhibitors of FPPS also inhibit UPPS. The benefits of 
screening existing compound library are obvious. First, the compounds are already synthesized 
and ready to use, and thus the costs and time (usually hundreds to thousands dollars and weeks 
to months per compound) to make them are not needed. Second, these compounds are likely to 
have been studied in other work, and thus their properties and activities are well characterized 
(physical properties such as solubility, logP, ionization, oral bioavailability, etc.; bioactivity such 
as toxicity, enzyme and/or cell inhibition, in vivo activity, etc.). This prior information can help 
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to progress my new projects and provide insights to design better inhibitors. However, this 
approach also has disadvantages. First, it is unlikely to discover new structural scaffolds that are 
active against my target protein other than those already in existing compound library. In the rise 
of drug resistance, new inhibitors with different scaffolds are crucial. To alleviate this problem, 
many other commercial available libraries can be included. However, a second problem will rise 
if doing so. Like all other screening-based drug discovery approaches, the success rate is not 
guaranteed. It is highly possible that screening a library of more than 1000 compounds will not 
yield a single hit. Or there might be too many hits, most of them being false positives. Despite 
not quite promising, screening needs a great deal of effort and the situation becomes even worse 
if high through-put screening facilities are not available, which is usually the case for most 
academic labs.  
 The second approach to discover inhibitors is rational drug design, which requires 
knowledge on either previously identified inhibitors, structures of the target protein, or both. If a 
compound is known to inhibit the target protein, I can design analogs of this inhibitor by 
structural modification in order to improve activity, deduce toxicity or improve druglikeness. By 
studying structure-activity relationships, I can further optimize the drug leads. On the other 
hand, if the structure of the target protein is available (though x-ray crystallography, solid state 
NMR, or electron microscopy), protein structure-based rational drug design can be utilized. Apo 
or un-liganded protein structures, though not as useful as liganded ones, do provide information 
on the overall three-dimensional structure of the protein and the possible binding pocket(s). 
Starting with an apo protein structure, we can use computer programs to dock ligands or 
compounds to the active sites to explore possible binding poses, ligand-protein interactions, and 
mechanisms of action. If ligand or inhibitor-bound protein structures are available, more 
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accurate and detailed information of the above mentioned analysis could be obtained. In 
addition, new inhibitors could be explored by replacing the bound ligand/inhibitor with the 
compounds I choose. More practically, computer-aid virtual screenings can be carried out by 
docking a large library of compounds to pre-defined protein activity sites using the 
ligand/inhibitor-bound structure. The advantages of this structure-based rational drug design is 
obvious: higher success rates, less labor-intensive and unlimited possibilities of new scaffolds. 
However, to obtain a useful protein structure at the first place is usually problematic, if not 
entirely impossible. Crystallographic experiments can take months or even years, not to mention 
some proteins especially membrane proteins are difficult to crystalize.   
 Fortunately the two approaches are not necessarily mutually exclusive. On the contrary, a 
combination of the two is usually more practical and useful. I can start a project with random 
screenings, and add structural information and analysis to validate or rationalize the hits 
obtained from the screenings to further improve their activity. Or I can start with a ligand or 
inhibitor-bound structure, design potential inhibitors using SAR analysis, and expand the 
potential hits to a larger set of compounds with structural variations for screening.   
 In this work, both screening-based approach and rational design based approach were 
adopted. Specifically, in chapter 2, I report the discovery and X-ray crystallographic structures of 
10 chemically diverse compounds (benzoic/diketo/phosphonic acids, as well as a bisamidine and 
a bisamine) resulting from virtual screening and structure-based rational drug design, which 
inhibit bacterial undecaprenyl diphosphate synthase (UPPS). In chapter 3, I describe the 
discovery of antibacterial leads, keto- and diketo-acids, known as HIV intergase inhibitors, 
targeting two prenyl transferases: UPPS and dehydrosqualene synthase (CrtM). The inhibitors 
are discovered by rational drug design. In chapter 4, I report the discovery of bisamidines 
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targeting both prenyl synthases and DNA. This discovery is an extension of the UPPS inhibitor 
development. In Chapter 5, I explore the possibility of bisphosphonates as chemo- 
immunotherapeutic anti-malarials by direct parasite killing as well as human γδ T cell activation. 
The original inhibitors were obtained by screening. In chapter 6, I describe the development of 
anti-cancer agents by selectively combining tumor cell killing bisphosphonates with 
polyoxometalates, resulting in an enhanced activity. 
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1.6	   Figures	  
Figure 1.1 Schematic illustration of bacterial cell wall biosynthesis (in e.g. S. aureus and E. 
coli). 
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Figure 1.2 Structures of EcUPPS with FSPP (PDB ID codes 1X06; 1X08; 1X09) and a 
bisphosphonate BPH-629 (PDB ID 2E98). (a, b) FSPP and IPP binding site. The Mg2+ are green 
spheres; A is the normal Mg2+ position, A’ is in a D26 mutant. (c, d) Binding sites for the 
bisphosphonate BPH-629. (e, f) Superpositon of the FSPP and BPH-629 structures. There are 
four bisphosphonate-binding sites (1-4); the FPP binds to site-1 with IPP close by. Additional 
ligand electron density is also seen in site-4 in the FPP structures. 
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Figure 1.3 Volume distribution of the UPPS binding pocket in the 2E98 crystal structure and 
the apo crystal structure. (a) Volume of the binding pocket along the MD trajectory. The black 
line shows data taken every 10 ps, the overlayed gray line is the average over every 100 ps. (a) 
Frequency at which different volumes of the pocket are sampled.  
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2.2	   Introduction	  
 
 Targeting isoprenoid biosynthesis is a potentially important route for antibiotic 
discovery because isoprenoids are involved in the very early steps of bacterial cell wall 
biosynthesis: the condensation of dimethylallyl diphosphate (DMAPP, 1) with two molecules of 
isopentenyl diphosphate (IPP, 2) to form farnesyl diphosphate (FPP, 3), catalyzed by the 
enzyme farnesyl diphosphate synthase (FPPS), followed by the addition of 8 more IPP 
molecules to form undecaprenyl diphosphate (UPP, 4) [1, 2], Figure 2.1. Formation of 4 is 
catalyzed by the enzyme undecaprenyl diphosphate synthase (UPPS), and several UPPS 
inhibitors have been reported [3-10]. UPP is then hydrolyzed to the monophosphate, which is 
next converted to Lipid I and Lipid II, leading to formation of cell wall peptidoglycan, Figure 
2.1 [11, 12]. Antibiotics such as methicillin and vancomycin act in the latter stages of 
peptidoglycan formation, again as shown in Figure 2.1. Here, we focus on the development of 
UPPS inhibitors since UPPS is an essential gene [13] not present in humans. UPPS inhibitors 
are predicted to synergize with the more conventional cell wall biosynthesis inhibitors, 
potentially reducing the toxicity of drugs such as vancomycin (by decreasing dosage), or 
restoring drug sensitivity (e.g. with MRSA, methicillin-resistant Staphylococcus aureus). The 
UPPS structure is unusual in that there are four known ligand binding sites [5], opening up the 
possibility of designing a diverse range of inhibitors. 
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2.3	   Results	  and	  Discussions	  
New UPPS inhibitors. In previous work, we and others reported the discovery of several UPPS 
inhibitors including bisphosphonates such as BPH-629 (5) [5], tetramic acids such as 6 [6], as 
well as diketoacids such as 7 [10], and benzoic acids such as 8 [9], Figure 2.2. Based on in silico 
high throughput screening [9] and hit development (Figure 2.3) we produced a small series of 
benzoic (9-12), phosphonic (13) and diketoacids (14, 15) that had activity against UPPS (Figure 
2.2). In addition to these anionic species, we discovered several potent cationic inhibitors (16-
18). This was unexpected from both a computational and experimental standpoint since these 
compounds do not mimic the (anionic) FPP substrate, and the UPPS mechanism is not thought to 
involve carbocation intermediates [14]. We thus sought to determine how these inhibitors bind to 
their UPPS target, by obtaining crystal structures of 8-16 and 18 bound to E. coli UPPS. 
 
The four inhibitor binding sites in UPPS. UPPS functions by sequentially adding IPP to an 
allylic substrate, initially FPP [15]. It might reasonably be expected, then, that anionic inhibitors 
with lipophilic side-chains would bind to the FPP substrate site, as shown in Figure 2.4a (in 
yellow; PDB ID code 1X06). However, in a second structure (PDB ID code 1V7U) two FPP 
molecules bind, one in the substrate site and the other in a second site at the “bottom” of the 
protein (Figure 2.4a, in green). Moreover, with the bisphosphonate inhibitor 5, there are actually 
four binding sites (sites 1-4 [5]) that can be occupied, Figure2.4b (cyan) (PDB ID code 2E98) in 
which the side chains in each of the four inhibitor molecules occupy the large hydrophobic 
center of the protein that normally accommodates the C55 side chain in the UPP product. With 
the two less-active benzoic acid inhibitors, 8 and 9, we find that only site-3 (Figure 2.4c; PDB ID 
code 3SGT) or sites 1, 2 and 3 are occupied (Figure 2.4d; PDB ID code 3SGV) – but the activity 
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of both of these inhibitors is weak (8, E. coli UPPS, IC50 = 150 µM; S. aureus UPPS, 170 µM; 9, 
E. coli UPPS, IC50 = 35 µM, S. aureus UPPS, 72 µM; Table 2.1). Full data acquisition and 
structure refinement details are in Table 2.2, electron densities (2Fo-Fc and simulated-annealing 
Fo-Fc OMIT maps) are in Figure 2.5 and 2.6. So, with these two benzoic acid inhibitors, binding 
to sites 1, 2 or 3 correlates only to weak UPPS inhibition. 
 
Potent benzoic acid inhibitors bind to site-4. We next determined the structures of the three 
potent benzoic acid inhibitors (10-12, Figure 2.2) bound to UPPS (Figure 2.7a-c). Each of these 
molecules contains a long hydrophobic side-chain and, on average, the IC50 values against both 
E. coli and S. aureus UPPS are ~3 µM, Table 2.1. What is notable about these x-ray structures is 
that in each case, site-4 is occupied, together with either sites 1, 2 or 3. Full data acquisition and 
structure refinement details are in Table 2.2, electron densities are in Figure 2.5 and 2.6. In 
addition, we found that the aryl phosphonate inhibitor 13 also occupied two sites, Figure 2.7d. 
However, there are two chains in one asymmetric unit and site-occupancies in the two chains are 
variable: the lower site-occupancy chains are shown in Figure 2.8. These four structures suggest 
that good UPPS inhibition correlates with occupancy of site-4. 
 
Diketoacids, a bisamidine and a bisamine also target site-4. In previous work [10], we found 
that the diketoacid 15 had potent cell growth inhibition activity with the following MIC90 values: 
0.25-0.5 µg/mL against S. aureus, 0.5 µg/mL against Bacillus anthracis, 4 µg/mL against 
Listeria monocytogenes and Enterococcus faecium, and 1 µg/mL against Streptococcus 
pyogenes, but little toxicity toward human cell lines (> 20 µM). We therefore next determined 
the structure of 15 and a second diketoacid (14), bound to UPPS. As can be seen in Figure 2.8a 
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and b, both diketoacids bind to site-4, with 14 also binding to site-3. The observation that 15 
binds only to site-4 is of interest since this inhibitor has very good antibiotic activity [10]. Plus, 
the occupation of site-4 in both structures is consistent with the results for the other potent 
anionic inhibitors, Figure 2.7. 
 A surprising result from the in silico screening work (Figure 2.3) was that bisamidines 
such as 16 had modest activity against UPPS. Moreover, the biphenyl bisamidine 17 showed 
potent activity against UPPS (IC50 value of 0.1 µM) as well as a MIC90 of 0.25 µg/mL against S. 
aureus (USA300, MRSA strain). We also found that another dicationic species 18 was a UPPS 
inhibitor active against S. aureus (Table 2.1). We were unable to obtain the structure of 17 bound 
to UPPS, but we did obtain structures of 16 and 18 bound to UPPS.  
With these two cationic inhibitors, rather than two individual molecules binding, we 
observe that a single molecule binds, with its polar, cationic groups located at or near the 
protein’s surface, while the hydrophobic “spacer” is buried inside the protein’s hydrophobic 
interior, Figure 2.9c and d (PDB ID codes 4H2J, 4H2M). While we did not succeed in 
crystallizing the most potent lead 17, a similar “polar-hydrophobic-polar” binding arrangement 
in which the biphenyl group is buried seems very likely for this species also, and is supported by 
the results of computational docking, as shown in Figure 2.10. 
 
Comparison of E. coli and S. aureus UPPS structures and their inhibition. In this work, we 
determined the activity of each inhibitor against both E. coli UPPS and S. aureus UPPS, finding 
that there is a very good correlation (R2 = 0.8) between the 14 sets of pIC50 (=-log10IC50) values 
(Table 2.1; Figure 2.11). This is not unexpected since 18 of the top 20 residues in a 
SCORECONS [16] analysis of E. coli UPPS are present in S. aureus UPPS, and most other 
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bacterial UPPSs (Table 2.3). We were not able to determine the x-ray structures of any inhibitor 
bound to S. aureus UPPS, but we did determine the structure of the protein with a bound FPP 
(PDB ID code 4H8E; full data acquisition and structure refinement details are in Table 2.4). S. 
aureus co-crystallized with FPP in site-1 together with a SO42- in the IPP binding sites, as 
reported in a patent application [17]. A superposition of the S. aureus and E. coli proteins is 
shown in Figure 2.12 where we find a Cα root-mean square deviation of 0.91 Å over 202 
residues, indicating that both structures are very similar (in the presence of FPP/FSPP and either 
IPP or SO42-), consistent with the pIC50 correlation. 
 
Relationship to other inhibitors: Is UPPS a missing link? The structures of several of the 
UPPS inhibitors described here are similar to (and with 18, the same as) those being developed 
as anti-infective drug leads but whose mechanisms of action are not clear. For example, the 
chemical structures of the benzoic acid inhibitors are similar to those of anthranilic (ortho- 
aminobenzoic) acids reported by Larsen et al. [18] and Mott et al. [19] having activity against S. 
aureus. The molecular mechanism of action of these inhibitors was initially thought to involve 
inhibition of translation/termination, but in later work this inhibition was not found to correlate 
with cell growth inhibition, and a new target (SA1575, of unknown function), as well as 
inhibition of cell wall biosynthesis, was reported. We find that a pharmacophore model (Figure 
2.13a) of seven potent benzoic acid UPPS inhibitors we synthesized (Figure 2.14), is very similar 
to that obtained for S. aureus cell growth inhibition (Figure 2.13b) using 5 structures reported by 
Larsen et al. (Figure 2.15b), making UPPS inhibition one likely mechanism for these inhibitors, 
in particular because they are already known to inhibit cell wall biosynthesis. In addition, we 
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found that the lead 19 reported by Larsen et al. is a ~1-2 µM UPPS inhibitor (Table 2.1), 
consistent with a role in S. aureus growth inhibition. 
In addition to the benzoic/anthranilic acids, there is also interest in the mechanisms of 
action of bisamidines, such as 20 [20, 21], as well as of other cationic species such as 21 [22], 
and it has been proposed that these and related compounds could bind to the minor groove of 
DNA [20], or that they could alter lipid bilayer structure [23-25], as illustrated schematically in 
Figure 2.13c and d. Based on our crystallographic (Figure 2.9c and d) as well as enzyme 
inhibition results it is clear, however, that in addition to these binding modes, “polar-
hydrophobic-polar” inhibitors (such as 17 or 18) can also bind to proteins, as shown in the 
cartoon in Figure 2.13e, with their polar headgroups located near polar protein residues (or at the 
protein-water interface), while their hydrophobic centers are buried inside the protein target 
(Figure 2.9c and 2.9d). 
Notably, as with the benzoic acids, bisamidines such as 20 can inhibit cell wall 
biosynthesis [26] and with 20 we find quite potent (470 nM) UPPS inhibition. The ability to 
inhibit UPPS in addition to e.g. DNA and lipid membrane targeting likely contribute to the 
potent activity of these compounds and, in some cases, the lack of resistance observed 
experimentally. In addition, it is also possible that other prenyl transferases such as FPPS, may in 
some cases be targeted. 
 
Synergy and in vivo results. The UPPS inhibition results suggested to us the possibility of 
synergistic activity with downstream cell wall biosynthesis inhibitors, such as methicillin (Fig. 
1). This is indeed the case as shown in Figure 2.16a in which we present the isobologram [27] for 
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17 + methicillin against a USA300 strain of MRSA. We observe a potent synergistic interaction 
with a FICI (fractional inhibitory concentration index), defined as: 
 
FICI = FICA + FICB = MIC90 (AB)/MIC90 (A) + MIC90 (BA)/MIC90 (B), 
 
where, FICA, FICB are the fractional inhibitory concentrations of drugs A and B, and MIC90 
(AB), MIC90 (BA) are the MIC90 values of the most effective combination of A or B in the 
presence of B or A [28, 29]. Using this method, FICI values of <0.5 represent synergism, >0.5 
and <1.0 represent additivity, >1 and <2 represent an indifferent effect, while ≥ 2 represents drug 
antagonism [30]. An FICI = 0.37 thus represents strong synergism, opening up the probability of 
restoring drug sensitivity in drug-resistant strains. But are such compounds active in in vivo 
models of infection?  
In previous work, it has been found that e.g. benzoic acids (such as 19) as well as 
tetramic acids (such as 6) have potent activity against bacteria, however, there have been no 
previous reports of in vivo activity, due perhaps to strong binding to plasma proteins. Since 17 
had potent activity against UPPS (110 nM), we tested it in a mouse model of infection using the 
USA200 Sanger 252 (MRSA) strain of S. aureus. As can be seen in Figure 2.16b, mice treated 
post-infection only with vehicle control all died, while mice treated with 17 (20/20 total, pooled 
results of 2 experiments) survived with no apparent adverse reactions. 
 
Computational results: FTMap, principal component and ROC/AUC analyses. The results 
described above represent the discovery of a series of new UPPS inhibitors – drug leads – some 
of which have potent activity in cells and a mouse infection model. From a structural 
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perspective, the most surprising result was that the most potent inhibitors all bound to site-4, not 
the substrate site, site-1. In previous work on bisphosphonate UPPS inhibitors [5] we found that 
a wide range of bisphosphonates bound to site-1 and that enzyme inhibition and site-1 docking 
scores were highly correlated [5]. However, with all of the new (non-bisphosphonate) inhibitors 
described here, we find that binding to site-4 is the common structural denominator for ligands 
with high affinity. Other sites are also often occupied, with either 2 molecules binding, or one 
inhibitor spans two sites (sites 4 and 2, with the dicationic species).  
Site-4 is quite removed from the most flexible loop region (residues 72-82) of the active 
site, suggesting that there may be less entropic costs due to constraining this loop, associated 
with inhibitor binding to site-4, rather than to sites 1-3, where the ligand directly contacts and 
restrains the loop. Site-4 is also predicted to be druggable when using the solvent mapping 
program FTMap [31], as shown in Figure 2.17a, again supporting the idea that inhibitors that 
bind to site-4 will be good drug leads. With the new inhibitors, we also see that the global 
structures are quite similar to apo UPPS (Figure 2.17b, red), using principal component analysis 
[32]. The bisphosphonate inhibitors (blue) and substrate (yellow) bound structures are altered to 
a greater extent from the apo form than are the new structures (red). This suggests less induced-
fit occurs on binding, which again will reduce any energetic costs associated with protein 
conformational changes upon binding.   
 Finally, since many of these inhibitors were the result of virtual screening, we assessed 
the predictive nature of each structure using a ROC/AUC (receiver operating characteristic – 
area under the curve) approach [33] with a 112 compound screening dataset (Figure 2.18). 
Enrichment results are shown in Figure 2.17c and Figure 2.19. Good results (AUC=0.768) are 
obtained when using the “open” structure containing 5 bound to sites 1-4, but the best result is 
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obtained using the 15 structure (PDB ID code 4H3A), an “ajar” (Figure 2.17b) or partially closed 
structure in which only site-4 is occupied (Figure 2.17c, bottom) where AUC=0.802. Taken 
together, these results strongly support the importance of developing compounds that bind to 
site-4 as UPPS inhibitor drug leads, and that computational models based on these new structures 
can significantly enrich the hit rate. 
	  
2.4	   Conclusions	  
 The results we have described above are of interest for several reasons. First, we obtained 
the x-ray structures of 10 new UPPS inhibitors covering a diverse range of structures: benzoic 
acids, diketoacids, an aryl phosphonate, a bisamidine and a bisamine. The surprising result was 
that both cationic as well as anionic compounds were inhibitors, the cationic species having an 
unusual polar-hydrophobic-polar structural motif. Second, we find evidence that occupancy of 
site-4 (not the FPP substrate site, site-1) correlates with the potent activity of these inhibitors, 
and that site-4 is predicted to be druggable. Third, we find that the cationic (bisamidine and a 
bisamine) inhibitors span both sites 2 and 4, with their polar groups at or near the protein/water 
interface, while their hydrophobic domains are buried. This result is of particular importance 
since this motif is very similar to that proposed to be important for DNA and lipid membrane 
binding with structurally related inhibitors, leading to the idea that such compounds may have 
multiple targets (including UPPS), thereby increasing potency. We also find that a closely related 
biphenyl analog (17) inhibits UPPS at ~ 100 nM levels, has a MIC90 of 0.25 µg/mL, and strongly 
synergistic activity (FICI = 0.37) with methicillin, in an MRSA strain otherwise resistant to the 
antibiotic. In addition, this compound shows clear therapeutic activity in a mouse model of 
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infection. Finally, we propose that anthranilic acids, known to be potent inhibitors of S. aureus 
growth that target cell wall biosynthesis, also target bacterial UPPS. Taken together, these results 
open up new routes to anti-infective therapies targeting bacterial isoprenoid biosynthesis and 
suggest that in some cases drug leads that have been proposed to target DNA and lipid 
membrane structure may also target bacterial cell wall biosynthesis, via UPPS inhibition.  
	  
2.5	   Materials	  and	  Methods	  
 
Synthetic aspects. All reagents utilized were purchased from Aldrich (Milwaukee, WI) or Alfa 
Aesar (Ward Hill, MA). NMR spectra were obtained on 400 MHz (1H) or 500 MHz Varian (Palo 
Alto, CA) Unity spectrometers. 10, 14, 15 were available from previous work [9, 10]. The 
syntheses of 11, 12, 13, 16, 17, 18 are described below.  
 
(Dodecyloxy)-6-hydroxybenzoic acid (11). To a mixture of 5-hydroxy-2, 2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (1 g, 5.2 mmol) and 1-dodecanol (1.6 g, 7.5 mmol) in THF (20 mL) at  
0 °C were added triphenyl phosphine (2.0 g, 7.5 mmol) and DIAD (1.5 mL, 7.5 mmol). The 
mixture was then stirred overnight at room temperature. The reaction mixture was concentrated 
and purified by column chromatography (ethyl acetate/hexane 1: 8). Saponification with 4M 
NaOH (5 equiv) under reflux and acidification with 1M HCl afforded 11 as a white solid (1.07 g, 
70%). 1H NMR (CDCl3, 500 MHz) δ: 7.36 (t, J = 8.5 Hz, 1 H), 6.68 (d, J = 8.5 Hz, 1 H), 6.45 (d, 
J = 8.5 Hz, 1 H), 4.20 (t, J = 6.5 Hz, 2 H), 1.91 – 1.87 (m, 2 H), 1.47 – 1.43 (m, 2 H), 1.28 – 1.24 
(m, 16 H), 0.86 (t, J = 6.5 Hz, 3 H) ppm. 13C NMR (CDCl3, 125MHz) δ: 171.2, 164.5, 158.3, 
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135.8, 130.3, 112.4, 102.4, 71.0, 32.1, 29.8, 29.7, 29.7, 29.6, 29.5, 29.40, 29.1, 26.1, 22.9, 14.4. 
HRMS (ESI): m/z [M + H]+ calcd. for C19H31O4 323.2222, found 323.2231. 
 
2-(3-(Decyloxy)benzamido)-5-nitrobenzoic acid (12). To a mixture of 3-(decyloxy)benzoyl 
chloride (296 mg, 1 mmol) and 2-amino-5-nitrobenzoic acid (182 mg, 1 mmol) in CH2Cl2 (20 
mL) was added Et3N (1 mL). The mixture was stirred overnight and washed with water  (5 mL) 
and 1M HCl (4 mL) and then concentrated. Recrystallization from ethyl acetate/hexane 1:1 
afforded 12 as white powder (185 mg, 42%). 1H NMR (CDCl3, 500 MHz) δ: 12.17 (s, 1 H), 9.16 
(d, J = 9.5 Hz, 1 H), 9.03 (d, J = 3.0 Hz, 1 H), 8.47 (dd, J = 9.5, 3.0 Hz, 1 H), 7.54 (d, J = 1.0 Hz, 
1 H), 7.53 (d, J = 8.0 Hz, 1 H), 7.42 (t, J = 8.0 Hz, 1 H), 7.13 (dd, J = 8.0, 1.0 Hz, 1 H), 4.03 (t, J 
= 6.5 Hz, 2 H), 1.82 – 1.78 (m, 2 H), 1.47 – 1.43 (m, 2 H), 1.26 – 1.22 (m, 12 H), 0.86 (t, J = 7.0 
Hz, 3 H). 13C NMR (CDCl3, 125MHz) δ: 169.6, 160.0, 147.6, 142.1, 135.3, 130.5, 130.3, 128.0, 
121.0, 120.1, 119.3, 114.2, 113.6, 68.6, 32.1, 29.80, 29.8, 29.6, 29.5, 29.4, 26.6, 22.9, 14.3. 
HRMS (ESI): m/z [M + H]+ calcd. for C24H31N2O6 443.2182; found 443.2174. 
 
 
(5-bromo-2-((3-(octyloxy)benzyl)oxy)phenyl)phosphonic acid (13). To a mixture of diethyl 
(5-bromo-2-hydroxyphenyl)phosphonate (1.54 g, 5.0 mmol) and 3-octyloxybenzyl alcohol (1.2 
g, 5.0 mmol) in THF (20 mL) at  0 °C were added triphenyl phosphine (2.0 g, 7.5 mmol) and 
DIAD (1.5 mL, 7.5 mmol). The mixture was then stirred overnight at room temperature. The 
reaction mixture was concentrated and purified by column chromatography (ethyl acetate/hexane 
1: 1). The diethyl ester of 13 was then treated with 8 equivalent of TMSBr in anhydrous CH2Cl2 
(15 mL) overnight. After removal of the solvent, the concentrated oil was treated with 10 mL 
29 
 
methanol to afford 13 as white solid (1.62 g, 68%, two steps). 1H NMR (DMSO-D6, 400 MHz) 
δ: 7.70 (dd, J = 14.8, 2.8 Hz, 1 H), 7.54 (dd, J = 8.8, 2.8 Hz, 1 H), 7.20 (t, J = 7.6 Hz, 1 H), 7.10 
(s, 1 H), 6.99 (m, 1 H), 6.98 (m, 1 H), 6.77 (dd, J = 2.4, 8.0 Hz, 1 H), 5.16 (s, 2 H), 4.13 (t, J = 
6.8 Hz, 2 H), 1.64 – 1.60 (m, 2 H), 1.36 – 1.32 (m, 2 H), 1.25 – 1.21 (m, 8 H), 0.81 (t, J = 6.8 
Hz, 3 H) ppm. 13C NMR (DMSO-D6, 125 MHz) δ: 171.4, 159.4, 159.1, 139.0, 136.2, 130.1, 
126.0, 124.6, 119.5, 115.9, 114.6, 113.3, 69.7, 60.6, 31.9, 31.3, 29.4, 29.3, 26.15, 22.7, 14.6.  
HRMS (ESI): m/z [M + H]+ calcd. for C21H29BrO5P 471.0936; found 471.0940.  
 
N1, N4-bis(3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)-2-nitroterephthalamide (16). 16 was 
obtained from the NCI screening library and its identity was confirmed by 1H NMR, 13C NMR 
and HRMS. 1H NMR (DMSO-D6, 500 MHz) δ: 8.72 (s, 1 H), 8.44 (d, J = 7.5 Hz, 1 H), 7.99 (d, J 
= 7.5 Hz, 1 H), 7.90-7.81 (m, 6 H), 7.71 (d, J = 8.5 Hz, 2 H), 3.60 (s, 8 H). 13C NMR (DMSO-
D6, 125 MHz) δ: 163.8, 163.5, 147.0, 141.0, 137.5, 135.0, 133.9, 130.5, 128.6, 128.4, 126.9, 
124.2, 120.5, 119.7, 39.8. HRMS (ESI): m/z [M + H]+ calcd for C26H24N7O4, 498.1890; found 
498.1882. 
 
N4, N4'-bis(3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)-[1,1'-biphenyl]-4,4'-dicarboxamide 
(17). To a mixture of 4,4’-diphenyl dicarbonyl chloride (1.39 g, 5 mmol), 3-aminobenzonitrile 
(1.18 g, 10 mmol) in anhydrous THF (20 mL) was added Et3N (2.1 mL, 15 mmol) and the 
mixture was stirred at room temperature overnight. After filtration, the white solid was washed 
with water (20 mL) and ethyl acetate (10 mL) and then dried. Sodium hydrosulfide hydrate  (100 
mg), ethylenediamine (2 mL) and dimethylacetamide (10 mL) were then added and stirred 
overnight at 140 °C. Upon removal of the solvent, the solid was washed thoroughly with water 
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and then ethyl acetate (10 mL). To the suspension of the crude product in 10 mL of water were 
added two equivalents of methyl sulfonic acid. Removal of water afforded 17 as its 
methanesulfonic acid salt (1.44 g, 40%). 1H NMR (DMSO-D6, 500 MHz) δ: 10.68 (s, 2 H), 
10.52 (s, 4 H), 8.50 (s, 2 H), 8.12 (d, J = 9.0 Hz, 4 H), 8.02 – 7.98 (m, 2 H), 7.96 (d, J = 9 Hz, 4 
H), 7.68 – 7.58 (m, 4 H), 4.00 (s, 8 H), 2.36 (s, 6 H). 13C NMR (DMSO-D6, 125 MHz) δ: 166.1, 
166.1, 143.0, 140.6, 134.4, 130.6, 129.2, 127.7, 127.0, 124.3, 123.5, 120.8, 45.3. HRMS (ESI): 
m/z [M + H]+ calcd. for C32H29N6O2 529.2361, found 529.2352. 
 
2,2'-((1,3-phenylenebis(ethyne-2,1-diyl))bis(3-bromo-5,1-phenylene))diethanamine (18). 18 
was synthesized as reported [25]. 1H NMR (DMSO-D6, 500 MHz) δ: 7.66-7.42 (m, 10 H), 3.19 
(t, J = 8.0 Hz，4 H), 2.95 (t, J = 8.0 Hz，4 H) ppm. 13C NMR (DMSO-D6, 125 MHz) δ: 158.8, 
141.2, 135.6, 133.6, 133.2, 132.8, 131.7, 130.4, 124.9, 123.3, 122.6, 89.7, 40.8, 32.9. HRMS 
(ESI): m/z [M + H]+calcd for C26H23Br2N2, 521.0228; found 521.0214. 
 
E. coli UPPS expression and purification. The E. coli UPPS plasmid was provided by 
Professor Andrew H.-J Wang. The purification of UPPS from E. coli followed the published 
protocol with modifications [34]. The plasmid was transformed into E. coli BL21 (DE3) cells 
(Novagen) for expression. A single transformant was grown up overnight at 37 °C in LB 
medium containing 100 µg/mL ampicillin. The 50 mL overnight cultures were transferred to 2 L 
fresh LB medium containing 100 µg/mL ampicillin and allowed to grow to OD600 = 0.6 before 
induction with 1 mM IPTG. The cultures were induced for 4 h at 37 °C and harvested by 
centrifugation. Cell pellets were suspended in 60 mL buffer (25 mM Tris-HCl, pH 7.5 and 150 
mM NaCl), followed by pulse sonication. The lysate was centrifuged and the cell debris 
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discarded. For purification, the cell free extract was loaded into a 20 mL Ni-NTA column pre-
equilibrated with 25 mM Tris-HCl (pH 7.5) and 150 mM NaCl. The column was washed with 30 
mM imidazole-containing buffer. The His-tagged UPPS was eluted with a 0% to 100% gradient 
buffer (25 mM Tris-HCl, pH 7.5, 150 mM NaCl and 300 mM imidazole). The protein solution 
was dialyzed against 3 × 2 L buffer (25 mM Tris-HCl, pH 7.5 and 150 mM NaCl). The His-
tagged UPPS was then digested with FXa protease to remove the His-tag. The solution was then 
loaded onto Ni-NTA. The UPPS in the flow through (25 mM Tris-HCl, pH 7.5, 150 mM NaCl 
and 30 mM imidazole) was pure as evidenced by to SDS-PAGE, and was dialyzed into buffer 
(25 mM Tris, pH 7.5 and 150 mM NaCl) for storage. The final concentration was determined by 
using a Bradford protein assay kit. 
 
S. aureus UPPS expression and purification. The gene encoding UPPS was amplified from a 
plasmid [9] containing the S. aureus UPPS gene. The forward primer was 5’ GTA TTG AGG 
GTC GCA TGT TTA AAA AGC TAA TAA ATA AAA AGA ACA C 3’, and the reverse 
primer was 5’ AGA GGA GAG TTA GAG CCC TAC TCC TCA CTC 3’. The amplified UPPS 
gene was purified and ligated into a pET-32 Xa ⁄LIC vector (Novagen, Madison, WI, USA). The 
plasmid with the S. aureus UPPS gene was subsequently expressed in E. coli BL21 (DE3) cells 
(Novagen). The protocol for expression and purification of S. aureus UPPS was the same as that 
for E. coli UPPS. 
 
X-Ray crystallography. Native E. coli UPPS crystals for use in soaking were obtained by using 
the hanging-drop method (Hampton Research, Laguna Niguel, CA) by mixing 1 µL of UPPS 
protein solution (~14 mg/ml UPPS in 25 mM Tris-HCl, pH 7.5 and 150 mM NaCl) with 1 µL of 
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mother liquor (25 mM Tris-HCl, pH 7.5, 150 mM NaCl and 5% PEG 2-4K) and then 
equilibrating with 400 µL mother liquor at room temperature. Tetragonal crystals appeared in 2 
days and were then soaked in a cryoprotectant solution (25 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 30% EG and 5% PEG 35K) containing 1-5 mM inhibitors for 1 day.  
 S. aureus UPPS crystals with FPP were obtained by using the hanging-drop method 
(Hampton Research, Laguna Niguel, CA) by mixing 1 µL of UPPS protein solution (~5 mg/ml 
UPPS in 1.5 mM MgCl2, 1.5 mM FPP, 25 mM Tris-HCl, pH 7.5 and 150 mM NaCl) with 1 µL 
of mother liquor (100 mM NaMES, pH 6.5, 200 mM (NH4)SO4, and 25% PEG MME 5K) and 
then equilibrating with 400 µL mother liquor at room temperature. Bi-pyramidal crystals 
appeared overnight.  
 X-ray diffraction data for both EcUPPS and SaUPPS were collected at the Life Science 
Collaborative Access Team (LS-CAT) 21-ID-D (F or G) at the Advanced Photon Source of 
Argonne National Laboratory. Diffraction data were processed and scaled by using the program 
HKL3000 (HKL Research Inc., Charlottesville, VA, USA) [35]. The statistics for data collection 
are listed in Table 2.2 and 2.4. 
The structures of the UPPS-complexes were determined by using a model prepared from 
the UPPS/BPH-629 complex structure (PDB ID 2E98) with ligands and solvent removed. 
Structure refinements were carried out by using Refmac [36, 37], Phenix [38] and Coot [39]. All 
structure figures were prepared by using PyMOL [40]. 
 
UPPS inhibition assays. E. coli UPPS and S. aureus UPPS inhibition assays were carried out as 
described previously [9]. Briefly, the condensation of FPP with IPP catalyzed by UPPS was 
monitored by using a continuous spectrophotometric assay [41] in 96 well plates with 200 µL 
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reaction mixtures containing 400 µM MESG, 350 µM IPP, 35 µM FPP, 25 mM Tris-HCl (pH 
7.5), 0.01% Triton X-100 and 1 mM MgCl2. The IC50 values were obtained by fitting the 
inhibition data to a standard rectangular hyperbolic dose-response function in GraphPad PRISM 
4.0 software (Graphpad Software, San Diego, CA). The IC50 values for the most active hits were 
verified by using a radiometric assay [42] with 2.5 µM FPP, 25 µM [14C] IPP and 0.01% Triton 
X-100. 
 
Computational aspects. Pharmacophore models were constructed in MOE [43] using the 
consensus pharmacophore module. The Glide [44-46] docking algorithm at the XP level [47] 
was used to perform all docking calculations with UPPS. X-ray structures were prepared with the 
protein preparation wizard [48] using standard parameters. Compounds were prepared with 
Ligprep [49] using standard parameters. For the calculation of the ROC/AUC curves, 112 E. coli 
UPPS inhibitors with IC50 < 100 µM were combined with the Schrödinger decoy library of 1000 
compounds (having an average molecular weight of 400 daltons) [44, 46].  Compounds from this 
combined library were ranked by their Glide XP docking scores and the AUC calculated. 
PCA was performed using the monomer that had the most ligands present or, if not 
applicable, the most residues resolved. An invariant “core” of Ca atoms [50] was first 
determined,  then structures were aligned with the core and PCA analysis performed using 
BIO3D [32]. The principal components plotted in Fig. 8B in the Text describe orthogonal 
eigenvectors with maximal variance. Hierarchical clustering was performed based on the 
Euclidian distance matrix of the first two principal components, then reduced to 3 groups of 
related “clusters” [51]. 
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Cell growth inhibition. The growth of S. aureus (USA300 strain) and determination of MIC 
values were as described previously [52]. E. coli growth and construction of isobolograms were 
also carried out basically as described previously [53]. 
 
In vivo experiments. Mice were infected intraperitoneally with 109 cfu MRSA (strain Sanger 
252) suspended in 4% hog gastric mucin. At 1 hr after infection, the mice were divided into 2 
groups (n = 10 per group) and treated intraperitoneally with either 17 (10 mg/kg) suspended in 
water or water alone (vehicle control). Treatment was continued once daily for 2 more 
days. Mortality was monitored twice daily. 
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2.6	   Tables	  and	  Figures	  
Table 2 . 1  Enzyme and cell growth inhibition results. 
 E.	  coli	  UPPS	   S.	  aureus	  UPPS	   E.	  coli	  	   S.	  aureus	  	  
 IC50	   IC50	   MIC90	   MIC90	  
ID (µM)	   (µM)	   (µg/mL)	   (µg/mL)	  
5	   0.30	   0.35	   >32	   >32	  
7	   0.56	   0.75	   >32	   >32	  
8	   150	   170	   >32	   N.D.	  
9	   35	   72	   >32	   N.D.	  
10	   3.2	   6.9	   16	   N.D.	  
11	   2.2	   1.7	   >32	   N.D.	  
12	   3.0	   0.49	   >32	   >32	  
13	   0.92	   2.5	   >32	   32	  
14	   1.9	   0.73	   >32	   0.50	  
15	   0.51	   2.0	   >32	   0.25	  
16	   4.8	   4.9	   8.0	   >32	  
17	   0.11	   0.11	   4.0	   0.25	  
18	   6.1	   1.4	   8.0	   >32	  
19	   1.4	   1.6	   >32	   1.0	  
 
36 
 
Table 2.2 Data collection and refinement statistics for E. coli UPPS.  
 
*Values in the parentheses are for the highest resolution shells. 
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Table 2 . 2 (cont.). 
*Values in the parentheses are for the highest resolution shells. 
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Table 2.3 SCORECONS [16] using E. coli UPPS as a target. Asp26 is the most 
essential residue and binds to Mg2+ in the active site. 
 
Ranking Residue No. 
SCORECONS 
Score 
Residue Alignment 
1	   26	   0.988	   D	   DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD	  
2	   30	   0.984	   R	   RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR	  
3	   28	   0.976	   N	   NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN	  
4	   74	   0.968	   N	   NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN	  
5	   20	   0.964	   H	   HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH	  
6*	   190	   0.960	   D	   DDDDDDDEDDDDEDDDDEDDDDDDDDDEDDDDDDDD	  
7	   77	   0.953	   R	   RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR	  
8	   204	   0.945	   F	   FFFFFFFFFFFFFFFFFFFFYFFFFFFFFFFFFFFFFFFFFFFFFFY	  
9	   145	   0.941	   Y	   YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY	  
10	   194	   0.937	   R	   RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR	  
11	   200	   0.933	   R	   RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR	  
12	   202	   0.925	   S	   SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS	  
13*	   18	   0.921	   C	   CPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPP	  
14	   71	   0.917	   S	   SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS	  
15	   32	   0.905	   A	   AAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAAAAAA	  
16	   207	   0.901	   W	   WWWWWWWWWWWWWWWWWWWWWWWW	  
17	   221	   0.897	   W	   WWWWWWWWWWWWWWWWWWWWWWWW	  
18	   81	   0.889	   E	   EEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE	  
19	   43	   0.881	   H	   HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH	  
20	   66	   0.874	   T	   TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTSTTTTTTTT	  
*Residues	  are	  different	  in	  E.	  coli	  UPPS	  and	  S.	  aureus	  UPPS.	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Table 2.4 Data collection and refinement statistics for S. aureus UPPS. 
 SaUPPS/FPP 
Crystals (4H8E) 
Data collection 
Space group P41212 
Unit cell dimension (Å)  
a, b, c (Å) 57.303, 57.303, 158.824 
X-ray source APS 21-ID-G 
Wavelength (Å) 0.97857 
Resolution (Å)* 50.00-1.30 (1.32-1.30) 
# of reflection observed 916,358 
Unique 66,126 (3,237) 
Completeness (%) 100.0 (100.0) 
R-merge 0.077 (0.400) 
I/σ(I) 33.9 (5.3) 
Multiplicity 13.9 (11.3) 
Refinement statistics 
Resolution range (Å) 32.64–1.30 
R-work/R-free (%) 17.4/19.4 
RMSD  
Bond lengths 0.032 
Bond angles 2.655 
No. of atoms  
Protein 1,918 
Ligand 30 
Occupancy of ligand 1.0 
B average (Å2): protein 13.11 
B average (Å2): ligand 11.70 
*Values in the parentheses are for the highest resolution shells. 
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Figure 2.1 Schematic outline of cell wall biosynthesis (in most bacteria) showing 
involvement of isoprenoid biosynthesis in the early stages of peptidoglycan formation. 
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Figure 2.2 Chemical structures of UPPS inhibitors and drug leads of interest. 
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Figure 2.3 Schematic illustration of hit-to-lead development. FPPS inhibitors obtained by in 
silico screening of the NCI diversity set II were screened against E. coli UPPS basically as 
described previously [9]: the most potent hit (~5 µM) was then used as a reference for a 
similarity search using Scifinder. 22 compounds suggested were obtained from the NIH 
Developmental Therapeutics Program. The most active lead was found to have ~110 nM IC50 
values against both E. coli UPPS and S. aureus UPPS.   
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Figure 2.4 X-Ray structures of E. coli UPPS showing substrate and inhibitor-binding sites. (a) 
FSPP (yellow) binds to site-1 (PDB ID code 1X06) and FPP (green) binds to sites 1, 4 (PDB ID 
code 1V7U). (b) A bisphosphonate (5) binds to sites 1-4 (PDB ID code 2E98). (c) Benzoic acid 
inhibitor 8 binds to site-3 (cyan, PDB ID code 3SGT), superimposed on FPP-bound structure 
(green, PDB ID code 1V7U). (d) Benzoic acid inhibitor 9 binds to sites 1-3 (cyan, PDB ID code 
3SGV), superimposed on FPP-bound structure (green, PDB ID code 1V7U). The large red 
numbers indicate sites 1-4. 
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Figure 2.5 Electron density maps (2Fo-Fc) for compounds investigated contoured at 1σ.  
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Figure 2.6 Electron density maps (simulated-annealing Fo-Fc OMIT) for compounds 
investigated contoured at 1σ.  
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Figure 2.7 Crystal structures of the more potent benzoic acids and a phosphonate inhibitor. 
(a) 10 (PDB ID code 3SGX). (b) 11 (PDB ID code 3HS0). (c) 12 (PDB ID code 4H2O). (d) 13 
(PDB ID code 4H38). In each case site-4 is occupied, together with either site 1, 2 or 3, 
indicating the likely importance of site-4 binding for good activity. The values shown are the 
IC50s for E. coli UPPS inhibition (Ec) or S. aureus UPPS inhibition (Sa). 
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Figure 2.8 Structures of inhibitors bound to E. coli UPPS. These sites typically are less 
highly occupied than those shown in the Text.  
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Figure 2.9 Crystal structures of diketo acids and two dicationic inhibitors bound to E. coli 
UPPS. (a) 14 (PDB ID code 4H3C). (b) 15 (PDB ID code 4H3A). (c) 16 (PDB ID code 4H2J). 
(d) 18 (PDB ID code 4H2M). The common feature in each case is binding to site-4. The values 
shown are the IC50s for E. coli UPPS inhibition (Ec) or S. aureus UPPS inhibition (Sa). 
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Figure 2.10 Glide XP docking result for 17 bound to E. coli UPPS showing binding to sites 2 
and 4. 
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Figure 2.11 Correlation between E. coli and S. aureus UPPS inhibition by the compounds listed in 
Table 2.1. 
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Figure 2.12 Superimposition of E. coli UPPS structure (green, PDB ID code 1X06) and S. aureus 
UPPS structure (cyan, PDB ID code 4H8E). The Cα root-mean square deviation is 0.91 Å over 202 
residues. 
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Figure 2.13 UPPS as a missing link: Models and cartoons. (a) Pharmacophore model for 
UPPS inhibition by benzoic acids. (b) Pharmacophore model for S aureus growth inhibition by 
benzoic acids. Common features are benzoic acid carboxylates (cyan) with electron-withdrawing 
meta substituents (red); an x-y spacer (dark pink); two aromatic features (orange) and more distal 
hydrophobic features (green). (c) Cationic-hydrophobic-cationic inhibitor binding to DNA. (d) 
Cationic-hydrophobic-cationic inhibitor binding to anionic lipids in a membrane. (e) Cationic-
hydrophobic-cationic inhibitor binding to a protein. 
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Figure 2.14 Structures of UPPS inhibitors used in pharm acophore modeling together with 
IC50 values (in S. aureus UPPS inhibition).   
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Figure 2.15 Structures of Larsen et al. [18] S. aureus benzoic acid growth inhibitors used to 
construct the pharmacophore model in Figure 2.13a, together with MIC values (in cell growth 
inhibition). 
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Figure 2.16 In vitro synergy and in vivo results with 17. (a) Isobologram for 17 + methicillin 
inhibition of S. aureus (USA300) cell growth. FICI = 0.37. (b) Activity of 17 in a mouse model 
of S. aureus (USA200) infection. Shown is one representative experiment repeated twice (n = 10 
mice per group per experiment).  No mice in the group treated once daily with 10 mg/kg of 17 (3 
doses total) died during either experiment. 
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Figure 2.17 Computational analysis of UPPS structural results. (a) FTMap computational 
solvent mapping of UPPS structures (PDB ID codes 2E98 and 3QAS) suggest that site 4 is 
druggable, in either inhibitor bound complexes, or unbound. UPPS is represented as a cartoon, 
small probes are colored spheres, black wireframe outlines site 4. (b) PCA of E. coli UPPS 
structures. Substrate-bound structures (yellow) are “closed” [54]; bisphosphonates (blue) are 
“open” [54]; the apo and non-bisphosphonate structures (red) are all “ajar”-slightly open. (c) 
ROC-AUC analysis of most predictive UPPS structures in terms of initial enrichment for actives 
under 100 µM (Figure 2.19). 
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Figure 2.18 Screening library used in ROC/AUC analysis. The IC50 values are for E. coli 
UPPS inhibition. 
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Figure 2.18 (cont.). 
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Figure 2.18 (cont.). 
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Figure 2.18 (cont.). 
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Figure 2.19 ROC/AUC analyses for compounds shown in Figure 2.19 based on the new 
crystal structures. 
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3.2	   Introduction	  
 
 There is currently an urgent need for new types of anti-bacterials exhibiting novel modes 
of action, due to the rapid rise in drug resistance [1], and isoprenoid biosynthesis [2, 3] is one 
attractive target. For example, cell wall biosynthesis can be inhibited by targeting farnesyl 
diphosphate synthase (FPPS) or undecaprenyl diphosphate synthase (UPPS), involved in lipid I 
biosynthesis (Figure 3.1). In addition, in S. aureus, formation of the virulence factor 
staphyloxanthin [4] can be blocked by inhibiting dehydrosqualene synthase (CrtM), resulting in a 
lowering of the anti-oxidant shield to host derived ROS [5] (Figure 3.1). The bisphosphonate 
class of drugs such as zoledronate (1, Scheme 3.1) are potent, low nM inhibitors of FPPS, but 1 
has little antibacterial activity (due presumably to lack of cell penetration), although more 
lipophilic bisphosphonates such as 2 (BPH-210, Scheme 1) have modest activity (IC50 ~30 µM) 
against E. coli [6]. More lipophilic bisphosphonates also potently target UPPS [7], as well as 
CrtM [5], but again they have essentially no activity in bacteria. Replacing one phosphonate 
group by a sulfonate to form a phosphonosulfonate results, however, in potent CrtM inhibitors 
(e.g. 3, BPH-652, Scheme 1, IC50 ~ 7.9 µM, Ki ~ 80 nM) that also blocks carotenoid pigment 
formation in cells (IC50 ~110 nM) [8]. In addition, there has recently been interest in developing 
phosphorus-free prenyl transferase inhibitors, which might have even more drug-like properties. 
For example, Jahnke et al. reported a series of FPPS inhibitors, dicarboxylic acids, that bound to 
a novel, allosteric site [9]. In addition, other species such as tetramic acid UPPS inhibitors have 
been described (e.g. 4, Scheme 4.1) [10], but to date their x-ray structures have not been 
reported, although an allosteric model has been proposed [11]. 
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Scheme 3.1 Chemical Structures of Selected Compounds and the Inhibition of CrtM, E. 
coli UPPS, and S. aureus UPPS by 7–9, 41, 42, 44, and 45. 
 
3.3	   Results	  and	  Discussions	  
 A key component of the active site of most prenyl transferases is a Mg2+/Asp motif that 
interacts with a substrate’s diphosphate group. We reasoned that HIV-1 integrase (IN) inhibitors 
[12] might provide clues for new prenyl transferase inhibitors, since IN contains a similar 
Asp/Mg2+ motif [13] and IN inhibitors such as 5 (L-708,906, Scheme 1) [14] and 6 (Elvitegravir, 
Scheme 1) [15], diketo-acids and  keto-acids, respectively, are thought to bind at or near the 
Mg2+/Asp motif in the IN active site [16, 17]. We thus made a small screening library (38 
compounds) of IN inhibitor-inspired molecules and their structures and inhibition of S. aureus 
CrtM, E. coli UPPS and S. aureus UPPS are shown in Figure 3.2. Most compounds were amide-
diketo acids (7-40, class I, Figure 3.2) and were conveniently prepared from the synthon (Z)-2,2-
dimethyl-5-carboxymethylene-1,3-dioxolan-4-one [18] by amine coupling. Among these 
compounds, 7 (Scheme 1) inhibited CrtM with IC50 ~24 µM, Ki ~ 250 nM (for comparison, Ki of 
3 ~ 70 nM [8]), and blocked staphyloxanthin pigment formation (IC50 = 4 µM). Inhibitors of 
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Class II were keto-acids, dihydropyridone-3-carboxylates, and were based on 6 (Elvitegravir) 
and dihydroquinoline-3-carboxylic acid IN inhibitors [19], which again are thought to bind via 
their carboxyl and carbonyl oxygens to Mg2+/Asp [20]. We made two analogs, 41, 42 (Scheme 
1), with alkoxy-aryl tails to mimic the substrate FPP. The longer-chain species 42 had no 
activity, but the shorter chain species 41 had a CrtM IC50= 45 µM, Ki = 450 nM and a loss of 
pigmentation IC50 of 33 µM.  
 To see how these inhibitors bound to CrtM, we carried out co-crystallization and soaking 
experiments with 7 (Class I) and 41 (Class II) and obtained crystals (by soaking) that diffracted 
to 2.3 Å and 1.9Å, respectively. Full x-ray crystallographic data and structure refinement details 
are given in Table 4.1. Electron density results for 7 are shown in Figure 3.3a and indicate the 
presence of 7 in addition to one molecule of farnesyl monophosphate (FMP) that co-purified 
with the protein. The identity of FMP was further confirmed by LC-MS (Figure 3.4) and the 
electron density results (Figure 3.3a). The diphenyl ether fragment in 7 (cyan) binds into the 
CrtM S1 site [21], and is shown in Figure 3.3b superimposed on one of the S-thiolo-farnesyl 
diphosphate (FSPP) inhibitors (in yellow, green) whose structures were reported previously [5]. 
This binding mode is similar to that seen with the phosphonosulfonate 3 (Figure 3.3c), with the 
diketo-acid head-group interacting with two of the three Mg2+ (Mg2+B,C) seen in the CrtM-FSPP 
structure (Figure 3.3d). The farnesyl side-chain in FMP bound to the S2 site and had a 0.8 Å 
rmsd from the S2 FSPP reported previously [5]. With 41, the ligand electron density is again 
well defined (Figure 3.5a), and the crystallographic results show the side-chain binds in S2, 
similar to the farnesyl side-chain in the FSPP structures (Figure 3.5b), as well as the 
phosphonoacetamide analog of 7 (43, BPH-830 [22], Figure 3.5c). There are 3 Mg2+ in the x-ray 
structure. However, these are not the Mg2+ABC seen in most prenyl transferases [23] but rather, 
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Mg2+BCD. That is, there is a new Mg2+ binding site, Mg2+D. The dihydropyridone side-chain 
interacts with Mg2+CD but surprisingly, via the two ring oxygens, not the carboxylate (Figure 
3.5d), which interacts with two water molecules (Figure 3.6). These inhibition and structural 
results for 7 and 41 clearly support the Mg2+ binding hypothesis, at least for CrtM.  
 CrtM is a so-called head-to-head prenyl transferase so we next sought to see if any of the 
molecules synthesized might also inhibit the head-to-tail prenyl transferase FPPS, or the cis-
prenyl transferase, UPPS. There was no activity against FPPS (probably due to the lack of a 
positively charged feature that mimics the carbocation involved in FPP biosynthesis) but most of 
the amide-diketo acids (Class I) were potent UPPS inhibitors with the most active one (8) having 
an IC50 ~ 240 nM and Ki ~ 120 nM, comparable to the most active bisphosphonate UPPS 
inhibitor BPH-629 (IC50 ~ 300 nM for E. coli UPPS) [7]. There are four different ligand-binding 
sites in UPPS (designated 1-4 in Ref [7]) found with bisphosphonate inhibitors. This is not 
unexpected since the UPPS product, undecaprenyl diphosphate (UPP) contains 55-carbon atoms 
and is thus much larger than the (C15) FPP substrate. In principle, then, novel inhibitors might 
occupy multiple binding sites.      
 Co-crystallization of E. coli UPPS with 9 (IC50 = 560 nM) produced well-formed crystals 
with E. coli UPPS, and the electron density was well resolved (Figure 3.7a). As can be seen in 
Figure 3.7b, 9 binds to site 1 [7], the FPP binding site and, as can be seen in Figure 3.7c, 9 (in 
cyan) closely maps the FPP backbone structure (in yellow) with the diketo-acid fragment being 
located close to two of the three most essential residues in UPPS, D26 and N28 (Figure 3.7d). 
We found no evidence for the presence of Mg2+, but this observation is not entirely unexpected 
since even with the 5 E. coli UPPS x-ray structures with strong Mg2+ chelators – 
bisphosphonates (PDB ID codes 2E98, 2E99, 2E9A, 2E9C, 2E9D) [7], Mg2+ was not observed.  
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 The amide-diketo acids were not growth suppressive towards S. aureus or E. coli, 
perhaps due to the instability of the amide bond inside the cells, or a lack of cell permeability. 
However, 44 and 45 (aryldiketo acids, Class III), had good activity against S. aureus UPPS (44, 
IC50= 0.73 µM, Ki = 230 nM; 45, IC50= 2.0 µM, Ki = 670 nM) and both were active against the 
USA300 (MRSA) strain of S. aureus with MIC90 values of 500 ng/mL (44) and 250-500 ng/mL 
(45). There was no appreciable activity against the Gram-negative E. coli, however, there was 
promising activity against other Gram-positives: ~500 ng/mL against Bacillus anthracis str. 
Sterne, ~4 µg/mL against Listeria monocytogenes and Enterococcus faecium U503, and ~1 
µg/mL for Streptococcus pyogenes M1. In addition, we found low toxicity against a human cell 
line (MCF-7; IC50 ~30 µM), consistent with poor FPPS inhibition. 
	  
3.4	   Conclusions	  
 These results are important for several reasons. First, we tested the hypothesis that keto- 
and diketo-acids might inhibit prenyl transferase enzymes, based on the presence of Mg2+/Asp 
motifs in their active sites – an “integrase inhibitor-inspired” approach. The best CrtM inhibitors 
had Ki ~ 250 nM and were active in blocking staphyloxanthin biosynthesis in S. aureus, and we 
solved two structures of lead compounds bound to CrtM. In both, the inhibitor head-groups 
bound to Mg2+, while the side-chains bound to one or the other of the two FPP side-chain 
binding sites. Second, we tested this small library for FPPS and UPPS inhibition. There was no 
FPPS inhibition, but the most potent UPPS inhibitor had an IC50 = 240 nM, and we determined 
the structure of one such lead bound to E. coli UPPS – the first UPPS x-ray structure reported for 
a non-bisphosphonate inhibitor. We also found low toxicity and promising activity against a 
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subset of Gram-positive bacteria with MIC90 values as low as 250-500 ng/mL against USA300 S. 
aureus and 500 ng/mL against Bacillus anthracis str. Sterne, and low activity against E. coli and 
a human cell line. Overall, these results indicate that integrase-inspired inhibitors may be 
engineered into drug leads that target isoprenoid biosynthesis. 
 
3.5	   Materials	  and	  Methods	  
Enzyme expression and purification. S. aureus CrtM was expressed and purified as described 
previously [8, 21]. Expression and purification of E. coli UPPS and S. aureus UPPS were also 
carried out as described previously [24, 25]. 
 
CrtM inhibition. The S. aureus CrtM inhibition assay was carried out as described in our 
previous work [21]. 
 
UPPS inhibition. The E. coli UPPS and S. aureus UPPS inhibition assays were carried out as 
described [24, 25]. 
 
X-ray crystallography. Native CrtM crystals (space group P3221) were grown by using the 
hanging-drop method by mixing equal amounts of reservoir with 0.2-1.0 M potassium sodium 
tartrate, at room temperature. Inhibitor bound crystals were obtained by either soaking the native 
crystals with 1 mM ligand for 1-4 hours, or incubating protein-ligand (1 mM) mixtures at RT for 
1-4 hours, then adding the reservoir solution. All CrtM crystals belonged to the P3221 space 
group and had similar lattice parameters.  
 Native E. coli UPPS crystals for soaking were obtained by using the hanging-drop 
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method (Hampton Research, Laguna Niguel, CA) by mixing 1 µL of UPPS protein solution (14 
mg/ml UPPS in 50 mM HEPES, pH 7.5) with 1 µL of mother liquor (50 mM HEPES, pH 7.5, 
5% PEG 2-4K) and then equilibrating with 500 µL mother liquor at room temperature. Crystals 
grew to 0.3×0.3×0.2 mm in 2 days and were then soaked in a cryoprotectant solution (50 mM 
HEPES, pH 7.5, 30% EG 5% PEG 35K) containing 2.5-5 mM inhibitor for 1 day.  
 Diffraction data were collected at sector 21 of the Advanced Photon Source, Argonne 
National Laboratory. The data were indexed, integrated and scaled by using the HKL2000 
program package [26]. Structures were determined by molecular replacement with the Phaser 
program [27], using apo CrtM (PDB ID 2ZCP, minus ligands) as a template. The structure of the 
UPPS-complex was determined by using a model prepared from the UPPS/BPH-629 complex 
structure (PDB ID 2E98) with ligands and solvent removed. Further model building, ligand 
preparation, and refinement employed Coot [28], ProDRG server [29], and Refmac in CCP4 [30, 
31], respectively. All figures were prepared using PyMol (http://www.pymol.org). 
 
Cell growth inhibition. The growth of S. aureus (USA300 strain) and determination of MIC 
were as described previously [32]. 
 
Synthesis of library compounds. All reagents used were purchased from Aldrich or Alfa Aesar. 
The purity of all compounds was routinely monitored by using 1H NMR spectroscopy on Varian 
(Palo Alto, CA) Unity spectrometers and by micro-chemical analysis or HRMS.  
 
General procedure for the synthesis of Class I compounds. To a solution of the appropriate 
amine (0.5 mmol) in dry CH2Cl2 (2 mL) was added dry triethylamine (1 mmol) and (Z)-2-(2,2-
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dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl chloride at 0 oC. The mixture was stirred for 3 h 
and then washed with water (4 mL). The organic layer was dried over Na2SO4, concentrated and 
subjected to flash chromatography affording the ester, which upon saponification (NaOH, 4 
equivalents; 4:1 THF/H2O, 10 mL) and acidification gave the final product ~ 60% overall yield. 
 
 
(Z)-2-hydroxy-4-oxo-4-((3-(3-phenoxyphenyl)propyl)amino)but-2-enoic acid (7). 1H NMR 
(400 MHz, DMSO-d6) δ 7.34-6.73 (m, 9H), 3.24 (s, 2H), 2.98 (m, 2H), 2.53 (m, 2H), 1.63 (m, 
2H). HRMS [M + H]+ calcd. for C19H20NO5 342.1341, found 342.1348. 
 
(Z)-4-((3-([1,1'-biphenyl]-3-yl)propyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (8). 1H NMR 
(400 MHz, CDCl3) δ 7.58 (d, J = 5.6 Hz, 2H), 7.45-7.33 (m, 6H), 7.17 (d, J = 6.0 Hz, 1H), 5.93 
(s, 1H), 5.74 (broad, 1H), 3.40 (dd, J = 5.2, 10.8Hz, 2H), 2.74 (t, J = 6.4 Hz, 2H), 1.95 (t, J = 
6.0 Hz, 2H). Anal. Calcd. for C19H19NO4: C, 70.14; H, 5.89; N, 4.31. Found: C, 69.76; H, 5.83; 
N, 4.40. 
 
(Z)-4-((3-(3-(hexyloxy)phenyl)propyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (9). 1H NMR 
(400 MHz, CDCl3) δ 7.18 (m, 1H), 6.72 (m, 3H), 5.89 (s, 1H), 5.65 (s, 1H), 3.92 (t, J = 6.4 Hz, 
2H), 3.36 (m, 2H), 2.63 (m, 2H), 1.88 (m, 2H), 1.75 (m, 2H), 1.43 (m, 2H), 1.32 (m, 4H), 0.88 (t, 
J = 6.4 Hz, 3H). HRMS [M + H]+ calcd. for C19H28NO5 350.1967, found 350.1970. 
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(Z)-4-(dodecylamino)-2-hydroxy-4-oxobut-2-enoic acid (10). 1H NMR (400 MHz, CDCl3) δ 
6.16 (broad, 1H), 5.90 (s, 1H), 3.27 (m, 2H), 1.49 (m, 2H), 1.21 (m, 18H), 0.84 (t, J = 6.8 Hz, 
3H). HRMS [M + H]+ calcd. for C16H30NO4 300.2175, found 300.2172. 
 
(Z)-2-hydroxy-4-oxo-4-((3-phenylpropyl)amino)but-2-enoic acid (11). 1H NMR (400 MHz, 
DMSO-d6) δ 8.54 (t, J = 5.6 Hz, 1H), 7.27-7.13 (m, 5H), 5.95 (s, 1H), 3.12 (dd, J = 6.4, 12.8 
Hz, 2H), 2.56 (t, J = 8.0 Hz, 2H), 1.71 (m, 2H). Anal. Calcd. for C13H15NO4: C, 62.64; H, 6.07; 
N, 5.62. Found: C, 62.61; H, 5.99; N, 5.65. 
 
(Z)-2-hydroxy-4-((3-(naphthalen-2-yl)propyl)amino)-4-oxobut-2-enoic acid (12). 1H NMR 
(400 MHz, DMSO-d6) δ 8.58 (broad, 1H), 7.80 (m, 3H), 7.68 (s, 1H), 7.46-7.36 (m, 3H), 5.96 (s, 
1H), 3.18 (dd, J = 6.8, 12.8 Hz, 2H), 2.74 (t, J = 7.6 Hz, 2H), 1.82 (m, 2H).  HRMS [M + H]+ 
calcd. for C17H18NO4 300.1236, found 300.1231. 
 
(Z)-4-((3-([1,1'-biphenyl]-4-yl)propyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (13). 1H 
NMR (400 MHz, DMSO-d6) δ  8.56 (t, J = 6.0 Hz, 1H), 7.61 (d, J = 8.0 Hz, 2H), 7.55 (d, J = 
8.0 Hz, 2H), 7.41 (t, J = 6.8 Hz, 2H), 7.31 (m, 3H), 5.96 (s, 1H), 3.16 (dd, J = 6.0, 12.8 Hz, 2H), 
2.61 (t, J = 7.2 Hz, 2H), 1.76 (m, 2H). Anal. Calcd. for C19H19NO4: C, 70.14; H, 5.89; N, 4.31. 
Found: C, 69.80; H, 5.74; N, 4.44. 
 
(Z)-4-((3-(3-(benzyloxy)phenyl)propyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (14). 1H 
NMR (400 MHz, DMSO-d6) 7.40-7.28 (m, 5H), 7.11 (m, 1H), 6.84-6.75 (m, 3H), 5.03 (s, 2H), 
3.32 (s, 2H), 2.99 (m, 2H), 2.51 (m, 2H), 1.64 (m, 2H). HRMS [M + H]+ calcd. for C20H22NO5 
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356.1498, found 356.1494. 
 
(Z)-2-hydroxy-4-oxo-4-(quinolin-2-ylamino)but-2-enoic acid (15). 1H NMR (400 MHz, D2O) 
δ 7.99 (d, J = 9.2 Hz, 1H), 7.69 (d, J= 8.8 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.55-7.47 (m, 2H), 
7.26 (t, J = 7.2 Hz, 1H). HRMS [M + H]+ calcd. for C13H11N2O4 259.0719, found 259.0724. 
 
(Z)-4-((3-(3-(decyloxy)phenyl)propyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (16). 1H 
NMR (400 MHz, CDCl3) δ 7.19 (m, 1H), 6.72 (m, 3H), 5.90 (s, 1H), 5.62 (broad, 1H), 3.91 (t, J 
= 6.8 Hz, 2H), 3.75 (m, 2H), 2.63 (m, 2H), 1.88 (m, 2H), 1.75 (m, 2H), 1.82-1.25 (m, 14H), 0.86 
(t, J = 6.8 Hz, 3H). Anal. Calcd. for C23H35NO5: C, 68.12; H, 8.70; N, 3.45. Found: C, 67.98; H, 
8.98; N, 3.70. 
 
(Z)-4-((9-ethyl-9H-carbazol-3-yl)amino)-2-hydroxy-4-oxobut-2-enoic acid (17). 1H NMR 
(400 MHz, D2O) δ 8.02 (s, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.38-7.28 (m, 4H), 7.07 (t, J = 6.8 Hz, 
1H), 4.18 (dd, J = 7.2, 14.4 Hz, 2H), 1.13 (t, J = 7.2 Hz, 3H). HRMS [M + H]+ calcd. for 
C18H17N2O4 325.1188, found 325.1195. 
 
(Z)-4-((3-(decyloxy)benzyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (18). 1H NMR (400 
MHz, CD3Cl) δ 7.22 (m, 1H), 6.79 (m, 3H), 6.06 (s, 1H), 4.45 (d, J = 5.2 Hz, 2H), 3.90 (m, 2H), 
1.73 (m, 2H), 1.41-1.19 (m, 14H), 0.85 (t, J = 6.8 Hz, 3H). HRMS [M + H]+ calcd. for 
C21H32NO5 378.2280, found 378.2275. 
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(Z)-4-([1,1'-biphenyl]-3-ylamino)-2-hydroxy-4-oxobut-2-enoic acid (19). 1H NMR (400 MHz, 
CDCl3) δ  9.26 (s, 1H), 7.84 (s, 1H), 7.54-7.53 (m, 4H), 7.40-7.28 (m, 5H), 6.22 (s, 1H). HRMS 
[M + H]+ calcd. for C16H14NO4 284.0923, found 284.0923. 
 
(Z)-2-hydroxy-4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)-4-oxobut-2-enoic acid (20). 1H 
NMR (400 MHz, DMSO-d6) δ 9.20 (broad, 2H), 8.06-7.97 (m, 3H), 7.65-7.55 (m, 4H), 7.02 (s, 
1H). HRMS [M + H]+ calcd. for C17H13N2O4S 341.0596, found 341.0598. 
 
(Z)-4-(4-benzhydrylpiperazin-1-yl)-2-hydroxy-4-oxobut-2-enoic acid (21). 1H NMR (400 
MHz, D2O) δ 7.32 (d, J = 6.0 Hz, 4H), 7.20 (t, J = 5.6 Hz, 4H), 7.11 (t, J = 5.6 Hz, 2H), 3.42 
(m, 2H), 3.28 (m, 2H), 2.29 (m, 4H). HRMS [M + H]+ calcd. for C21H23N2O4 367.1658, found 
367.1667. 
 
(Z)-4-(((E)-3,7-dimethylocta-2,6-dien-1-yl)amino)-2-hydroxy-4-oxobut-2-enoic acid (22). 1H 
NMR (400 MHz, CDCl3) δ5.95 (s, 1H), 5.64 (broad, 1H), 5.17 (m, 1H), 5.04 (m, 1H), 3.92 (t, J 
= 6.0 Hz, 2H), 2.06 (m, 4H), 1.67 (s, 6H), 1.58 (s, 3H). HRMS [M + H]+ calcd. for C14H22NO4 
268.1549, found 268.1540. 
 
(Z)-4-((3-(hexyloxy)benzyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (23). 1H NMR (400 
MHz, DMSO-d6) δ 8.92 (t, J = 5.6 Hz, 1H), 7.20 (m, 1H), 6.78 (m, 3H), 5.99 (s, 1H), 4.30 (d, J 
= 6.0 Hz, 2H), 3.89 (m, 2H), 1.65 (t, J = 8.0 Hz, 2H), 1.35-1.25 (m, 6H), 0.83 (t, J = 6.8 Hz, 
3H). HRMS [M + H]+ calcd. for C17H24NO5 322.1654, found 322.1658. 
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(Z)-4-((3-(3-(3,4-dichlorophenoxy)phenyl)propyl)amino)-2-hydroxy-4-oxobut-2-enoic acid 
(24). 1H NMR (400 MHz, CDCl3) δ 7.35-7.2 (m, 2H), 7.02-6.78 (m, 5H), 5.92 (broad, 1H), 5.90 
(s, 1H), 3.36 (m, 2H), 2.62 (m, 2H), 1.83 (m, 2H). HRMS [M + H]+ calcd. for C19H18Cl2NO5 
410.0562, found 410.0563. 
 
(Z)-2-hydroxy-4-oxo-4-((3-(4-phenoxyphenyl)propyl)amino)but-2-enoic acid (25). 
1H NMR (400 MHz, DMSO-d6) δ 8.56 (t, J = 4.4 Hz, 1H), 7.35 (m, 2H), 7.20 (d, J = 7.2 Hz, 
2H), 7.09 (t, J = 6.0 Hz, 1H), 6.95 (d, J = 6.4 Hz, 2H), 6.91 (d, J = 7.2 Hz, 2H), 5.97 (s, 1H), 
3.16 (dd, J = 5.6, 10.4 Hz, 2H), 2.57 (t, J = 7.8 Hz, 2H), 1.73 (m, 2H). HRMS [M + H]+ calcd. 
for C19H20NO5 342.1341, found 342.1338. 
 
(Z)-2-hydroxy-4-oxo-4-((3-(3-(p-tolyloxy)phenyl)propyl)amino)but-2-enoic acid (26). 
1H NMR (400 MHz, CDCl3) δ 7.24 (t, J = 6.0 Hz, 1H), 7.14 (d, J = 6.8 Hz, 2H), 6.91 (d, J = 6.8 
Hz, 2H), 6.88 (m, 1H), 6.81 (s, 2H), 5.95 (s, 1H), 5.73 (broad, 1H), 3.38 (m, 2H), 2.64 (t, J = 6.0 
Hz, 2H), 2.34 (s, 3H), 1.90 (m, 2H). ). HRMS [M + H]+ calcd. for C20H22NO5 356.1498, found 
356.1494. 
 
(Z)-4-((3-(9-ethyl-9H-carbazol-3-yl)propyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (27). 
1H NMR (400 MHz, DMSO-d6) δ 8.58 (t, J = 5.2 Hz, 1H), 8.06 (d, J = 7.6 Hz, 1H), 7.93 (s, 
1H), 7.52 (d, J = 8.4 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.27 (d, J = 8.4 
Hz, 1H), 7.12 (t, J = 7.2 Hz, 1H), 5.97 (s, 2H), 4.36 (d, J = 7.2 Hz, 2H), 3.18 (m, 2H), 2.73 (t, J 
= 7.2 Hz, 2H), 1.81 (t, J = 7.2 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H). HRMS [M + H]+ calcd. for 
C21H23N2O4 367.1658, found 367.1660. 
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(Z)-2-hydroxy-4-((3-(3-((4-nitrobenzyl)oxy)phenyl)propyl)amino)-4-oxobut-2-enoic acid 
(28). 1H NMR (400 MHz, DMSO-d6) δ 8.53 (t, J = 7.6 Hz, 1H), 8.22 (d, J = 8.4 Hz, 2H), 7.68 
(d, J = 8.4 Hz, 2H), 7.16 (dd, J = 3.6, 8.0 Hz, 1H), 6.86-6.77 (m, 2H), 5.94 (s, 1H), 5.22 (s, 2H), 
3.15-3.08 (m, 2H), 2.52 (dd, J = 7.2, 14.8 Hz, 2H), 1.72-1.63 (m, 2H). HRMS [M + H]+ calcd. 
for C20H21N2O7 401.1349, found 401.1346. 
 
(Z)-4-((3-(3-((2,5-dichlorobenzyl)oxy)phenyl)propyl)amino)-2-hydroxy-4-oxobut-2-enoic 
acid (29). 1H NMR (400 MHz, DMSO-d6) δ 8.52 (s, 1H), 7.52 (s, 1H), 7.53-7.47 (m, 3H), 7.38 
(s, 1H), 7.18-7.15 (m, 1H), 6.84-6.77 (m, 2H), 5.94 (s, 1H), 5.07 (s, 2H), 3.14-3.09 (m, 2H), 2.52 
(dd, J = 6.8, 14.0 Hz, 2H), 1.70 (t, J = 6.4 Hz, 2H). HRMS [M + H]+ calcd. for C20H20Cl2NO5 
424.0719, found 424.0723. 
 
(Z)-4-((3-(3-((3,5-dichlorobenzyl)oxy)phenyl)propyl)amino)-2-hydroxy-4-oxobut-2-enoic 
acid (30). 1H NMR (400 MHz, DMSO-d6) δ 8.52 (s, 1H), 7.52 (s, 1H), 7.53-7.47 (m, 3H), 7.38 
(s, 1H), 7.18-7.15 (m, 1H), 6.84-6.77 (m, 2H), 5.94 (s, 1H), 5.07 (s, 2H), 3.14-3.09 (m, 2H), 2.52 
(dd, J = 6.8, 14.0 Hz, 2H), 1.70 (t, J = 6.4 Hz, 2H). HRMS [M + H]+ calcd. for C20H20Cl2NO5 
424.0719, found 424.0723. 
 
(Z)-4-((3-butoxybenzyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (31). 1H NMR (400 MHz, 
DMSO-d6) δ 8.90 (broad, 1H), 7.18 (m, 1H), 6.76 (m, 3H), 6.00 (s, 1H), 4.28 (d, J = 6.0 Hz, 
2H), 3.85 (m, 2H), 1.62 (m, 2H), 1.38 (m, 2H), 0.82 (t, J = 6.8 Hz, 3H). HRMS [M + H]+ calcd. 
for C15H20NO5 294.1341, found 294.1345. 
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(Z)-2-hydroxy-4-((3-(octyloxy)benzyl)amino)-4-oxobut-2-enoic acid (32). 1H NMR (400 
MHz, DMSO-d6) δ 7.15 (m, 1H), 6.76 (m, 3H), 4.22 (d, J = 6.0 Hz, 2H), 3.91 (m, 2H), 3.42 (s, 
2H), 1.66 (m, 2H), 1.34-1.23 (m, 10H). 0.83 (t, J = 6.4 Hz, 3H). HRMS [M + H]+ calcd. for 
C19H28NO5 350.1967, found 350.1975. 
 
(Z)-4-((3-((2,5-dichlorobenzyl)oxy)benzyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (33). 1H 
NMR (400 MHz, DMSO-d6) δ 13.50(broad, 1H), 8.98 (s, 1H), 7.63-7.24 (m, 4H), 6.88 (m, 3H), 
6.00 (s, 1H), 5.10 (s, 2H), 4.34 (d, J = 5.6 Hz, 2H). HRMS [M + H]+ calcd. for C18H16 Cl2NO5 
396.0406, found 396.0413. 
 
(Z)-2-hydroxy-4-oxo-4-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)amino)but-2-
enoic acid (34). 1H NMR (400 MHz, CDCl3) δ 6.38 (broad, 1H), 5.94 (s, 1H), 5.18 (dd, J = 7.2, 
14.8 Hz, 1H), 5.06 (t, J = 6.4 Hz, 2H), 3.90 (m, 2H), 2.10-1.95 (m, 8H), 1.65 (s, 6H), 1.57 (s, 
6H). HRMS [M + H]+ calcd. for C19H30NO4 336.2175, found 336.2170. 
 
(Z)-4-((4-(benzyloxy)benzyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (35). 1H NMR (400 
MHz, DMSO-d6) δ 8.91 (s, 1H), 7.41-7.28 (m, 5H), 7.17 (d, J = 8.0 Hz, 2H), 6.94 (d, J = 8.4 
Hz, 2H), 5.98 (s, 1H), 5.06 (s, 2H), 4.26 (d, J = 5.6 Hz, 2H). HRMS [M + H]+ calcd. for 
C18H18NO5 328.1185, found 328.1181. 
 
(Z)-4-((4-(benzyloxy)phenyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (36). 1H NMR (400 
MHz, DMSO-d6) δ 7.43-7.07 (m, 8H), 6.75 (dd, J = 1.6, 8.4 Hz, 1H), 6.15 (s, 1H), 5.05 (s, 2H).  
HRMS [M + H]+ calcd. for C17H16NO5 314.1028, found 314.1030.
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(Z)-4-((3-(benzyloxy)benzyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (37). 1H NMR (400 
MHz, DMSO-d6) δ 7.42-7.27 (m, 5H), 7.20 (m, 1H), 6.92-6.80 (m, 3H), 6.00 (s, 1H), 5.05 (s, 
2H), 4.31 (d, J = 5.6 Hz, 2H). HRMS [M + H]+ calcd. for C18H18NO5 328.1185, found 328.1182. 
 
(Z)-2-hydroxy-4-oxo-4-(3-oxo-4-(3-phenoxybenzyl)piperazin-1-yl)but-2-enoic acid (38). 1H 
NMR (400 MHz, DMSO-d6) δ 7.38-7.30 (m, 3H), 7.11 (t, J = 7.2 Hz, 1H), 6.98 (s, 2H), 6.97 (s, 
1H), 6.89-6.84 (m, 2H), 4.50 (s, 2H), 4.13 (s, 1H), 4.04 (s, 1H), 3.63 (t, J = 4.2 Hz, 2H), 3.44 (d, 
J = 3.2 Hz, 2H), 3.19 (m, 2H). HRMS [M + H]+ calcd. for C21H21N2O6 397.1400, found 
397.1408. 
 
(Z)-2-hydroxy-4-oxo-4-(propylamino)but-2-enoic acid (39). 1H NMR (400 MHz, CDCl3) δ 
5.96 (s, 1H), 5.63 (broad, 1H), 3.31 (m, 2H), 1.58 (m, 2H), 0.94 (m, 3H). HRMS [M + H]+ calcd. 
for C7H12NO4 174.0766, found 174.0768. 
 
(Z)-4-(dodecyl(methyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (40). 1H NMR (400 MHz, 
CDCl3) δ 6.28 (s, 1H), 3.45 (m, 2H), 3.03 (m, 3H), 1.59 (m, 2H), 1.26 (m, 18H), 0.88 (t, J = 6.8 
Hz, 3H). HRMS [M + H]+ calcd. for C17H32NO4  314.2331, found  314.2327. 
 
41 and 42 were prepared using a similar protocol [33] starting from 2H-1,3-oxazine-2,6(3H)-
dione. 
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1-(3-(hexyloxy)benzyl)-1,2-dihydro-4-hydroxy-2-oxopyridine-3-carboxylic acid (41). 1H 
NMR (400 MHz, D2O) δ 7.11 (t, J = 8 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.68 (d, J = 8.4 Hz, 
1H), 6.61 (s, 1H), 6.59 (s, 1H), 5.68 (d, J = 7.8 Hz, 1H), 4.79 (s, 2H), 3.82 (t, J = 6.8 Hz, 2H), 
1.68-1.49 (m, 2H), 1.18-1.06 (m, 6H), 0.63 (t, J = 6.8 Hz, 3H). HRMS [M + H]+ calcd. for 
C17H32NO5  314.2331, found  314.2327. HRMS [M + H]+ calcd. for C19H24NO5  346.1654, found  
346.1649. 
 
1-(3-(decyloxy)benzyl)-1,2-dihydro-4-hydroxy-2-oxopyridine-3-carboxylic acid (42). 1H 
NMR (400 MHz, D2O) δ 7.13 (t, J = 8 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 8.4 Hz, 
1H), 6.61 (s, 1H), 6.59 (s, 1H), 5.71 (d, J = 7.8 Hz, 1H), 4.67 (s, 2H), 3.8 (t, J = 6.8 Hz, 2H), 
1.66-1.51 (m, 2H), 1.18-1.06 (m, 14H), 0.60 (t, J = 6.8 Hz, 3H). HRMS [M + H]+ calcd. for 
C23H31NO5  401.2202, found  401.2205. 
 
44, 45 were prepared according to reported procedures [34]. 
 
(Z)-4-(3-(decyloxy)phenyl)-2-hydroxy-4-oxobut-2-enoic acid (44). 1H NMR (400 MHz, 
CDCl3) δ7.58 (d, J = 6.4 Hz, 1H), 7.50 (s, 1H), 7.41 (t, J = 6.4 Hz, 1H), 7.16 (m, 2H), 4.02 (t, J = 
4.2 Hz, 2H), 1.80 (m, 2H), 1.50-1.28 (m, 14H), 0.88 (t, J = 6.0 Hz, 3H). HRMS [M + H]+ calcd. 
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for C20H29O5 349.2015, found 349.2017. 
 
(Z)-2-hydroxy-4-(4-(octyloxy)phenyl)-4-oxobut-2-enoic acid (45). 1H NMR (400 MHz, 
CDCl3) δ7.96 (d, J = 8.8 Hz, 2H), 7.07 (s, 1H), 6.95 (d, J = 8.8 Hz, 2H), 4.02 (t, J = 6.4 Hz, 2H), 
1.79 (m, 2H), 1.44 (m, 2H), 1.29 (m, 10H), 0.86 (t, J = 7.2 Hz, 3H). HRMS [M + H]+ calcd. for 
C18H25O5 321.1702, found 321.1701. 
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3.6	   Tables	  and	  Figures	  
Table 3.1 Data collection and refinement statistics of CrtM-inhibitor and UPPS-inhibitor 
complexes. 
 
Crystal 
PDB ID code # 
      7 
(Soaking) 
(3P00) 
     41    
(Soaking) 
(3PAI) 
    9 
(Soaking) 
(3TH8) 
Radiation source APS 21-ID-F APS 21-ID-G APS 21-ID-F 
Wavelength (Å) 0. 97857 0.97857 0.97872 
Space group P3221 P3221 P212121 
a(Å) 80.712 80.194 62.603 
b(Å) 80.712 80.194 68.862 
c (Å) 90.864 91.333 112.297 
Resolution (Å) 50.00-2.30 50.00-1.91 50.00-2.12 
 (2.34-2.30) (1.94-1.91) (2.16-2.12) 
No. of reflections 29147 (1422) 26704 (1132) 27971 (1389) 
Completeness (%) 98.8 (95.4) 98.7 (87.0) 98.2 (100.0) 
Redundancy 3.2 (3.0) 5.5 (3.9) 6.0 (6.2) 
Rmerge (%) 8.3 (33.3) 7.2 (30.5) 9.8 (60.4) 
I/s(I) 18.6 (3.0) 39.5 (3.9) 24.4 (2.3) 
Refinement 
Resolution (Å) 50.00-2.06 30.00-1.98 41.80-2.11 
No. of reflections 14844 (779) 23039 (1357) 29046 (1400) 
Rwork (%) 19.9 (23.6) 20.2 (22.8) 24.9 (34.9) 
Rfree (%) 26.67 (25.6) 23.8 (29.5) 30.9 (37.6) 
Geometry deviations 
Bond lengths (Å) 0.005 0.007 0.021 
Bond angles (°) 0.62 1.01 1.791 
Mean B-values (Å2) / number of non-H atoms 
All refined atoms 33.2 / 2547 32.8 / 2590 36.0 / 3401 
Ligand atoms 53.3 / 55 43.6 / 21 51.7 / 25 
Mg ions 51.6 / 2 43.3 / 3  
Water molecules 36.4 / 123 35.2 / 178  37.0 / 63 
Ramachandran plot (%) 
Most favored 97.8 97.1 91.9 
Additionally allowed 1.8 2.5 7.6 
Generously allowed 0.4 0.4 0.5 
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Figure 3.1 Biosynthetic reactions catalyzed by CrtM and UPPS, with the end products of the 
pathways shown. 
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Figure 3.2 Chemical structures of the screening library compounds and their inhibition for 
CrtM, E. coli UPPS (EcUPPS) and S. aureus UPPS (SaUPPS), IC50 values, µM. 
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Figure 3.3 CrtM crystallographic structures. (a) 7 (cyan) plus FMP (yellow) electron density, 
bound to CrtM. (b) 7 (cyan) bound to CrtM, superimposed on two FSPP molecules (yellow, 
green; PDB ID code 2ZCP). Also shown is the farnesyl monophosphate (magenta) that co-
crystallized. The Mg2+ are from the FSPP structure. (c) Comparison between 7 (cyan) and 3 
(magenta, PDB ID code 2ZCQ) bound to CrtM. Both diphenyl ether side-chains bind in S1. (d) 
Interactions between 7 (cyan), FMP (magenta) and Mg2+ in CrtM. 
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Figure 3.4 Mass spectrum of farnesyl monophosphate that co-purified with CrtM. The 
sample was obtained by dissolving CrtM+7+FMP crystals and injecting the solution into an LC-
MS instrument. 
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Figure 3.5 CrtM crystallographic structures. (a) Electron density of 41 bound to CrtM. (b) 
Structure of 41 (cyan) bound to CrtM shown superimposed on two FSPP molecules (yellow, 
green). (c) Comparison between 41 (cyan) and the phosphonoacetamide 7(BPH-830) [22] 
(magenta) bound to CrtM (PDB ID code 2ZY1). (d) Interactions between 41 (cyan) and Mg2+ in 
CrtM.  
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Figure 3.6 Ligand-protein interactions for 41 binding to CrtM.  
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Figure 3.7 UPPS crystallographic structures. (a) Electron density of 9 bound to UPPS. (b) 
Structure of 9 (cyan) bound to UPPS, superimposed on FSPP/Mg2+ (from PDB ID code 1X06) 
and 4 bisphosphonate inhibitors (PDB ID code 2E98). (c) Superposition of 9 (cyan) on FSPP 
(yellow) in site-1 in UPPS. The Mg2+ is from the FSPP structure. (d) The diketo-acid head-group 
of 9 binds into the active site of UPPS and interacts with D26 and N28. 
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4.2	   Introduction	  
Many drugs target isoprenoid biosynthesis pathway [1]. For example, the most widely 
prescribed drug, the statin Lipitor, blocks cholesterol biosynthesis at the level of HMG-CoA 
reductase [2]; bisphosphonate drugs such as risedronate and zoledronate (Zometa), used to treat 
bone resorption diseases, inhibit farnesyl diphosphate (FPP) synthase [3, 4], and azoles such as 
miconazole and posaconazole [5] inhibit lanosterol 14α-demethylase, blocking ergosterol 
biosynthesis in yeasts and fungi. There is, therefore, considerable interest in the discovery and 
development of novel isoprenoid biosynthesis inhibitors as anti-infectives, not least because of 
the rapid increase in resistance in bacteria and protozoa to current drugs, e.g. Staphylococcus 
aureus resistance to methicillin [6] (MRSA) and the discovery of resistance to artemisinin [7] in 
Plasmodium falciparum, the causative agent of the most serious form of malaria.   
Here, we describe recent work aimed at developing new leads against bacterial infections 
in which we target two enzymes: farnesyl diphosphate synthase (FPPS) [8] and undecaprenyl 
diphosphate synthase (UPPS) [9], two important drug targets in isoprenoid biosynthesis. Using in 
silico high-throughput screening we have identified a number of high nano-molar/low micro-
molar bisamidine inhibitors of the two enzymes. The inhibition of two targets at the same time is 
likely to increase the activity of the inhibitors and decrease the possibility of drug resistance. In 
addition, several of these compounds also had potent activity in cell-based assays. We also find 
that these compounds bind to DNA, opening up possibilities for synergistic effect with protein 
targeting in anti-tumor or antibacterial drug design. Specifically, DSC experiments showed that 
upon inhibitor binding, the melting temperature (Tm) of DNA shifted by more than 10 degrees, 
and a crystallographic investigation revealed that the inhibitor bound to the central AATT site 
located in the minor groove of the DNA dodecamer d(CGCGAATTCGCG)2 duplex. These 
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results provide new leads for antibacterial development based on a poly-pharmaceutical 
approach targeting DNA and isoprenoid biosynthesis.  
	  
4.3	   Results	  and	  Discussion	  
Targeting the FPPS allosteric binding site. Historically, bisphosphonates were the first FPPS 
inhibitors identified [10, 11]. However, bisphosphonates have several undesirable features for 
anti-infective or anti-cancer drug leads in that they are highly polar as well as being prone to 
rapid removal from the circulatory system by binding to bone mineral [12]. There has thus been 
interest in the development of more apolar bisphosphonates and even non-bisphosphonate FPPS 
inhibitors [13-15]. In particular, a fragment-based approach identified several non-
bisphosphonate FPPS inhibitors that targeted a new, allosteric binding site [16]. These non-
bisphosphonate FPPS inhibitors may represent novel anti-cancer drug leads since they are not 
expected to bind to bone mineral [12]. To build on this work, we have carried out a virtual 
screening study targeting the FPPS allosteric binding site. For this, we used the relaxed complex 
scheme, an in silico drug screening method that accounts for receptor flexibility by using 
molecular dynamics simulations [17-19]. A previously reported MD and docking study on FPPS 
did not target the allosteric site [13]. Virtual screens were performed with AutoDock Vina [20] 
and Glide [21, 22] on crystal structure data as well as numerous structures from a FPPS 
molecular dynamics simulation. A neural network re-scoring was performed to optimize the 
ranking of known inhibitors, and ten consensus predictions were screened experimentally 
yielding one hit which was further improved by a similarity search, yielding three low (1.8-2.5) 
micro-molar leads.  
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Docking known non-bisphosphonate inhibitors into the FPPS allosteric site. For control and 
benchmarking purposes, the 12 compounds (1-12, Figure 4.1) described in [16] were docked 
using AutoDock Vina [20] and Schrödinger’s Glide [21-23]. These compounds have IC50 values 
between 80 nM and 500 µM and all are thought to target a previously unreported allosteric 
binding site. Compound 11, the most potent inhibitor with a published structure (PDB-ID 
3N6K), has an IC50 of 200 nM. No structure was published for compound 12, the best (80 nM) 
inhibitor.  
The bound pose of compound 11, as well as the relative binding affinities of the 12 
compounds, were then used as positive controls to fine-tune the virtual screen parameters. First, 
compound 11 was docked into the allosteric site of 3N6K using AutoDock Vina. The top scoring 
model (predicted binding affinity -7.8 kcal/mol) recaptured the published binding pose to within 
0.8 Å RMSD (Figure 4.2). Similarly, Glide correctly found the experimentally determined 
binding pose of compound 11 (0.6 Å RMSD, Figure 4.2). This establishes that both AutoDock 
Vina and Glide can correctly predict bound poses for the FPPS allosteric site which, as is 
apparent from Figures 4.2a and b, is distinct from the bisphosphonate (zoledronate) or IPP 
binding sites. 
A much harder task is to computationally predict the relative binding affinities of 
multiple known binders. To address this question, all 12 compounds were docked into 3N6K and 
the 23 ensemble structures from MD, using AutoDock Vina. Encouragingly, compound 12 (the 
most potent compound) scored best, with a predicted binding affinity of -9.3 kcal/mol. AutoDock 
Vina was not, however, able to properly recapture the relative affinities of the 12 compounds. 
More specifically, 3 and 4 had high predicted affinity (rank 4 and 2, respectively), while 9 and 10 
were only predicted to be weak binders.  
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We thus next used a neural network approach (NNScore 1.0, [24]) to re-rank the 
compounds. NNScore has been developed to characterize the binding affinities of docked 
protein-ligand complexes by distinguishing between well-docked high-affinity ligands and well-
docked, low-affinity decoy compounds, through neural-network-based re-scoring. Testing this 
approach by re-scoring the AutoDock Vina docked poses of the 12 compounds, we found that 
the relative ranking amongst the compounds (as well as the relative rankings against a large drug 
database) improved considerably. Now, compounds 9, 10 and 12 were the top three scoring 
docked compounds, so we then rescored all the AutoDock Vina virtual screen results with 
NNScore.  
 All 12 compounds were also docked into the 3N6K crystal structure and the 23 ensemble 
structures from MD, using Glide. Here, 11 was the top scoring compound (with a predicted 
binding affinity of -7.5 kcal/mol). Also, Glide identified 9, 10 and 11 as the top three scoring 
compounds. Given the excellent internal ranking, no re-scoring was performed on the Glide 
docking results. 
 
Virtual screen of NCI diversity set II. The 3N6K FPPS crystal structure and the 23 structurally 
representative snapshots from the FPPS MD simulation were then used as receptors for the 
relaxed complex scheme docking protocol [17-19]. The dataset used in the virtual screen was the 
NCI diversity set II. The rationale behind using two docking programs (AutoDock Vina and 
Glide) was that a consensus result would have a better chance of producing good leads. The 
Glide docking results were ranked according to the predicted docking score, and the AutoDock 
Vina results were re-scored with NNScore since, as discussed previously, this strategy gave the 
best ranking for the set of known allosteric site inhibitors. A consensus score was used to build 
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up a list of compounds that scored well with both methods. The top ten compounds from this list 
had either an NNScore value of >0.71 (the NNScore value for control compound 11) or a Glide 
score of < -7.46 kcal/mol (the Glide score for control compound 11), and were selected for 
experimental investigation. Upon confirmation of the experimental activity of 13, a 
computational similarity search of the entire NCI database was then performed based on 13, 
using a Tanimoto index of 90% or higher as the search criterion. The receptors that contributed 
to the good consensus score of compound 13 were cluster centers 10 (Vina / NNScore) and 18 
(Glide). The docked pose of compound 13 shows several stabilizing interactions such as π-
stacking interactions with F251 and hydrogen bonds with N49 and R50. Obtaining a crystal 
structure is the focus of active ongoing research, so that we decided to not include the docked 
pose here until confirmed by X-ray crystallography.  
 
Experimental results for the hits from virtual screening.  The top ten compounds identified by 
the virtual screen were tested experimentally. Compound 13 (Figure 4.3) was the only 
experimental hit, and had an IC50 value of 110 µM. Following the similarity search and lead 
optimization, additional compounds were screened. Three compounds having IC50 values in the 
~2-3 micro-molar range were identified: 14, IC50 1.8 µM; 15, IC50 1.9 µM and 16, IC50 2.5 µM. 
Table 4.1 summarizes the experimentally determined IC50 results. What we see from the 
structure of the most active compound investigated so far is that it is a bisamidine containing a 
central hydrophobic, biphenyl core and that polar substitutions into this central hydrophobic core 
region abolish activity. The lead compounds have IC50 values that are larger than those found 
with the bisphosphonate zoledronate (IC50 = 0.2 µM in this assay). However, since they lack the 
bisphosphonate feature, they are likely to have longer residence times in plasma, since they will 
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not bind to bone mineral, as well as better cell permeability. Also of interest is the observation 
that several of these compounds had potent activity against UPPS (Table 4.1) with 14 having an 
IC50 value of 0.11 µM against both E. coli and S. aureus UPPS as reported previously [25].  
 
Tumor cell growth inhibition. We then tested these bisamidine hits in a human tumor cell line 
(MCF-7). Results are given in Table 4.1. The most active compound was 24 (15) with an IC50 of 
0.3 µM. This is to be compared to 16 µM for zoledronate. One possibility for this enhanced 
activity is that there is enhanced cell permeability for the bisamidine over that for zoledronate. 
However, an alternative possibility in that this bisamidine targets DNA, binding to the minor 
groove. 
 
DSC results. To test our hypothesis, we carried out DSC experiments to investigate DNA 
binding using a well-studied dodecamer d(CGCGAATTCGCG)2. As can be seen in Figure 4.4, 
the melting temperature shifted more than 10 °C in the presence of 24 compared to the 
dodecamer DNA alone. This result suggests that 24 does bind to DNA. Indeed, other bisamidines 
such 14 (figure 4.5) binds to DNA as well, suggesting that DNA binding is a common feature of 
bisamidine type of inhibitors, due to the fact that they all share a cationic-hydrophobic-cationic 
structural motif. But how do they bind to DNA? Do they act as DNA intercalates such as 
ethidium bromide, or do they bind to the minor groove, as reported by other researchers for many 
Hoechst compounds [26]? To answer these questions, we carried out crystallography 
investigations using the same DNA dodecamer. 
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Crystallography results. We successfully obtained crystals of 24 bound to the DNA dodecamer 
and the structure showed that one molecule of 24 binds to central AATT site located in the minor 
groove of the DNA dodecamer duplex (Figure 4.6a). The electron density for the middle part of 
the inhibitor is clearly seen, however, the two bisamidine rings at the ends are not well resolved, 
due to we believe the fact that they are out of the binding pocket and exposed to water. The 
LigPlot (Figure 4.6b) revealed that there are not many electrostatic interactions between the 
inhibitor and the DNA. Instead, hydrophobic interaction contributes most to the binding.  
	  
4.4	   Conclusions	  
 The results we have described above are of interest for a number of reasons. First, a 
number of leads for non-bisphophonate FPPS inhibitors have been identified in a relaxed 
complex scheme virtual screen of the allosteric binding site. The most potent leads, 14-16, were 
all bisamidines with IC50 values in the ~2-3 mM range that also satisfy Lipinski’s rule of five 
[27] (Suite 2012: QikProp, version 3.5, Schrödinger, LLC, New York, NY, 2012.)  Second, in 
other work and this work, we have also found that bisamidines are also inhibitors of 
undecaprenyl diphosphate synthase (e.g. 14, IC50 ~100 nM [25]), opening up the possibility of 
developing dual FPPS/UPPS inhibitors. Third, we find this type of inhibitors have enhanced 
activity against tumor cells, due to the fact that they also target DNA, as revealed by the DSC 
experiments. Fourth, we report an x-ray structure of a DNA dodecamer in which a molecule of 
24 binds to the minor groove. Given the importance of FPPS as a drug target (in e.g. inhibitors 
Ras prenylation; γδ T cell activation; M1/M2 phenotype switching in tumor associated 
macrophages; invasiveness and amgiogenesis), and the interest in non-bisphosphonate inhibitors 
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that do not bind to bone mineral, these results are of broad general interest in providing new 
leads for drug discovery. 
 
4.5	   Materials	  and	  Methods	  
Crystal structures and structural ensemble from molecular dynamics simulations. We 
carried out a virtual screen of the FPPS allosteric site using the crystal structures described by 
Jahnke et al. [16]. In addition, we carried out a second virtual screen using representative 
snapshots from an MD simulation of FPPS. The setup for the MD simulation is described in 
detail in [13]. Frames every 20 ps were extracted from the MD trajectories; the frames were 
aligned using all Cα atoms in the protein, and subsequently clustered by RMSD using 
GROMOS++ conformational clustering [28]. The chosen RMSD cutoff resulted in 23 clusters 
that reflected most of the trajectory. The central members of each of these clusters were chosen 
to represent the protein conformations within the cluster and, thereby, the conformations sampled 
by the trajectory. The central member of a cluster (also referred to as “cluster center”) is the 
structure that has the lowest pairwise RMSDs to all other members of the cluster. 
 
Docking and rescoring of known non-bisphosphonate allosteric site inhibitors. To assess the 
abilities of the docking software, the 12 ligands described in [16] were docked. For those 
compounds where no crystal structure information was available, the ChemDraw file was 
converted to pdb format using Open Babel [29]. For the AutoDock Vina screens, pdb2pqr [30, 
31] was used to add hydrogen atoms to the crystal structure receptor. The AutoDock scripts [32] 
prepare_ligand4.py and prepare_receptor4.py were used to prepare ligand and receptor pdbqt 
files. A docking grid of size 18.0 Å x 18.0 Å x 18.0 Å, centered on the position of the ligand in 
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the allosteric site, was used for docking. For Glide docking, the ligands were prepared using 
LigPrep and the receptors were prepared using the tools provided in the Maestro Protein 
Preparation Wizard and the Glide Receptor Grid Generation. 
 For rescoring of AutoDock Vina docked poses we used the python implementation of 
NNScore 1.0 in combination with a consensus of the top three scoring networks (12.net, 16.net 
and 20.net). 
 
Virtual screen of NCI diversity set II. The virtual screen was performed using the National 
Cancer Institute (NCI) diversity set II, a subset of the full NCI compound database. Ligands were 
prepared using LigPrep, adding missing hydrogen atoms, generating all possible ionization 
states, as well as tautomers. The final set used for virtual screening contained 1541 compounds. 
Docking simulations were performed with both AutoDock Vina [20] as well as Glide [21-23]. 
An additional rescoring was performed on the AutoDock Vina results using NNScore. Finally, 
the individual Glide rankings and NNScore results were combined to form a consensus list of 
compounds that scored well with both methods. 
 
Human FPPS purification and inhibition. Human FPPS was expressed and purified as 
described previously [15]. Briefly, FPPS inhibition assays were carried out using 96 well plates 
with a 200 µL reaction mixture in each well. The condensation of geranyl diphosphate (100 µM 
final) and isopentenyl diphosphate (100 µM final) was monitored at room temperature by using a 
continuous spectrophotometric assay for phosphate-releasing enzymes [33]. The reaction buffer 
contained 50 mM Tris-HCl (pH 7.4), 1 mM MgCl2, and 0.01 % Triton X100. The compounds 
investigated were pre-incubated with enzyme for 30 min at room temperature. The IC50 values 
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were obtained by fitting dose-response curve using Prism 4.0 (GraphPad Software, Inc., La Jolla, 
CA; www.graphpad.com).  
 
E. coli and S. aureus UPPS purification and inhibition. E. coli and S. aureus UPPS were 
expressed and purified as described previously [25]. UPPS inhibition assays were carried out 
using 96 well plates with 200 µL reaction mixture in each well. The condensation of farnesyl 
diphosphate and isopentenyl diphosphate was monitored at room temperature by a continuous 
spectrophotometric assay for phosphate releasing enzymes [34]. The reaction buffer contained 50 
mM Tris-HCl (pH 7.4), 1 mM MgCl2, and 0.01% Triton X100. The compounds investigated 
were pre-incubated with enzyme for 30 min at room temperature. The IC50 values were obtained 
from fitting the dose-response curve using Prism 4.0 (GraphPad Software, Inc., La Jolla, CA). A 
radiometric assay was used to verify the hits. The reaction was carried out in 50 µL reaction 
mixture containing 50 mM Tris-HCl (pH 7.4), 1 mM MgCl2, 2.5 µM FPP and 25 µM IPP. After 
30 min incubation at 25 °C, the reaction was terminated by adding 200 µL of 0.5 M EDTA. The 
reaction product was extracted with 500 µL butanol. 300 µL of the organic (upper) layer was 
then mixed with 3 mL scintillation cocktail and counted for 1 min in a scintillation counter. The 
IC50 values were obtained as noted above. 
 
Tumor cell growth inhibition assay. Human tumor cell line MCF-7 (breast adenocarcinoma) 
was obtained from the National Cancer Institute and maintained at 100% humidity and 5% CO2 
at 37 °C. Cell lines were cultured in RPMI-1640 medium supplemented with 2 mM L-glutamine 
and 10% fetal bovine serum (Gibco, Grand Island, NY) at 37°C in a 5% CO2 atmosphere with 
100% humidity. Compound stock solutions were typically prepared in water at a concentration of 
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0.02 M. A broth microdilution method was used to determine the bisphosphonate growth 
inhibition IC50 values. Compounds were half log serial diluted using cell culture media into 96-
well TC-treated round bottom plates (Corning Inc., Corning, NY). Cells were plated at a density 
of 5000 cells/well. Cells were then incubated under the same culture conditions for 2 days at 
which time an MTT ((3-(4,5-dimethylthi-azole-2-yl)-2,5-diphenyltetrazolium bromide) cell 
proliferation assay (ATCC, Manassas, VA) was performed to obtain dose response curves.  
 
DSC experiments. The de-salted DNA dodecamer d(CGCGAATTCGCG) was purchased from 
the Intergraded DNA Technologies, Inc in the form of white powders. The concentration of stock 
solutions for the dodecamer was adjusted to 10 mM (single strand) in water. The single-stranded 
dodecamer was annealed into a duplex before use by incubation in a PCR cycler at 85 °C for 10 
min and then left at room temperature to cool gradually for more than 2 hours. The DNA and 
ligand solutions for DSC were prepared in Mes buffer (0.01 M Mes, 0.001 M EDTA, 0.2 M 
NaCl, pH 6.2). Concentrations of DNA were 0.1 mM. All ligand solutions were prepared by 
adding appropriate amount of compound power into the 0.1 mM DNA solution. Concentrations 
of 14 were 0.1 mM.  
 The DSC experiments were performed on a Microcal VP-DSC instrument. The scans 
cover the temperature range from 10 to 110 °C at a scan rate of 90 °C/h. The DSC thermograms 
were analyzed using the Origin 7.1 software. Buffer vs. buffer scans were used for background. 
 
Crystallization and data collection. The HPLC-purified DNA dodecamer 
d(CGCGAATTCGCG) was purchased from the Intergraded DNA Technologies, Inc in the form 
of white powders. The concentration of stock solutions for the dodecamer was adjusted to 12 
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mM (single strand) in water. The single-stranded dodecamer was annealed into a duplex before 
use by incubation in a PCR cycler at 85 °C for 10 min and then left at room temperature to cool 
gradually for more than 2 hours. The annealed dodecamer was then diluted to 0.6 mM (double 
strand) in 40 mM sodium cacodylate, pH 6.9, 50 mM Mg(OAc)2 and 6 mM spermine-4HCl. 
 The dodecamer apo crystals were grown at 22 °C from hanging drops by mixing 1.5 mL 
0.6 mM dodecamer and and 1.5 µL water. The droplets were equilibrated by vapor diffusion 
against a reservoir of 40% MPD. Tetragonal crystals appeared within a week. DNA/BPH1503 
complex crystals were obtained via co-crystallization by mixing equivalent amount of the 0.6 
mM dodecamer and the minor groove binder BPH1503 at various concentrations (50, 40, 30, 20, 
10, 5, 2 and 1 mM) and left on ice overnight. The mixtures were then spinned down and the 
supernatant was used to grow crystals from hanging drops against a reservoir of 40% MPD. 
Sheet-shaped crystals appeared in a month.   
 X-ray diffraction data for both apo dodecamer and dodecamer/BPH1503 complex were 
collected at the Life Science Collaborative Access Team (LS-CAT) 21-ID-D (G) at the Advance 
Photon Source of the Argonne National Laboratory. Diffraction data were processed and scaled 
by using the program HKL3000 (HKL Research Inc., Charlottesville, VA, USA) [35].  
The structures of the apo dodecamer and complex were determined by using a model 
prepared from the previously reported dodecamer structure (PDB ID 436D) with ligands and 
solvent removed. Structure refinements were carried out by using Refmac [36, 37], Phenix [38] 
and Coot [39]. All structure figures were prepared by using PyMOL [40]. 
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4.6	   Tables	  and	  Figures	  
Table 4.1 Enzyme and cell growth inhibition results.  
 
  H. Sapiens FPPS E. coli UPPS S. aureus UPPS MCF-7 
ID BPH # IC50  (µM) IC50 (µM) IC50  (µM) IC50  (µM) 
13 1354 110 4.8 4.9 6.9 
14 1358 1.8 0.11 0.11 2.2 
15 1362 1.9 3.0 4.1 Not tested 
16 1368 2.5 1.0 1.2 1.5 
17 1356 7.0 >100 >100 29 
18 1375 11 1.5 1.5 19 
19 1355 14 >100 >100 0.94 
20 1360 20 1.6 1.8 3.8 
21 1359 21 >100 >100 2.4 
22 1370 22 3.4 2.0 0.77 
23 1371 35 >100 >100 >100 
24 1503 16 7.5 2.7 0.31 
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Figure 4.1 Set of 12 compounds known to bind to the FPPS allosteric site. These ligands 
were used as positive controls and benchmark compounds to optimize the virtual screens.  
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Figure 4.2 Stereo presentation of docked poses of compound 11 into the FPPS allosteric site 
(green; PDB ID code 3N6K), superimposed on zoledronate and IPP-bound structure (cyan; PDB 
ID code 2F8Z). (a) The RMSD between the crystallographic (green) and docked pose for 11 is 
0.8 Å and 0.6 Å, using AutoDock Vina (purple) and Glide (yellow), respectively. Also shown for 
reference are zoledronate (in the allylic binding site) and IPP (in the homoallylic binding site; 
PDB ID code 2F8Z). (b) Expanded view of the ligand binding sites in (a). 
 
 
  
114 
 
Figure 4.3 Structures of the bisamidine inhibitors from virtual screening.   
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Figure 4.4 DSC data for the naked dodecamer DNA (red) as well as for the 24 saturated 
DNA complexes (blue).  
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Figure 4.5 DSC data for the naked dodecamer DNA (red) as well as for the 14 saturated 
DNA complexes (blue).  
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Figure 4.6 Crystal structure of 14 bound to DNA dodecamer minor groove. (a) 2Fo-Fc 
density map for 14 contoured at 0.5 σ. (b) LigPlot showing the majority of the interaction is 
hydrophobic interaction. 
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5.2	   Introduction	  
 
 
 Malaria is a major cause of mortality and morbidity from parasitic protozoan diseases 
worldwide [1] and drug resistance is of concern [2, 3]. There is thus interest in new drugs and 
new drug targets, as well as unconventional approaches involving host innate immunity [4]. 
Activated γδ T cells are of interest in this context since not only can they kill tumor cells [5], 
bacteria [6] as well as influenza virus-infected cells [7], γδ T cells produce TNF-α on activation, 
and TNF-α is known to prevent the development of pre-erythrocytic stage parasites [8]. One 
class of drug molecules called bisphosphonates are known to activate γδ T cells (containing the 
Vγ2Vδ2 T cell receptor), so these molecules might be used as immunomodulators [9]. Most 
bisphosphonates are, however, poorly taken up into cells and bind tightly to bone mineral [10]. 
Recently, we showed that ‘lipophilic’ bisphosphonates [11] did not bind to bone mineral [10] 
and in addition, were more active in γδ T cell activation [12] than were the current 
bisphosphonate drugs used to treat bone resorption diseases and cancer. We also discovered that 
lipophilic bisphosphonates were active in killing liver stage malaria parasites [13], and that a 
lipophilic analog of the bisphosphate zoledronate was a potent inhibitor of intra-erythrocytic 
Plasmodium both in vitro and in vivo, in mice [14].  
Bisphosphonates such as zoledronate (1) activate γδ T cells by inhibiting the enzyme 
farnesyl diphosphate synthase (FPPS). This results in accumulation of the FPPS substrates, 
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), both of which are 
“phosphoantigens” that activate γδ T cells [12, 15]. However, zoledronate has essentially no 
effect on the intra-erythrocytic form of the malaria parasites, since it is poorly membrane 
permeable. In contrast, lipophilic bisphosphonates (containing N-alkyl side-chains) do kill the 
parasites [14]. Here, the target is the Plasmodium geranylgeranyl diphosphate synthase 
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(GGPPS). This enzyme is unusual in that is structurally more similar to human FPPS than 
human GGPPS and – unlike human GGPPS, is potently inhibited by bisphosphonates. Inhibiting 
GGPPS in the parasite blocks formation of protein prenylation [16] as well as carotenoid [17], 
menaquinone [18] and vitamin E formation [19], Figure 5.1, and results in “direct”  parasite 
killing. Plus, this killing effect is blocked by addition of geranylgeraniol [14], confirming a 
GGPPS target.  
Here, we sought to find a lipophilic bisphosphonate that would kill malaria parasites as 
well as activate γδ T cells, a possible new route to malaria chemo-immunotherapy. 
	  
5.3	   Results	  and	  Discussion	  
 We synthesized the 16 pairs of zoledronate (1) species (1-32) shown in Figure 5.2a in 
which we varied the length of the alkyl chain (n=0 through n=15 carbons) and the presence or 
absence of the 1-OH group that is involved in bone-binding and that has been proposed (with 
zoledronate, 1) to be important in γδ T cell activation [10, 20]. Synthesis and characterization 
details are provided in the Supporting Information. We then tested all 32 compounds for human 
FPPS inhibition activity. The most potent FPPS inhibitors were those with medium length side-
chains and these were ~3-10x more potent than zoledronate itself, Figure 5.2b and Table 5.1. As 
the N-alkyl chain length increases beyond C10, FPPS inhibition decreases, due presumably to the 
onset of steric repulsion with the highly conserved Phe 98, 99 residues in the FPPS active site 
that limit chain elongation [21].  
 We next investigated the effects of chain-length and the presence/absence of the 1-OH 
group on γδ T cell activation, as determined in a TNF-α release assay [22]. As can be seen in 
Table 5.1 and Figure 5.2c, there is a monotonic increase in activity beyond C4 with both series of 
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compounds with increasing chain length up to n~11, then activity rapidly decreases with n>12. 
The decrease in activity with the longer chain species occurs at a longer chain length in cells than 
in FPPS inhibition due, we believe, to the importance of hydrophobicity with the more lipophilic 
species, which facilitates cell entry. These results also clearly show–at least with the γδ T cell 
lines we have used–that there is no major difference in activity due to the presence or absence of 
the 1-OH group.  
 To see how these lipophilic zoledronate derivatives bound to FPPS, we obtained the x-ray 
crystallographic structure of 5 (IC50 ~ 30 nM) bound to human FPPS (HsFPPS), as shown in 
Figure 5.3a (in cyan; PDB ID code 4GA3). Full crystallographic data acquisition and structure 
refinement details are given in Supporting Information Table 5.2. 5 binds into the same site as 
does zoledronate [23, 24] with its two phosphonate groups bound to the [Mg2+]3 cluster, and there 
is a 0.7 Å rmsd between the [Mg2+]3, bisphosphonate and imidazole rings in the two structures. 
The alkyl chain extends into the GPP/FPP side-chain site, Figure 5.3b (FPPS structures, PDB ID 
code 1UBX and 1UBW). The origin of the more potent FPPS inhibition by the N-alkyl 
bisphosphonates over that seen with the unsubstituted species is likely due to an enhanced 
hydrophobic interaction as opposed to a purely Coulombic interaction, since the results of a 
solid-state NMR and quantum chemical investigation [25] show that the imidazole nitrogen in 
zoledronate also carries a +1 charge (due there to protonation), when bound to FPPS.  
 We next investigated the inhibition of Plasmodium vivax GGPPS (PvGGPPS) by 1-32, as 
well as the direct killing of intra-erythrocytic parasites by these compounds. As can be seen in 
Figure 5.2d, e and Table 5.1, several of the compounds most effective in inhibiting PvGGPPS 
were also very effective in inhibiting P. falciparum growth. The correlation between PvGGPPS 
and cell growth inhibition was poor (R = 0.26) but improved to R = 0.80 on addition of the logP 
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and solvation energy descriptors reported previously [26]. The ability to inhibit FPPS as well as 
GGPPS with the same chain length compounds is likely due to their mimicking the FPP product 
(in human FPPS) or the FPP substrate (in Plasmodium GGPPS), together with the presence of 
the “third Asp” in PvGGPPS that is essential for bisphosphonate binding to [Mg2+]3 with, and as 
can be seen in Figure 5.3c, the structures of 5 bound to HsFPPS and 29 bound to PvGGPPS 
being very similar (rmsd=0.9 Å). 
	  
5.4	   Conclusions	  
 In conclusion, the results we have presented here are of interest for a number of reasons. 
First, we constructed a library of 31 N-alkyl analogs of the bisphosphonate drug, zoledronate, 
with and without 1-OH groups, and tested them (and zoledronate) for activity in inhibiting 
human FPPS. The results show that medium chain length species inhibit human FPPS most 
potently, while longer chain species are inactive, due we propose, to a steric clash with the FPPS 
chain-length-determining residues Phe 98, 99. Second, we investigated the activity of all 32 
compounds in γδ T cell activation: the most active species had 10±1 carbons in the N-alkyl side-
chain. We propose that the increased activity of these lipophilic zoledronate-analog 
bisphosphonates in cells compared with zoledronate itself is due to the improved cell uptake of 
the more lipophilic compounds. Third, we determined the x-ray crystallographic structure of one 
potent inhibitor of human FPPS bound to the enzyme, finding that the bisphosphonate and 
imidazole groups occupied the same position as in zoledronate bound to FPPS, as well as 29 
bound to GGPPS. Fourth, we find that the most potent Vγ2Vδ2 T cell activators also kill malaria 
parasites in vitro (and in vivo [14]). This opens up the intriguing possibility of a combined 
chemo-immunotherapeutic approach to the development of new anti-malarials in which both 
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host innate immunity (host FPPS inhibition/γδ T cell activation/TNF-α-mediated killing) as well 
as direct killing (via parasite GGPPS inhibition, carotenoid, menaquinone and vitamin E 
biosynthesis inhibition) are targeted by a single molecule.  
	  
5.5	   Materials	  and	  Methods	  
Synthetic aspects. 1 and 17 were available from previous work [10]. The synthesis of 2-16 and 
18-32 are described below. 
 
General procedure for the synthesis of lipophilic zoledronate analogs (2-16):  
 
 
 A mixture of imidazole (100 mmol), alkyl bromide (100 mmol) and K2CO3 (200 mmol) 
in acetone (200 mL) was refluxed overnight. Upon filtration and removal of solvent, the residue 
was subjected to flash chromatography with ethyl acetate as eluant to give product with > 90 % 
yield. N-alkylimidazole was stirred with methyl bromoacetate in ethyl acetate at room 
temperature to give the imidazolium salt which was hydrolyzed under reflux in HCl (6 M) to 
give the carboxylic acid in quantitative yield. A mixture of the carboxylic acid (3 mmol), H3PO3 
(15 mmol), and toluene (8 mL) was heated to 80 °C with stirring. After all solids melted, POCl3 
(15 mmol) was added slowly and the reaction mixture vigorously stirred at 80 °C for 5 h. The 
mixture was cooled, toluene decanted and 6 M HCl (3 mL) added to the residue. The resulting 
solution was refluxed for 1 h, then most of the solvent was removed in vacuo. i-PrOH (25 mL) 
was added to precipitate a 1-hydroxymethylene bisphosphonate as a white powder, which was 
filtered, washed with 2-propanol (5 x 5 mL), dried, and further purified by recrystallization in 
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H2O/i-PrOH. In some cases, the bisphosphonate was neutralized with NaOH and crystallized as 
its sodium salt, from H2O/i-PrOH. 
 
1-Hydroxy-2-(N-methyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (2). 1H NMR 
(400 MHz, D2O) δ: 8.50 (s, 1H), 7.28 (s, 1H), 7.13 (s, 1H), 4.44 (t, J = 7.2 Hz, 2H), 3.66 (s, 
3H). 31P NMR (162 MHz, D2O) δ: 15.09. Anal. Calcd. for C6H12N2O7P20.5H2O  C, 24.42; H, 
4.44; N, 9.49. Found, C, 24.36; H, 4.18; N, 9.18. 
 
1-Hydroxy-2-(N-ethyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (3). 1H NMR 
(400 MHz, D2O) δ: 8.60 (s, 1H), 7.32 (s, 1H), 7.25 (s, 1H), 4.48 (t, J = 7.2 Hz, 2H), 4.04 (q, J = 
7.2 Hz, 2H), 1.31 (t, J = 6.8 Hz, 3H). 31P NMR (162 MHz, D2O) δ: 15.15. Anal. Calcd. for 
C7H14N2O7P2: C, 28.01; H, 4.70; N, 9.33. Found: C, 28.32; H, 4.57; N, 8.96. 
 
1-Hydroxy-2-(N-propyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (4). 1H NMR 
(400 MHz, D2O) δ: 8.61 (s, 1H), 7.34 (s, 1H), 7.25 (s, 1H), 4.48 (t, J = 7.2 Hz, 2H), 3.99 (m, 
2H), 1.70 (q, J = 6.8 Hz, 2H), 0.73 (t, J = 6.8 Hz, 3H). 31P NMR (162 MHz, D2O) δ: 15.14. 
Anal. Calcd. for C8H16N2O7P2: C, 30.58; H, 5.13; N, 8.92. Found: C, 30.33; H, 5.07; N, 8.64. 
 
1-Hydroxy-2-(N-butyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (5). 1H NMR 
(400 MHz, D2O) δ: 8.55 (s, 1H), 7.29 (s, 1H), 7.19 (s, 1H), 4.43 (t, J = 9.6 Hz, 2H), 3.97 (t, J = 
7.2 Hz, 2H), 1.66 (m, 2H), 1.07 (m, 4H), 0.64 (t, J = 7.2 Hz, 3H). 31P NMR (162 MHz, D2O) δ: 
15.07. Anal. Calcd. for C10H20N2O7P2: C, 35.10; H, 5.89; N, 8.19. Found: C, 35.01; H, 5.67; N, 
8.24. 
 
1-Hydroxy-2-(N-pentyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (6). 1H NMR 
(400 MHz, D2O) δ: 8.55 (s, 1H), 7.29 (s, 1H), 7.19 (s, 1H), 4.43 (t, J = 9.6 Hz, 2H), 3.97 (t, J = 
7.2 Hz, 2H), 1.66 (m, 2H), 1.07 (m, 4H), 0.64 (t, J = 7.2 Hz, 3H). 31P NMR  (162 MHz, D2O) δ: 
15.07. Anal. Calcd. for C10H20N2O7P2: C, 35.10; H, 5.89; N, 8.19. Found: C, 35.01; H, 5.67; N, 
8.24. 
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1-Hydroxy-2-(N-hexyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (7). 1H NMR 
(400 MHz, D2O) δ: 8.55 (s, 1H), 7.29 (s, 1H), 7.20 (s, 1H), 4.43 (t, J = 10.0 Hz, 2H), 3.97 (t, J 
= 7.2 Hz, 2H), 1.64 (m, 2H), 1.07 (m, 6H), 0.64 (t, J = 7.2 Hz, 3H). 31P NMR (162 MHz, D2O) 
δ: 15.20. Anal. Calcd. for C11H22N2O7P2: C, 37.09; H, 6.22; N, 7.86. Found: C, 36.79; H, 6.59; 
N, 7.48. 
 
1-Hydroxy-2-(N-heptyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (8). 1H NMR 
(400 MHz, D2O) δ: 8.57 (s, 1H), 7.31 (s, 1H), 7.21 (s, 1H), 4.45 (t, J = 10.0 Hz, 2H), 3.99 (t, J = 
7.2 Hz, 2H), 1.67 (m, 2H), 1.07 (m, 8H), 0.64 (t, J = 6.8 Hz, 3H). 31P NMR (162 MHz, D2O) δ: 
15.07. Anal. Calcd. for C12H24N2O7P2: C, 38.92; H, 6.53; N, 7.57. Found: C, 38.63; H, 6.50; N, 
7.47. 
 
1-Hydroxy-2-(N-octyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (9). 1H NMR 
(400 MHz, D2O) δ: 8.54 (s, 1H), 7.30 (s, 1H), 7.18 (s, 1H), 4.42 (t, J = 10.0 Hz, 2H), 3.98 (t, J = 
6.4 Hz, 2H), 1.67 (m, 2H), 1.07 (m, 10H), 0.64 (t, J = 6.8 Hz, 3H). 31P NMR (162 MHz, D2O) δ: 
14.85. 
Anal. Calcd. for C13H26N2O7P20.7H2O  C, 39.34; H, 6.96; N, 7.06. Found: C, 39.04; H, 6.68; N, 
7.00. 
 
1-Hydroxy-2-(N-nonyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (10). 1H NMR 
(400 MHz, D2O) δ: 8.56 (s, 1H), 7.03 (s, 1H), 7.20 (s, 1H), 4.44 (t, J = 9.6 Hz, 2H), 3.98 (t, J = 
7.2 Hz, 2H), 1.66 (m, 2H), 1.05 (m, 12H), 0.64 (t, J = 7.2 Hz, 3H). 31P NMR (162 MHz, D2O) δ: 
15.04. Anal. Calcd. for C14H28N2O7P20.25H2O: C, 41.74; H, 7.13; N, 6.95. Found: C, 41.65; H, 
6.99; N, 6.83. 
 
1-Hydroxy-2-(N-decyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (11). 1H NMR 
(400 MHz, D2O) δ: 8.55 (s, 1H), 7.30 (s, 1H), 7.20 (s, 1H), 4.46 (t, J = 9.6 Hz, 2H), 3.98 (t, J = 
7.2 Hz, 2H), 1.66 (m, 2H), 1.05 (m, 14H), 0.64 (t, J = 7.2 Hz, 3H). 31P NMR (162 MHz, D2O) δ: 
15.10. Anal. Calcd. for C15H30N2O7P2: C, 43.69; H, 7.33; N, 6.79. Found: C, 43.69; H, 7.47; N, 
6.58. 
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1-Hydroxy-2-(N-undecyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (12). 1H NMR 
(400 MHz, D2O) δ: 8.54 (s, 1H), 7.30 (s, 1H), 7.19 (s, 1H), 4.43 (t, J = 9.6 Hz, 2H), 3.98 (t, J = 
7.2 Hz, 2H), 1.66 (m, 2H), 1.05 (m, 16H), 0.64 (t, J = 7.2 Hz, 3H). 31P NMR (162 MHz, D2O) δ: 
14.81. Anal. Calcd. for C16H32N2O7P20.33H2O: C, 44.44; H, 7.61; N, 6.48. Found: C, 44.35; H, 
7.62; N, 6.40. 
 
1-Hydroxy-2-(N-dodecyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (13). 1H NMR 
(400 MHz, D2O) δ: 8.65 (s, 1H), 7.39 (s, 1H), 7.14 (s, 1H), 4.42 (t, J = 9.6 Hz, 2H), 3.98 (t, J = 
7.2 Hz, 2H), 1.65 (m, 2H), 1.05 (m, 18H), 0.64 (t, J = 7.2 Hz, 3H). 31P NMR (162 MHz, D2O) δ: 
15.18. Anal. Calcd. for C17H34N2O7P2H2O: C, 44.54; H, 7.92; N, 6.11. Found: C, 44.72; H, 7.83; 
N, 6.36. 
 
1-Hydroxy-2-(N-tridecyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (14). 1H NMR 
(400 MHz, DMSO-d6) δ: 9.01 (s, 1H), 7.59 (s, 2H), 4.48 (s, 2H), 4.02 (m, 2H), 1.69 (m, 2H), 
1.19 (m, 20H), 0.80 (t, J = 7.2 Hz, 3H). 31P NMR (162 MHz, D2O) δ: 15.27. Anal. Calcd. for 
C18H36N2O7P2H2O: C, 45.76; H, 8.11; N, 5.93. Found: C, 5.65; H, 7.82; N, 5.69. 
 
1-Hydroxy-2-(N-tetradecyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (15). 1H 
NMR (400 MHz, DMSO-d6) δ: 9.01 (s, 1H), 7.59 (s, 2H), 4.48 (s, 2H), 4.02 (m, 2H), 1.69 (m, 
2H), 1.19 (m, 22H), 0.80 (t, J = 7.2 Hz, 3H). 31P NMR (162 MHz, DMSO-d6) δ: 15.17. Anal. 
Calcd. for C19H38N2O7P20.2H2O: C, 48.34; H, 8.20; N, 5.93. Found: C, 48.07; H, 8.13; N, 5.88. 
 
1-Hydroxy-2-(N-pentadecyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (16). 1H 
NMR (400 MHz, DMSO-d6) δ: 9.01 (s, 1H), 7.59 (s, 2H), 4.48 (s, 2H), 4.02 (m, 2H), 1.69 (m, 
2H), 1.19 (m, 24H), 0.80 (t, J = 7.2 Hz, 3H). 31P NMR (162 MHz, DMSO-d6) δ: 15.20. Anal. 
Calcd. for C20H38N2Na2O7P20.1H2O: C, 45.47; H, 7.29; N, 5.30. Found: C, 5.12; H, 7.68; N, 
5.33. 
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General procedure for the synthesis of lipophilic deoxy-zoledronate analogs (18-32).
 
 To a solution of ethene-1,1-diyldiphosphonic acid (1 mmol) in HOAc (5 mL) was added 
an N-alkylimidazole  (1 mmol), and the solution refluxed overnight with stirring. Upon removal 
of solvent, recrystallization was carried out from H2O/i-PrOH (1/10) to give the products as 
white powders.  
 
2-(N-methyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (18). 1H NMR (400 MHz, 
D2O) δ: 8.56 (s, 1H), 7.34 (s, 1H), 7.18 (s, 1H), 4.41 (dt, J = 7.2, 13.2 Hz, 2H), 3.67 (s, 3H), 2.54 
(tt, J = 6.4, 21.2 Hz, 1H). 31P NMR (162 MHz, D2O) δ: 16.05. Anal. Calcd. for 
C6H12N2O6P20.1H2O: C, 26.68; H, 4.48; N, 10.37; Found: C, 26.94; H, 4.30; N, 10.32. 
 
2-(N-ethyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (19). 1H NMR (400 MHz, 
D2O) δ: 8.68 (s, 1H), 7.40 (s, 1H), 7.31 (s, 1H), 4.47 (dt, J = 7.2, 13.2 Hz, 2H), 4.05 (t, J = 7.2 
Hz, 2H), 2.58 (tt, J = 7.2, 21.6 Hz, 1H), 1.31 (t, J = 7.2 Hz, 3H). 31P NMR (162 MHz, D2O) δ: 
16.19. Anal. Calcd. for C7H14N2O6P2: C, 29.59; H, 4.97; N, 9.86; Found: C, 29.71; H, 4.76; N, 
9.90. 
 
2-(N-propyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (20). 1H NMR (400 MHz, 
D2O) δ: 8.65 (s, 1H), 7.38 (s, 1H), 7.27 (s, 1H), 4.45 (dt, J = 7.2, 13.2 Hz, 2H), 3.96 (t, J = 6.8 
Hz, 2H), 2.58 (tt, J = 7.2, 21.6 Hz, 1H), 1.68 (m, 2H), 0.70 (t, J = 7.2 Hz, 3H). 31P NMR (162 
MHz, D2O) δ: 16.20. Anal. Calcd. for C8H16N2O6P20.4H2O: C, 31.46; H, 5.55; N, 9.17. Found: 
C, 31.25; H, 5.33; N, 8.84. 
 
2-(N-butyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (21). 1H NMR (400 MHz, 
D2O) δ: 8.60 (s, 1H), 7.35 (s, 1H), 7.28 (s, 1H), 4.36 (dt, J = 7.2, 13.2 Hz, 2H), 3.97 (t, J = 7.2 
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Hz, 2H), 2.10 (tt, J = 6.8, 20.4 Hz, 1H), 1.64 (m, 2H), 1.12 (m, 2H), 0.70 (t, J = 7.6 Hz, 3H). 31P 
NMR (162 MHz, D2O) δ: 15.36. Anal. Calcd. for C9H18N2O6P2: C, 34.62; H, 5.81; N, 8.97. 
Found: C, 34.42; H, 5.92; N, 9.05; 
 
2-(N-pentyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (22). 1H NMR (400 MHz, 
D2O) δ: 8.66 (s, 1H), 7.39 (s, 1H), 7.21 (s, 1H), 4.48 (dt, J = 6.8, 12.8 Hz, 2H), 4.00 (t, J = 7.2 
Hz, 2H), 2.59 (tt, J = 6.4, 20.0 Hz, 1H), 1.68 (m, 2H), 1.12 (m, 4H), 0.68 (t, J = 7.2 Hz, 3H). 
31P NMR (162 MHz, D2O) δ: 16.23. Anal. Calcd. for C10H20N2O6P20.8H2O: C, 35.26; H, 6.39; 
N, 8.22. Found: C, 34.93; H, 6.00; N, 8.36. 
 
2-(N-hexyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (23). 1H NMR (400 MHz, 
D2O) δ: 8.60 (s, 1H), 7.36 (s, 1H), 7.21  (s, 1H), 4.36 (dt, J = 7.2, 13.2 Hz, 2H), 3.97 (t, J = 7.2 
Hz, 2H), 2.26 (tt, J = 6.8, 20.4 Hz, 1H), 1.66 (m, 2H), 1.10 (m, 6H), 0.66 (t, J = 4.8 Hz, 3H). 
31P NMR (162 MHz, D2O) δ: 15.34. Anal. Calcd. for C11H22N2O6P20.1i-PrOH: C, 37.11; H, 
6.26; N, 7.87. Found: C, 7.17; H, 6.38; N, 7.88. 
 
2-(N-heptyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (24). 1H NMR (400 MHz, 
D2O) δ: 8.61 (s, 1H), 7.35 (s, 1H), 7.21  (s, 1H), 4.38 (dt, J = 7.2, 13.2 Hz, 2H), 3.96 (t, J = 7.2 
Hz, 2H), 2.30 (tt, J = 6.8, 20.4 Hz, 1H), 1.66 (m, 2H), 1.08 (m, 8H), 0.66 (t, J = 4.8 Hz, 3H). 
31P NMR (162 MHz, D2O) δ: 15.33. Anal. Calcd. for C12H24N2O6P2: C, 40.68; H, 6.83; N, 7.91; 
Found: C, 40.41; H, 6.78; N, 7.59. 
 
2-(N-octyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (25). 1H NMR (400 MHz, 
D2O) δ: 8.61 (s, 1H), 7.36 (s, 1H), 7.23 (s, 1H), 4.43 (dt, J = 7.2, 13.6 Hz, 2H), 3.96 (t, J = 7.2 
Hz, 2H), 2.45 (tt, J = 7.6, 21.2 Hz, 1H), 1.66 (m, 2H), 1.06 (m, 10H), 0.63 (t, J = 6.8 Hz, 3H). 31P 
NMR (162 MHz, D2O) δ: 15.75. Anal. Calcd. for C13H26N2O6P20.7H2O: C, 40.99; H, 7.25; N, 
7.35. Found: C, 40.92; H, 7.07; N, 7.19. 
 
2-(N-nonyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (26). 1H NMR (500 MHz, 
D2O) δ: 8.63 (s, 1H), 7.40 (s, 1H), 7.24 (s, 1H), 4.40 (dt, J = 7.5, 13.0 Hz, 2H), 4.00 (t, J = 6.0 
Hz, 2H), 2.21 (tt, J = 7.5, 20.0 Hz, 1H), 1.71 (m, 2H), 1.10 (m, 12H), 0.69 (t, J = 7.5 Hz, 3H). 31P 
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NMR (202 MHz, D2O) δ: 15.75. Anal. Calcd. for C14H27N2NaO6P2: C, 41.59; H, 6.79; N, 6.93. 
Found: C, 41.91; H, 6.85; N, 6.66. 
 
2-(N-decyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (27). 1H NMR (500 MHz, 
D2O) δ: 8.65 (s, 1H), 7.40 (s, 1H), 7.28 (s, 1H), 4.45 (dt, J = 7.0, 13.5 Hz, 2H), 4.01 (t, J = 7.5 
Hz, 2H), 2.45 (tt, J = 7.5, 21.5 Hz, 1H), 1.70 (m, 2H), 1.13 (m, 14H), 0.68 (t, J = 7.5 Hz, 3H). 31P 
NMR (202 MHz, D2O) δ: 15.54; Anal. Calcd. for C15H30N2O6P2: C, 45.45; H, 7.63; N, 7.07. 
Found: C, 45.40; H, 7.56; N, 7.00. 
 
2-(N-undecyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (28). 1H NMR (400 MHz, 
D2O) δ: 8.61 (s, 1H), 7.38 (s, 1H), 7.22 (s, 1H), 4.39 (dt, J = 7.2, 13.6 Hz, 2H), 3.98 (t, J = 7.2 
Hz, 2H), 2.23 (tt, J = 6.8, 20.4 Hz, 1H), 1.68 (m, 2H), 1.07 (m, 16H), 0.68 (t, J = 7.2 Hz, 3H). 31P 
NMR (162 MHz, D2O) δ: 15.17; Anal. Calcd. for C16H32N2O6P2: C, 43.54; H, 7.31; N, 6.35. 
Found: C, 43.67; H, 7.29; N, 7.43. 
 
2-(N-dodecyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (29). 1H NMR (400 MHz, 
D2O) δ: 8.68 (s, 1H), 7.42 (s, 1H), 7.22 (s, 1H), 4.42 (dt, J = 7.2, 13.2 Hz, 2H), 3.43 (t, J = 7.2 
Hz, 2H), 2.42 (tt, J = 7.2, 21.6 Hz, 1H), 1.65 (m, 2H), 1.04 (m, 18H), 0.68 (t, J = 7.2 Hz, 3H). 
31P NMR (162 MHz, D2O) δ: 15.33. Anal. Calcd. for C17H34N2O6P21.55H2O: C, 39.93; H, 6.72; 
N, 5.48. Found: C, 40.30; H, 7.11; N, 5.45. 
 
2-(N-tridecyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (30). 1H NMR (400 MHz, 
D2O) δ: 8.61 (s, 1H), 7.38 (s, 1H), 7.22 (s, 1H), 4.37 (dt, J = 7.2, 13.2 Hz, 2H), 3.98 (t, J = 7.2 
Hz, 2H), 2.19 (tt, J = 7.2, 21.6 Hz, 1H), 1.67 (m, 2H), 1.07 (m, 20H), 0.66 (t, J = 7.2 Hz, 3H). 31P 
NMR (162 MHz, D2O) δ: 15.40. Anal. Calcd. for C18H36N2O6P2H2O: C, 47.36; H, 8.39; N, 6.14. 
Found: C, 47.4; H, 8.11; N, 6.05. 
 
2-(N-tetradecyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (31). 1H NMR (400 
MHz, D2O) δ: 8.75 (s, 1H), 7.48 (s, 1H), 7.21 (s, 1H), 4.44 (dt, J = 7.2, 13.2 Hz, 2H), 3.99 (t, J = 
7.2 Hz, 2H), 2.38 (tt, J = 7.2, 21.6 Hz, 1H), 1.66 (m, 2H), 1.07 (m, 22H), 0.66 (t, J = 7.2 Hz, 
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3H). 31P NMR (162 MHz, D2O) δ: 15.40. Anal. Calcd. for C19H38N2O6P20.5H2O: C, 49.45; H, 
8.52; N, 6.07. Found: C, 49.33; H, 8.63; N, 6.02. 
 
2-(N-pentadecyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid (32). 1H NMR (400 
MHz, D2O) δ: 8.68 (s, 1H), 7.45 (s, 1H), 7.16 (s, 1H), 4.40 (dt, J = 7.2, 13.2 Hz, 2H), 3.97 (t, J = 
7.2 Hz, 2H), 2.16 (tt, J = 7.2, 21.6 Hz, 1H), 1.66 (m, 2H), 1.07 (m, 24H), 0.67 (t, J = 7.2 Hz, 
3H). 31P NMR (162 MHz, D2O) δ: 15.40. Anal. Calcd. for C20H40N2O6P20.5H2O: C, 50.52; H, 
8.69; N, 5.89. Found: C, 50.30; H, 8.72; N, 5.96. 
 
Human FPPS expression. Truncated human FPPS (6-353) was cloned into NdeI/BamHI 
restriction sites of pET28a vector by using forward primer (5’-
CTTCATATGAATTCAGATGTTTATGCCCAAGAAAAGCAGGATTTCG-3’) and reverse 
primer (5’-CTTGGATCCTCACTTTCTCCGCTTGTAGATTTTGCGCG-3’). pET28a-
(His)6HsFPPS_6~353 was transformed into BL21(DE3) Tuner cells to ensure proper distribution 
of inducers across the cells. Transformed cells were spread onto LB plates with 50 µg/mL 
kanamycin and were incubated for 16 hours. A single colony that carried pET28a-(His)6HsFPPS 
6-353 was inoculated in 100 mL LB broth with 50 µg/mL kanamycin and incubated at 37 °C 
overnight. 10 mL of inoculated cells were added into 1L LB broth with 50 µg/mL kanamycin and 
incubated until the OD600 reached 0.6~0.8. Cells were induced by 1 mM IPTG and incubated at 
24°C for at least 16 hours, then centrifuged, and the pellets frozen at -80 °C. The cell pellets 
were then thawed in wash buffer (10 mM HEPES, pH 7.5, 500 mM NaCl and 35 mM imidazole) 
with addition of Benzonase (EMD Millipore) and EDTA-free protease cocktail (Roche). Thawed 
cells were sonicated (10 sec active, 20 sec rest, for 10 min) then centrifuged at 23,000 rpm for 30 
min. The supernatant was loaded on a Ni-NTA column and eluted with 0~100 % elution buffer 
(10 mM HEPES, 500 mM NaCl and 500 mM imidazole). Fractions were subjected to SDS-
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PAGE and only pure (His)6HsFPPS was collected. The protein was digested with thrombin and 
dialyzed against dialysis buffer (10 mM HEPES, pH 7.4 and 150 mM NaCl) at 4 °C for 30 hours 
to remove the N-terminal His-tag. HsFPPS was further purified by using S200 gel filtration 
chromatography with storage buffer (10 mM Tris, pH 7.4 and 25 mM NaCl). The pure HsFPPS 
fraction was concentrated to 37 mg/mL, then quickly frozen in liquid nitrogen and stored at -
80°C. 
 
Human FPPS inhibition assays. Human FPPS inhibition assays were carried out using 96 well 
plates with 200 µL reaction mixture in each well. The condensation of geranyl diphosphate (100 
µM final) and isopentenyl diphosphate (100 µM final) was monitored at room temperature by 
using a continuous spectrophotometric assay for phosphate-releasing enzymes [27]. The reaction 
buffer contained 50 mM Tris-HCl (pH 7.4), 1 mM MgCl2, and 0.01 % Triton X100. The 
compounds investigated were pre-incubated with enzyme for 30 min at room temperature. The 
IC50 values were obtained from fitting dose-response curve using Prism 4.0 (GraphPad Software, 
Inc., La Jolla, CA, www.graphpad.com). 
 
P. vivax GGPPS expression. A clone encoding P. vivax GGPPS (PlasmoDB gene ID: 
Pv092040) with an N-terminally His6-tagged fusion protein and a tobacco etch virus protease site 
was expressed in Escherichia coli BL21-codon Plus (DE3) RIL (Stratagene) at 15 °C in baffled 
flasks. Cells were lysed by sonication in the presence of Benzonase Nuclease (Novagen) and a 
protease inhibitor cocktail (Sigma), and the protein purified chromatographically by using a Ni-
nitrilotriacetate resin. EDTA was added immediately to the elution fraction to 1 mM, and 5 mM 
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DTT added after 15 min. The eluted protein was then concentrated and loaded onto a Sephadex 
S-200 gel filtration column, and fractions containing PvGGPPS collected.  
 
P. vivax GGPPS inhibition assays. The P. vivax GGPPS inhibition assays were carried out by 
using 96-well plates with 200 µL of reaction mixture in each well. The condensation of geranyl 
diphosphate (100 µM) with isopentenyl diphosphate (100 µM) was monitored at room 
temperature by using a continuous spectrophotometric assay for phosphate-releasing enzymes 
[27] in a reaction mixture containing 50 mM Tris-HCl (pH 7.4), 1 mM MgCl2, and 0.01% Triton 
X100. The inhibitors were pre-incubated with the enzyme for 30 min, at room temperature. The 
IC50 values were obtained from fitting the dose-response curve using Prism 4.0 (GraphPad 
Software, Inc., La Jolla, CA, www.graphpad.com). 
 
γδ T cell activation assays. Vγ2Vδ2T cell activation was assessed by TNF-α release as 
described previously [28]. Briefly, the CD4+ Vγ2Vδ2T cell clone, JN.23, was stimulated with 
bisphosphonates in the presence of the antigen presenting cell line, CP.EBV (an EBV 
transformed human B cell line). For TNF-α release, supernatants were harvested 16 h later and 
assayed for TNF-α levels by sandwich ELISA (R&D Systems). Concentrations required to 
achieve 50% of the observed maximal T cell response (EC50) were obtained by using the Prism 
4.0 program (Graphpad Software, La Jolla, CA, www.graphpad.com), using a sigmoidal dose-
response function. Curve fitting minima for each experiment were determined using the Global 
Fitting technique, as implemented in Prism 4.0. Curve fitting maxima were optimized for each 
individual compound without the use of any constraints.  
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Crystallization, data collection and refinement of the HsFPPS/5 complex. Co-crystallization 
of human FPPS was carried out as follows. 34 mg/mL HsFPPS was mixed with 1 mM 5 and 2 
mM MgCl2. The mixture was then incubated at 4 °C overnight. The mixture was centrifuged and 
any precipitate discarded. The protein solution was then mixed with mother liquor (1.2 M Na/K 
phosphate, pH 5.2 and 25% glycerol) in a ratio of 1:1. Hanging drops were incubated at 18 °C. 
Large, hexagon-like crystals appeared in ~ 1-3 days and grew to maximum size in one week. The 
crystals were mounted, then frozen in liquid nitrogen. Diffraction data was collected at the Life 
Science Collaborative Access Team (LS-CAT) at the Argonne National Laboratory (Argonne, 
IL). Data was processed by using HKL2000 [29] and refined by using Refmac [30, 31] and Coot 
[32]. Refined statistics are shown in Table 5.2. Graphics were created by using PyMOL [33]. 
 
P. falciparum growth inhibition assays. P. falciparum growth inhibition assays were carried 
out as described in our previous work [14]. A P. falciparum culture was adjusted to 2% 
hematocrit, 0.5% parasitemia, then dispensed by a WellMate (Thermo) into 384 well plates 
(Greiner) containing the compounds (final volume 50 µL) and incubated for 72 h. Chloroquine, 
artemisinin, and DMSO were used within the assay plates to serve as controls. After 3 d, a 
parasite lactate dehydrogenase (pLDH) assay was used to assess compound efficacy. At the end 
of 72 h, the plates were frozen overnight at −20 °C. After thawing, the plates were shaken for 45 
s at 1,700 rpm in a Mix Mate (Eppendorf) and 5 µL of the lysate transferred into the 
corresponding well of another plate containing 30 µL of Malstat Reagent [34] and incubated for 
2 h. The absorbance (650 nm) was read using a Spectramax M5 (Molecular Devices). IC50 
values were obtained from fitting the dose-response curve using Prism 4.0 (GraphPad Software, 
Inc., La Jolla, CA, www.graphpad.com).
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5.6	   Tables	  and	  Figures	  
Table 5.1 Enzyme inhibition together with γδ T cell activation and P. falciparum cell 
growth inhibition. 
 
 
Sidechain HsFPPS TNF-α PvGGPPS P. falciparum 
 
Length IC50 IC50 IC50 IC50 
ID (n, OH/H) (µM) (µM) (µM) (µM) 
1 0, OH 0.10 170 0.13 >400 
2 1, OH 0.080 210 0.15 >400 
3 2, OH 0.049 160 0.12 >400 
4 3, OH 0.034 190 0.16 >400 
5 4, OH 0.030 250 0.14 390 
6 5, OH 0.049 170 0.12 97 
7 6, OH 0.044 81 0.12 25 
8 7, OH 0.040 47 0.11 14 
9 8, OH 0.036 23 0.10 9.6 
10 9, OH 0.080 11 0.12 5.9 
11 10, OH 0.23 7.6 0.12 3.6 
12 11, OH 0.21 8.0 0.32 4.1 
13 12, OH 0.49 8.8 0.40 5.6 
14 13, OH 4.2 110 2.7 44 
15 14, OH 42 160 3.2 >400 
16 15, OH 60 280 7.1 >400 
17 0, H 0.14 140 0.16 >400 
18 1, H 0.19 210 0.16 >400 
19 2, H 0.08 180 0.17 >400 
20 3, H 0.066 200 0.14 >400 
21 4, H 0.079 280 0.13 51 
22 5, H 0.11 160 0.20 22 
23 6, H 0.058 56 0.21 8.6 
24 7, H 0.044 36 0.17 7.2 
25 8, H 0.040 17 0.16 4.1 
26 9, H 0.043 12 0.10 3.3 
27 10, H 0.10 11 0.11 1.3 
28 11, H 0.28 10 0.14 2.5 
29 12, H 0.37 13 0.31 2.7 
30 13, H 0.35 51 0.38 8.8 
31 14, H 3.0 94 1.1 120 
32 15, H 8.3 210 4.5 150 
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Table 5.2 Data collection and refinement statistics. 
Crystal HsFPPS/5 
(PDB ID) (4GA3) 
 Co-crystallization  
Data collection 
Radiation source LS-CAT 21-ID-G 
Wavelength (Å) 0.97857 
Space group P41212 
a (Å) 112.29 
b (Å) 112.29 
c (Å) 68.55 
Resolution (Å) 50.0-2.40 
 (2.44-2.40) 
No. of reflections 17314 (882) 
Completeness (%) 97.4 (99.7) 
Redundancy 16.1 (16.4) 
Rmerge (%) 8.3 (63.5) 
I/σ(I) 53.9 (7.52) 
Refinement 
Resolution (Å) 40.5-2.40 (2.44-2.40) 
No. of reflections 16394 (987) 
Rwork (%) 20.4 (26.0) 
Rfree (%) 28.2 (35.1) 
Geometry deviations 
Bond lengths (Å) 0.016 
Bond angles (°) 1.937 
Mean B-values (Å2) / number of non-H atoms 
All refined atoms 43.5/2909 
Compound atoms 30.2/20 
PO4 ions 54.4/10 
Mg ions 20.4/3 
Water molecules 39.0/70 
Ramachandran plot (%) 
Most favored 93.9 
Additionally allowed 6.1 
Generously allowed 0 
Disallowed 0 
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Figure 5.1 Schematic illustration of pathways involved in zoledronate- analog activity in γδ 
T cells and in malaria parasites. Green = human cell; cyan = malaria parasite. HMG-CoA = 
hydroxymethylglutaryl coenzyme A; IPP = isopentenyl diphosphate; DMAPP = dimethylallyl 
diphosphate; FPP = farnseyl diphosphate; GAP = glyceraldehyl-3-phosphate; HMBPP = 4-
hydroxyl-3-methyl-but-2-enyl diphosphate; GGPP = geranylgeranyl diphosphate; TNF-α = 
tumor necrosis factor α. 
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Figure 5.2 Chain length dependence of enzyme and cell growth inhibition/activation and 
effects of the 1-OH group. (a) Structures of compounds investigated. (b) HsFPPS. (c) γδ T cell 
activation/ TNF-α release; (d) PvGGPPS inhibition; (e) Intra-erythrocytic P. falciparum cell 
growth inhibition.
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Figure 5.3 Structural results in stereo representation. (a) X-ray structure of HsFPPS/5 
complex (cyan, PDB ID code 4GA3) superimposed on PvGGPPS structure (purple, PDB ID 
code 3RBM). The Cα rmsd over 331 residues in 1.44 Å. (b) Comparison between the x-ray 
structures of 5 bound to HsFPPS, GPP (yellow) and FPP (green) bound to avian FPPS (PDB ID 
codes, 1UBX and 1UBW). The bisphosphonate 5 binds to the allylic (GPP) site. Chain elogation 
in FPP is blocked by F98, F99, corresponding to decreased HsFPPS inhibition by 
bisphosphonate inhibitors with N-alkyl chains longer than ∼C10. (c) Structures of HsPPPS/5 
(cyan) overlaid on 29 (BPH-703; pink) bound to PvGGPPS (PDB ID code 3RBM). The 
bisphosphonate, imidazolium and N-alkyl side-chain structures are quite similar. Optimum 
activity in PvGGPPS is at ∼C11, then steric repulsion ensures.
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6.2	   Introduction	  
Bisphosphonates (BPs) such as alendronate (Fosamax®), risedronate (Actonel®), 
ibandronate (Boniva®) and zoledronate (Zometa®) are important drugs used to treat osteoporosis, 
Paget’s disease and hypercalcemia due to malignancy [1]. In addition, they also have potent 
activity against some parasitic protozoa and tumor cells [2] and zoledronate has been found to 
switch tumor associated macrophages from an M2, tumor promoting to an M1, tumor killing 
phenotype [3]. The biologically active molecules having the general formula 
H2O3PC(OH)(R)PO3H2, possess a hydroxyl group that increases affinity of BPs for bone 
mineral, with R determining the potency of the bisphosphonates. Compared to etidronate (R = 
CH3), compounds containing a basic primary nitrogen atom, such as alendronate (R = 
(CH2)3NH2, noted Ale), were found to be 10-100 times more potent, while those with a nitrogen 
atom within a heterocyclic ring, such as zoledronate (R = CH2(C3H3N2), noted Zol) were up to 
10,000x more potent [4]. Zoledronate is at present the most potent commercially available 
bisphosphonate drug and such BPs are generally referred to as NBPs, nitrogen-containing BPs. 
The cationic N center can also be replaced by a cationic S, and a previous study of sulfonium 
BPs showed that this category of BPs can have high activities in killing tumor cells [5]. 
Bisphosphonates are also known to be good metal complexing agents, and many bisphosphonate 
complexes have been structurally characterized, varying from molecular complexes to three-
dimensional coordination frameworks [6]. Among these complexes, polyoxometalates (POMs) 
are of interest since POMs themselves have interesting medicinal properties, including 
antitumoral and antiretroviral activity [7, 8]. 
Here, and in previous work [9], we have explored the possibility that bisphosphonates 
might act as ligands, binding to polyoxoanions (polyoxometalates, noted POMs). POMs are 
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discrete anionic metal-oxygen clusters, which are often considered as soluble oxide fragments. 
They are built from the connection of {MOx} polyhedra, M being a d-block element in high 
oxidation state, usually VIV,V, MoV,VI or WVI [10, 11]. These inorganic species exhibit great 
diversity in size, nuclearity and shape that can be extended at will by the incorporation of 
suitable organic ligands [12]. POMs have been studied for some time for their biological activity 
[13, 14]. For example, [NH3Pri]6[Mo7O24], also known as PM-8, has exhibited growth 
suppression against Co-4 (human colon cancer), MX-1 (human breast cancer) and CAT (human 
lung cancer) cell lines [8], and its photo-reduced form suppressed the growth of several types of 
tumors, in vivo [15]. Covalent hybrid POMs have also been tested, for example [Mo8O26L2]4- (L 
= alanine, glycylglycine [16], proline [17]) octamolybdate derivatives, which inhibit the growth 
of HePG2 (hepatocellular carcinoma) and MCF-7 (human breast cancer) cells. Preliminary 
growth inhibition tests also showed that organoimido derivatives of the Lindqvist 
polyoxomolybdates [Mo6O17(NAr)2]2- (Ar = 3-NO2-C6H4, 2-CH3-4-NO2-C6H3, 2-CH3-5-NO2-
C6H3) have good inhibitory activities against K562 (human leucocythemia) cells, lower than the 
antitumor drug 5-fluorouracil but better than that of the parent [Mo6O19]2- POM at the same 
concentration [18]. The anti-cancer activity of polyoxotungstates including organotin [19, 20] 
and organotitanium [21] substituted heteropolyoxotungstates bearing {Sn(CH2)2CN}3+ or 
{CH2CH(CH3)C(O)OCH3}3+ and {CpTi}3+ groups have also been reported. However, there are 
very few reports of studies on POMs in which the covalently grafted organic ligand itself 
possesses a recognized biological activity [22]. 
          In recent work, we initiated studies on the anti-cancer activity of hybrid molybdenum-
bisphosphonate (alendronate) POMs [9] in which the activities of three MoV/Ale and one 
MoVI/Ale (noted as Mo12(Ale)4) molecules against three human tumor cell lines, MCF-7 (human 
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breast cancer), NCI-H460 (human large cell lung cancer), and SF-268 (human central nervous 
system cancer), were investigated, in vitro [9]. The MoV/Ale compounds had weak but 
measurable activity while Mo12(Ale)4 had IC50 values of ~10 µM, about four times the activity of 
the parent alendronate molecule on a per-alendronate basis. Furthermore the low activity of the 
ligand-free [Mo7O24]6- POM seemed to indicate a synergistic effect. Here, we report the results 
of an extensive study on the synthesis and characterization of a series of POM/BP complexes in 
order to determine which parameters govern the biological activity of these compounds. Both the 
nature of the POM and of the BP have been varied. However, as MoVI POMs have proven to be 
more active than MoV compounds [9], we have focused our study here on MoVI/BP 
polyoxomolybdates, combining POM cores with various BPs reported in the literature (Scheme 
6.1). Complexes with Mo nuclearities equal to 1 or 6 have been isolated. Additionally, a 
mononuclear WVI/Ale POM and four new hybrid polyoxovanadates with BP ligands have been 
synthesized and characterized, in order to help clarify the relative effects of metal-versus-ligand. 
Finally, the activity of ten such hybrid BP-POMs against three tumor cell lines is reported.  
 
Scheme 6.1 Formulas of the bisphosphonates used for this study. 
 
6.3	   Results	  and	  Discussion	  
Structures. We first describe briefly the structure of the dodecanuclear and hexanuclear 
compounds reported previously which set the stage for a structural analysis of the new 
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compounds, as well as a discussion of the cell-growth inhibition results. The Mo12(Ale)4 
compound is built from the connection of four trimeric units (Figure 6.1) via two oxygen atoms, 
one from a P-O bond and one from a Mo-O bond and there is a central sodium ion [23-25]. The 
Mo6(Ale)2 complex (Figure 6.2a, b) has also been recently reported and studied for its 
photochromic [23, 24] and catalytic properties [25]. This hexanuclear POM can be described as 
being essentially half of a dodecanuclear anion. Two trimeric units are linked via an Mo-O 
bound. Two conformers (hereafter labeled A and B, Figure 6.3) are observed [23]. In the A 
conformer, the six MoVI ions are approximately coplanar. The B conformer results from a 
rotation around the central oxygen atom, labeled Oi, of one of the trimeric unit (Figure 6.2 and 
2.3). In this conformer the three MoVI ions of a trimeric unit are located in a plane perpendicular 
to the three MoVI ions of the other trimeric unit. The molecular structures of Mo6L2 (L = Sul, 
Zol) are very similar to that observed for the other hexanuclear Mo6L2 species and has the A 
conformation, which is the conformation most frequently observed [23, 26]. In Mo6(Sul)2, the 
sulfur atoms of the sulfonium groups exhibit the expected pyramidal geometry (Figure 6.2a) and 
are located on one side or the other of the plane defined by the six MoVI ions. In Mo6(Zol)2, the 
plane of the imidazolium groups is almost perpendicular to the plane of the POM core (Figure 
6.2b). In the mononuclear M(Ale)2 (M = Mo, W) complexes, the central metal atom adopts a 
distorted octahedral coordination: two terminal oxo groups occupy cis vertices of the octahedron, 
four oxygen atoms of two different BP ligands occupy the four remaining vertices (Figure 6.4). 
A strong trans effect is observed resulting in a significant weakening of the Mo-O(P) bond trans 
to the Mo=O bond. These complexes possess neither a mirror plane nor a center of inversion and 
are thus chiral. The M(Ale)2 compounds crystallizes in a centrosymmetric space group and both 
enantiomers, the so-called Δ and Λ isomers, are present in the unit-cell. Furthermore, unlike what 
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is observed with the other MoVI/BP structures, the hydroxyl group of the alendronate ligand 
remains protonated and non-coordinated. 
The polyoxovanadates have nuclearities ranging from 3 to 6. The anion in V6(Ale)4 is a 
cage complex in which three parallel planes can be defined: one plane has four VV ions at the 
vertices of a pseudo rectangle, and the two planes located above and below contain one VIV ion 
and four P atoms of the BP ligands (Figure 6.5a). The VIV ions are in a distorted octahedral 
coordination, with one short V=O bond trans to a long V-OH2 bond. Four V-O(P) bonds with 
oxygen atoms from two different BP ligands complete the coordination sphere. The VV ions 
adopt a distorted trigonal bipyramid coordination with two cis terminal V=O bonds, two V-O(P) 
bonds with two phosphonate groups from two BP ligands, and a V-O(C) bond with a 
deprotonated hydroxyl group of one of the alendronates. The -(CH2)3NH3+ chains of the four 
organic ligands are almost parallel. The anion in V5(Ale)2 can be seen as a part of V6(Ale)4, in 
which one VIV ion connected to two BPs has been removed (Figure 6.5b). However, the penta-
nuclear core appears more symmetric in V5(Ale)2 than in V6(Ale)4 (Figure 6.6). In V5(Ale)2, the 
four VV ions are closer in one direction of the rectangle, due to the existence of two bridging V-
O(V) bonds which are not present in V6(Ale)4, and a pseudo-symmetry plane passing through the 
VIV ion intersects the VV pairs. In V5(Zol)2, the alendronate ligand has been replaced by 
zoledronate, inducing a change in the conformation of the complex. In V5(Ale)2 the plane 
containing the four VV ions and the plane containing the VIV ion and the four P of the BP ligands 
are parallel; this is not the case in the analogous complex V5(Zol)2, in which these two planes 
intersect, two VV ions being above the VIV plane and two VV ions below (Figure 6.5c). The anion 
in V5(Ale)2 can thus be designated a cis isomer and the anion in V5(Zol)2 a trans isomer. In 
V5(Zol)2, one potassium ion connects two neighbouring complexes (Figure 6.6). Three terminal 
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oxo ligands (O=VV, O=VIV, O=P) of one complex, the same three terminal oxo groups of a 
neighbouring complex together with a water molecule constitute its coordination sphere. The 
presence of this potassium ion may account for the trans configuration of the V5(Zol)2 complex. 
In the trinuclear anion in V3(Zol)3 three VIV ions form an isosceles triangle (Figure 6.5d). Their 
octahedral coordination sphere is highly distorted. V2 and V3 have similar environment, with 
one short (~1.6 Å) V=O bond pointing outside the molecule, trans to a very long V-O (~2.6 Å) 
bond with the central O atom and four V-O(P) bonds of two tetradentate BP ligands. V1 has a 
terminal V=O bond with the central O atom trans to a V-OH2 (~2.3 Å) bond with a water 
molecule, and four V-O(P) bonds with two zoledronate ligands. The hydroxyl group of the BP 
ligand remains protonated. The vanadium core possesses pseudo C2v symmetry, with one mirror 
plane containing the three V ions, a C2 axis passing through V1 and the central O atom and a 
mirror plane perpendicular to the V plane and containing the C2 axis. However, the whole 
molecule does not possess any symmetry element due to the position of the organic ligands. The 
trimeric VIV/BP core present in V3(Zol)3 has already been encountered in two complexes with 
etidronate (R = CH3) ligands: the first was isolated from an aqueous solution of 
[(C2H5)2NH2]2VO(H2L) (L = etidronate) [27], the second is the anionic unit of a lanthanide-
vanadium-organic framework [28]. However both of these structures were severely disordered, 
unlike the structure of V3(Zol)3. 
Finally, the purity of these eight new crystalline phases has been checked on the bulk 
materials by comparison of the experimental powder X-ray diffraction data with the data 
calculated from the single X-ray diffraction analysis (Figure 6.7).  
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Synthesis and characterization. The synthetic pathways are shown in Figure 6.8. As observed 
by Sergienko et al. [26], the oligomerization degree of the MoVI anionic complexes depends both 
on the Mo/L ratio and on the pH medium during synthesis, the counter-ion also having an 
important role in the ability to isolate complexes in the solid state. For a given Mo/L ratio, an 
increase of the pH results in the decrease in the extent of the oligomerization. Mo12(Ale)4 was 
synthesized in water at room temperature at pH 3, from the reaction of Na2MoO4 with the BP 
reactants, as previously described. The presence of sodium ions is crucial as is the acidic pH 
value. In less acidic media, POMs with lower nuclearities are obtained. In a NH4Oc/HOAc 
medium at pH 4.75, the hexanuclear Mo6L2 (L = Ale, Sul, Zol) POMs are isolated while at pH 
7.5, the mononuclear Mo(Ale)2 POM forms. Hydrothermal conditions were used in cases of 
products (or reactants) with low solubility, in order to increase product yield and crystallinity. 
Addition of cations such as K+, Rb+ or Cs+ was also sometimes necessary, presumably for similar 
reasons. The V6(Ale)4 and V3(Zol)3 polyoxovanadates were synthesized at room temperature 
from NaVO3. Full or partial reduction of the VV precursor is likely due to the presence of 
triethylamine. V6(Ale)4 and V3(Zol)3 were isolated under similar synthetic conditions, but have 
different molecular structures. V6(Ale)4 contains two VIV ions and four VV ions, while in 
V3(Zol)3, all the metal ions are VIV. The V5(Ale)2 (L = Ale, Zol) POMs were isolated under 
hydrothermal conditions from VOSO4. In this case, air oxidation of the VIV precursor led to the 
mixed valent polyoxovanadates which can be considered structurally to be part of the V6(Ale)4 
complexes.  
All the POMs are soluble in water, but the polyoxovanadates were far less soluble than 
the Mo derivatives. 31P NMR spectroscopy was used in order to determine whether structures 
characterized in the solid state were maintained in solution. The 31P NMR spectrum of the 
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hexanuclear Mo6(Sul)2 compound exhibits two singlets at 17.08 and 16.95 ppm with relative 
intensities 0.6:1.4 (Figure 6.9a). The same behavior is observed for Mo6(Zol)2 with two singlets 
at 16.92 and 16.61 ppm with relative intensities 1:1. Only one singlet was expected if the 
structure observed in the solid state (Figure 6.4b) was retained in solution, corresponding to four 
equivalent phosphorus nuclei. The presence of another singlet close to the expected one has 
already been observed in other Mo6L2 species and has been attributed to an equilibrium between 
the A and B conformers (Figure 6.3) following the dissolution of the POM. The attribution of 
each peak to one form or the other and a correlation between the different proportions of the A 
and B conformers and the nature of the BP cannot, however, be readily performed. The 31P NMR 
spectrum of the mononuclear Mo(Ale)2 complex exhibits four set of signals when dissolved in 
water at room temperature: one sharp singlet at 18.08 ppm, which accounts for 70% of the total 
intensity, a doublet of doublets representing 9% (at 20.16, 19.93, 18.84 and 18.61 ppm) two 
singlets at 21.72 and 22.09, and a doublet at 19.24 and 19.43 ppm  (Figure 6.9b). The effects of 
temperature on the evolution of this 31P NMR spectrum indicate that an increase in temperature 
induces a broadening of the singlet at 18.08 ppm, together with the progressive disappearance of 
the other signals. At 275 K, the doublet of doublet represents 29% of the total intensity. This 
behavior can be explained by the presence of five species in solution: the expected mononuclear 
anion, three intermediate species resulting from its hydrolysis, and free alendronate ligands. The 
two alendronate ligands of the anion in Mo(Ale)2 are related by a C2 axis but within each ligand, 
the P nuclei are not equivalent. The doublet of doublet can thus be attributed to this mononuclear 
species. The value of the coupling constant (J = 28.2 Hz) is in agreement with values observed 
for other Mo complexes [5]. The intensity of the singlet at 18.08 ppm increases upon addition of 
around three equivalents of free alendronate in the solution, as does that of the doublet of 
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doublets (Figure 6.10a), and no other signals are observed. The singlet at 18.08 ppm can thus be 
attributed to the free Ale. The similarities of the 31P NMR spectra of Mo(Ale)2 in physiological-
like conditions [29] (Figure 6.10b), of a solution of Mo(Ale)2  heated at 350 K and then cooled 
down to room temperature, and of the initial solution before being heated, show that i) Mo(Ale)2 
also hydrolyzes in physiological-like conditions and ii) surprisingly, the degradation is 
reversible. Finally, the 31P spectrum of a solution of W(Ale)2 in water at room temperature 
(Figure 6.10c) is close to that observed for Mo(Ale)2 and indicates that W(Ale)2 also hydrolyzes.  
 
Cell-growth inhibition. We tested a series of Mo, W and V-containing bisphosphonates against 
3 human tumor cell lines: NCI-H460, MCF-7 and SF-268. Results are shown in Table 6.1 for 
each cell line in addition to the average IC50 values over all three cell lines, together with the 
average IC50 per bisphosphonate ligand, for comparison with free BP results. As can be seen in 
Table 6.1, the most active compounds are Mo6(Zol)2, V6(Ale)4, V5(Ale)2, V5(Zol)2 and V3(Zol)3 
which have (mean) IC50 values of 5, 2, 1.2, 0.9 and 0.9 µM, respectively (Table 6.1). Clearly 
then, all V compounds are active, but with the Mo and W compounds, potent activity is only 
found with the zoledronate-containing species, suggesting that here, the bisphophonate plays a 
larger part in tumor cell killing than in the V-containing systems. However, there is also a clear 
effect of both the nature of the metal and of the structure of the POM. Indeed, for a given BP 
(here Ale), the W compound is less active than is the Mo analogue. Furthermore, the average 
activity per bisphosphonate ligand decreases in the following order: Mo(Ale)2 > Mo12(Ale)4 >> 
Mo6(Ale)2 ~ Ale. All the MoVI/Ale complexes are more active than alendronate, with a tenfold 
increase in potency for Mo(Ale)2, however, it remains to be determined if this effect is due to 
increased uptake into cells, more rapid dissociation within cells, or more subtle effects. 
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Nevertheless, considering that Mo6(Zol)2 is 30x more active than is Mo6(Ale)2, it can be 
anticipated that the activity of an hypothetical complex with the formulae Mo(Zol)2 would be of 
the order of 500 nM.  
	  
6.4	   Conclusions	  
We have synthesized eight new hybrid bisphosphonate POMs with MoVI, WVI, VIV,V cores and 
nuclearities from 1 to 6. Our results show that bisphosphonate molecules of the general formula 
H2O3PC(OH)(R)PO3H2 (R = (CH2)3NH2, CH2(C3H3N2), CH2S(CH3)2) can act as ligands in POM 
complexes with various compositions and geometries. The hydroxyl group of the BP ligand is 
found deprotonated in all the complexes, except in the trinuclear VIV POM and the mononuclear 
Mo and W compounds. The absence of the additional P-O(M) (M = Mo, W) bond between the 
deprotonated hydroxo group and the metallic ion may account for the greater instability of the 
mononuclear species in aqueous medium, as evidenced by 31P NMR spectroscopy. The most 
potent compounds in a tumor cell growth inhibition assay contained either vanadium or the most 
potent bisphosphonate, zoledronate, and had promising sub-micromolar IC50 values. In the 
future, synthetic efforts aimed at the preparation of mononuclear Mo complexes with 
zoledronate, as well as other potent bisphosphonate ligands, appear warranted, not least because 
the mevlonate pathway (in particular activity involving geranylgeranyl diphosphate) is now 
recognized as a therapeutic target for tumors having mutations in p53 [30] and that the main site 
of action of zoledronate is in protein geranylgeranylation [31]. 
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6.5	   Materials	  and	  Methods	  
Experimental procedures and characterization data. H2O3PC(C3H6NH2)(OH)PO3H2 (Ale) 
[32], H2O3PC(C3H8S)(OH)PO3H2 (Sul) [5], H2O3PC(C4H6N2)(OH)PO3H2 (Zol) [33], 
Na2Rb6[(Mo3O8)4(O3PC(C3H6NH3)(O)PO3)4]·26H2O (Mo12(Ale)4) [9], and 
Rb0.25(NH4)5.75[(Mo3O8)2O(O3PC(C3H6NH3)(O)PO3)2]·10H2O (Mo6(Ale)2) [23] were 
synthesized according to literature procedures.  
Rb0.75(NH4)5.25[(Mo3O8)2O(O3PC(CH2S(CH3)2)OPO3)2]·8H2O (Mo6(Sul)2): To a solution 
of (NH4)6Mo7O24·4H2O (0.660 g, 0.53 mmol) in 10 cm3 of water was added Sul (0.362 g, 1.25 
mmol). The solution was let stirring for 10 min. 2M hydrochloric acid was added dropwise to pH 
= 3. The solution was then stirred for 1 hour before addition of solid RbCl (0.500 g, 4.96 mmol). 
The solution was allowed to stir for another 1 hour. The white powder was filtered and dried 
with ethanol and diethyl ether (yield: 0.690 g). The product was then dissolved in 25 cm3 of 1M 
CH3COONH4/CH3COOH buffer and insoluble impurities removed by centrifugation and the 
solution left to evaporate at room temperature. Colourless crystals were collected after five days. 
Yield 0.490 g (47 % based on Mo).  
31P NMR (200 MHz, D2O): δ  17.08 (s, 0.6 P), 16.95 (s, 1.4 P). 1H NMR (200 MHz, 
D2O): δ 3.80 (t, 2H, CH2, 3JHP = 10.6 Hz), 2.91 (s, 4H, CH3) and 2.85 (s, 2H, CH3). Anal. calc. 
(found) for C8H53Mo6N5.25O39P4Rb0.75S2 (1674.7): C 5.74 (5.68), H 3.19 (2.85), N 4.40 (4.27), S 
3.83 (3.76), P 7.40 (7.34), Mo 34.37 (34.33), Rb 3.83 (3.37). IR (FTR): ν (cm-1) = 1625 (w), 
1419 (vs), 1276 (vw), 1138 (s), 1110 (w), 1086 (s), 1042 (s), 1003 (w), 980 (w), 909 (vs), 871 
(vs), 814 (m), 720 (s), 675 (s), 612 (sh), 577 (vw), 558 (w), 531 (w), 487 (w), 454 (vw). 
(NH4)6[(Mo3O8)2O(O3PC(C4H6N2)OPO3)2]·9H2O (Mo6(Zol)2): (NH4)6Mo7O24·4H2O 
(0.330 g, 0.265 mmol) and Zol (0.180 g, 0.625 mmol) were dissolved in 8 cm3 of 0.5 M 
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CH3COONH4/CH3COOH. The solution was sealed in a 23 cm3 Teflon-lined stainless steel 
reactor before heating to 130 °C over a period of 4 h, kept at this temperature for 20 h, then 
cooled to room temperature over a period of 36 h. The colourless crystals were collected by 
filtration. Yield 0.350 g (68 % based on Mo). 31P NMR (200 MHz, D2O): δ  16.92 (s, 1 P), 16.61 
(s, 1 P). 1H NMR (200 MHz, D2O): δ 8.83 and 8.76 (2 s, 1H, NCHN), 7.55 (s, 1H, NCHCHN), 
7.32 (s, 1H, NCHCHN), 4.56 (t, 2H, NCH2C, 3JHP = 9.5). Anal. calc. (found) for 
C10H54Mo6N10O40P4 (1654.1): C 7.26 (7.36), H 3.29 (3.17), N 8.47 (8.39), P 7.49 (7.43), Mo 
34.80 (34.52). IR (FTR): ν (cm-1) = 1623 (w), 1580 (w), 1544 (w), 1423 (vs), 1135 (sh), 1082 (s), 
1051 (s), 979 (m), 917 (s), 876 (vs), 819 (vw), 722 (m), 692 (s), 625 (m), 614 (m), 563 (m), 518 
(m), 480 (m). 
(NH4)5Br[(MoVIO2)(O3PC(C3H6NH3)(OH)PO3)2]·6H2O (Mo(Ale)2): To a solution of 
Na2MoO4·2H2O (0.121 g, 0.50 mmol) in 10 cm3 of 1M CH3COONH4/CH3COOH buffer was 
added Ale (0.249 g, 1.00 mmol). The solution was stirred for 10 min then 2M sodium hydroxide 
added dropwise to pH = 7.5. The solution was then stirred for a further 1 hour before addition of 
solid tetra-n-butylammonium bromide (0.300 g, 0.93 mmol). The solution was allowed to stir for 
another 1 hour and the white powder filtered off and the solution left to evaporate at room 
temperature. Colourless crystals were collected after five days. Yield 0.380 g (85 % based on 
Mo). 1H NMR (200 MHz, D2O): δ 2.91 (t, 2H, CH2NH3, 3J = 6.9 Hz), 1.85 (s, 4H, CCH2CH2). 
Anal. calc. (found) for C8H50BrMoN7O22P4 (896.3): C 10.72 (11.44), H 5.62 (5.57), N 10.93 
(11.26), Br 8.91 (7.88), Mo 10.70 (11.43), P 13.82 (14.51). IR (FTR): ν (cm-1) = 1457 (s), 1405 
(vs), 1145 (w), 1110 (s), 1040 (m), 1001 (sh), 966 (m), 948 (vw), 903 (m), 876 (s), 804 (w), 687 
(m), 602 (vw), 567 (w), 524 (vw), 478 (m), 447 (vw), 440 (w), 487 (w). 
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(NH4)4.5Cs0.5Cl[(WVIO2)(O3PC(C3H6NH3)(OH)PO3)2]·7H2O (W(Ale)2): Na2WO4·2H2O 
(0.164 g, 0.50 mmol), Ale (0.249 g, 1.00 mmol) and CsCl (0.200 g, 1.18 mmol) were dissolved 
in 5 cm3 of 1M CH3COONH4/CH3COOH buffer and 2M sodium hydroxide added dropwise to 
pH = 7.5. The solution was sealed in a 23 cm3 Teflon-lined stainless steel reactor before heating 
to 130 °C over a period of 4 h, kept at this temperature for 20 h, then cooled to room temperature 
over a period of 36 h. The white powder was filtered off and the solution left to evaporate at 
room temperature. Colourless crystals were collected after five days. Yield 0.210 g (41 % based 
on Mo). Anal. calc. (found) C8H52ClCs0.5N6.5O23P4W (1017.2): C 9.44 (10.01), H 5.15 (5.01), N 
8.95 (8.86), Cl 3.48 (3.47), Cs 6.53 (6.51), P 12.18 (12.34), W 18.07 (17.69). 1H NMR (200 
MHz, D2O): δ 2.90 (t, 2H, CH2NH3, 3J = 6.9 Hz), 1.89-1.76 (m, 4H, CCH2CH2). IR (FTR): ν 
(cm-1) = 1557 (m), 1402 (vs), 1156 (w), 1122 (s), 1042 (s), 1004 (s), 960 (m), 937 (vw), 902 (m), 
872 (s), 806 (w), 688 (m), 523 (sh), 478 (m), 408 (m), 393 (w), 361 (w). 
Na6Rb2[(V6O10(H2O)2(O3PC(C3H6NH3)OPO3)4]·20H2O (V6(Ale)4) : To a solution of 
NaVO3·H2O (0.067 g, 0.55 mmol) in 5 cm3 of water was added Ale (0.124 g, 0.50 mmol) and 
RbCl (0.040 g, 0.33 mmol). The solution was stirred for 1 h then triethylamine added dropwise 
to pH = 5. The solution was then stirred for a further 1 h at 80°C then left to evaporate at room 
temperature. Green crystals were collected after five days. Yield 0.050 g (25 % based on V). 
Anal. calc. (found) for C16H80N4Na6O60P8Rb2V6 (2151.1):  C 8.94 (9.77), H 3.75 (3.93), N 2.61 
(2.84), Na 6.41 (5.30), P 11.52 (12.31), Rb 7.94 (6.41), V 14.20 (13.80). IR (FTR): ν (cm-1) = 
1625 (s), 1503 (w), 1081 (w), 1038 (s), 1004 (vw), 975 (m), 903 (s), 667 (vw), 593 (w), 543 (w), 
582 (w), 353 (m). 
Na3[V3O3(H2O)(O3PC(C4H6N2)(OH)PO3)3]·12H2O (V3(Zol)3) : To a solution of 
NaVO3·H2O (0.067 g, 0.55 mmol) in 5 cm3 of water was added Zol (0.136 g, 0.50 mmol). The 
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solution was stirred for 1 h then triethylamine was added dropwise to pH = 5. The solution was 
stirred for a further1 h at 80°C and left to evaporate at room temperature. Pale blue platelets were 
collected after five days. Yield 0.190 g (79 % based on V). Anal. calc. (found) for 
C15H47Na3N6O37P6V3 (1311.2): C 13.74 (13.42), H 3.61 (3.68), N 6.41 (6.23), Na 5.26 (5.14), P 
14.17 (14.05), V 11.65 (11.35). IR (FTR): ν (cm-1) = 1636 (m), 1577 (m), 1547(w), 1445 (w), 
1404 (w), 1354 (w), 1314 (w), 1290 (w), 1099 (sh,s), 1080 (vs), 1053(sh, s), 996 (vs), 966 (s), 
928 (m), 896 (w), 834 (m), 751 (w), 717 (w), 689 (w), 603 (s), 571 (s), 492 (m), 479 (m), 450 
(m). 
(NH4)2Rb2[(V5O9(OH)2(H2O)(O3PC(C3H6NH3)OPO3)2]·8H2O (V5(Ale)2) : VOSO4·5H2O 
(0.190 g, 0.75 mmol), Ale (0.063 g, 0.25 mmol) and RbCl (0.150 g, 1.24 mmol) were dissolved 
in 8 cm3 of 0.5 M CH3COONH4/CH3COOH buffer. The solution was sealed in a 23 cm3 Teflon-
lined stainless steel reactor before heating to 130 °C over a period of 4 h, kept at this temperature 
for 20 h, then cooled to room temperature over a period of 36 h. A small quantity of powder was 
filtered off and the solution left to evaporate at room temperature. After three days, black crystals 
of a non identified ligand-free vanadate were removed by filtration then pale green crystals of 
V5(Ale)2 were collected by filtration after 2 more days. Yield 0.040 g (21 % based on V). Anal. 
calc. (found) for C8H46N4O34P4Rb2V5 (1292.0): C 7.44 (7.70), H 3.59 (3.34), N 4.33 (4.77), P 
9.59 (9.85), Rb 13.23 (11.26), V 19.71 (19.66). IR (FTR): ν (cm-1) = 1648 (s), 1401 (vs), 1173 
(m), 1142 (m), 1100 (m), 1059 (s), 1032 (w), 982 (w), 919 (vs), 700 (vw), 641 (s), 513 (vw). 
(NH4)2.5K1.5[(V5O9(OH)2(H2O)(O3PC(C4H6N2)OPO3)2]·8H2O (V5(Zol)2) : VOSO4·5H2O (0.570 
g, 2.25 mmol), Zol (0.205 g, 0.75 mmol) and KCl (0.450 g, 6.05 mmol) were dissolved in 24 cm3 
of 0.5 M CH3COONH4/CH3COOH buffer. The solution was sealed in a 125 cm3 Teflon-lined 
stainless steel reactor before heating to 130 °C over a period of 4 h, kept at this temperature for 
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20 h, then cooled to room temperature over a period of 36 h. A small quantity of powder was 
filtered off and the solution left to evaporate at room temperature. After three days, dark crystals 
of a non identified ligand-free vanadate were removed by filtration and pale green crystals of 
V5(Zol)2 were collected by filtration after 2 more days. Yield 0.030 g (6 % based on V). Anal. 
calc. (found) for C10H42N6.5K1.5O34P4V5 (1234.7): 9.72 (9.92), H 3.43 (3.31), N 7.37 (7.71), K 
4.75 (4.40), P 10.03 (9.93), V 20.63 (20.06). IR (FTR): ν (cm-1) = 1646 (s), 1418 (s), 1095 (sh), 
1052 (s), 1040 (s), 982 (m), 905 (s), 698 (w), 667 (vw), 631 (m), 603 (m), 505 (w). 
 
X-ray crystallography. Data collection was carried out by using a Siemens SMART three-circle 
diffractometer for Mo6(Sul)2, Mo6(Zol)2, and V3(Zol)3 and by using a Bruker Nonius X8 APEX 
2 diffractometer for Mo(Ale)2, W(Ale)2, V6(Ale)4, V5(Ale)2 and V5(Zol)2. Both were equipped 
with a CCD bi-dimensional detector using the monochromatized wavelength λ(Mo Kα) = 
0.71073 Å. Absorption correction was based on multiple and symmetry-equivalent reflections in 
the data set using the SADABS program [34] based on the method of Blessing [35]. The 
structures were solved by direct methods and refined by full-matrix least-squares using the 
SHELX-TL package [36]. In all structures there are small discrepancies between the formulae 
determined by elemental analysis and those deduced from the crystallographic atom list because 
of the difficulty in locating all disordered water molecules (and sometimes the cations), a 
common feature found in other polyoxometalate structural investigations [37-40]. The data set 
for V3(Zol)3.  which has the largest “voids”  and for which the sodium cations could not be 
located in the structure due to severe disorder, was corrected with the program SQUEEZE [41], a 
part of the PLATON package of crystallography software used to calculate the solvent or 
counter-ion disorder, and to remove its contribution to the overall intensity data. In the structures 
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of Mo6(Sul)2, Mo6(Zol)2, and V5(Ale)2, NH4+ and H2O could not be distinguished based on the 
observed electron densities; therefore, all the positions were labelled O and assigned the oxygen 
atomic diffusion factor. The program ADDSYM, a part of the PLATON package, detects a 
pseudo center of symmetry for the structure of V6(Ale)4. However, the mean |E2-1| value is equal 
to 0.774, very close to the value expected for a non-centrosymmetric structure (0.736). 
Furthermore, the refinement in the centrosymmetric Pnma space group is not satisfactory and 
leads to a high R1 value (0.25).  
Crystallographic data are given in Table 6.2. Powder diffraction data was obtained on a 
Bruker D5000 diffractometer using Cu radiation (1.54059 Å).  
 
NMR measurements. 31P NMR spectra were recorded in 5 mm tubes with 1H decoupling by 
using a Bruker AC-300 spectrometer operating at 121.5 MHz. The 31P NMR spectra shown in 
the supplementary information were recorded on a Bruker AC-200 spectrometer. 31P chemical 
shifts were referenced with respect to an external standard, 85% H3PO4. For all compounds ≈ 20 
mg of sample was dissolved in D2O (700 µL), except for Mo6(Zol)2, which was dissolved in 700 
µL of a mixture of D2O (50%) and NH4OAc/HOAc buffer (50%, 1M). The concentrations thus 
varied in the 1-30 mM range.  
 
Cell-growth inhibition assays. Human tumor cell lines MCF-7 (human breast cancer), NCI-
H460 (human large cell lung cancer), and SF-268 (human central nervous system cancer) were 
obtained from the National Cancer Institute and maintained at 100% humidity and 5% CO2 at 37 
°C. Cell lines were cultured in RPMI-1640 medium supplemented with 5 mM L-glutamine and 
10% fetal bovine serum (Gibco, Grand Island, NY) at 37°C in a 5% CO2 atmosphere with 100% 
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humidity. Compound stock solutions were typically prepared in water at a concentration of 0.04 
M. A broth microdilution method was used to determine the bisphosphonate growth inhibition 
IC50 values. Compounds were half log serial diluted using cell culture media into 96-well TC-
treated round bottom plates (Corning Inc., Corning, NY) typically from 1264 µM to 40 nM, but 
in some cases compounds were run over a larger concentration range to enable accurate IC50 
determinations. Cells were plated at a density of 5000 cells/well. Cells were then incubated under 
the same culture conditions for 4 days at which time an MTT ((3-(4,5-dimethylthi-azole-2-yl)-
2,5-diphenyltetrazolium bromide) cell proliferation assay (ATCC, Manassas, VA) was 
performed to obtain dose response curves. Briefly, cells were incubated for 2 h under culture 
conditions with the tetrazolium salt, lysed with detergent, incubated overnight, protected from 
light at room temperature. The absorbance at 600 nm was read the following day using a 
SpectraMax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA). The compound 
concentration for 50% growth inhibition values (IC50) were obtained by fitting absorbance data 
to a rectangular hyperbolic function: I = (Imax)(C)/IC50 + C where I is the percent inhibition, Imax 
= 100% inhibition and C is the concentration of the inhibitor, using GraphPad PRISM 3.0 
software for windows (Graphpad Software Inc., San Diego, CA). 
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6.6	   Tables	  and	  Figures	  
Table 6.1 Human tumour cell inhibition data. 
 
 
NCI-H460 
IC50 [µM] 
MCF-7 
IC50 [µM] 
SF-268 
IC50 [µM] 
Average 
IC50 [µM] 
Average/BP 
IC50 [µM] 
Mo12(Ale)4 9.2 ± 5.0 5.6 ± 0.4 5.0 ± 0.1 6.6 ± 3.1 26 ± 12 
Mo6(Ale)2 48 ± 38 56 ± 0.0 130 ± 16 78 ± 45 160 ± 89 
Mo6(Sul)2 46 ± 0.3 35 ± 17 100 ± 11 61 ±33 120 ±66 
Mo6(Zol)2 2.4 ± 0.2 2.2 ± 0.1 3.0 ± 1.0 2.5 ± 0.6 5.0 ± 1.2 
Mo(Ale)2 6.6 ± 2.2 9.4 ± 4.1 8.0 ± 0.8 8.0 ± 2.4 16 ± 4.9 
W(Ale)2 11 ± 3.0 12 ± 3.6 63 ± 3.6 29 ± 27 57 ± 53 
V6(Ale)4 0.4 ± 0.0 0.5 ± 0.3 0.5 ± 0.2 0.5 ± 0.2 2.0 ± 0.7 
V5(Ale)2 0.5 ± 0.1 0.5 ± 0.2 0.8 ± 0.2 0.6 ± 0.2 1.2 ± 0.4 
V5(Zol)2 0.5 ± 0.1 0.4 ± 0.2 0.4 ± 0.0 0.4 ± 0.1 0.9 ± 0.2 
V3(Zol)3 0.3 ± 0.2 0.3 ± 0.0 0.3 ± 0.2 0.3 ± 0.1 0.9 ± 0.3 
Ale 200 ± 43 130 ± 2.2 140 ± 13 150 ± 42 150 ± 42 
Zol 8.1 ± 1.7 7.7 ± 2.6 12.4 ± 1.4 9.4 ± 2.8 9.4 ± 2.8 
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Table 6.2 Crystallographic data.  
 
 Mo6(Sul)2 Mo6(Zol)2 Mo(Ale)2 W(Ale)2 
Empirical 
formula 
C8H53Mo6N5.25O39P4Rb0.
75S2 
C10H54Mo6N10O40
P4 
C8H20BrMoN7O19
P4 
C8H52ClCs0.5N6.5O23P
4W 
Formula 
weight, g 
1674.8 4963.8 818.0 1017.2 
Temperature
, K 
296 296 296 296 
Crystal 
system 
Triclinic Monoclinic Monoclinic Monoclinic 
Space group P-1 P21/c C2/c C2/c 
a / Å 9.3739(8) 17.642(3) 17.6396(13) 17.526(3) 
b / Å 15.2154(13) 16.841(2) 10.3314(8) 10.382(2) 
c / Å 17.8484(15) 17.587(3) 17.5641(14) 17.522(3) 
α / deg 104.176(2) 90 90 90 
β / deg 94.472(2) 108.198(3) 109.898(3) 109.726(6) 
γ / deg 96.615(2) 90 90 90 
V / Å3 2436.8(4) 4963.8(12) 3009.8(4) 3001.3(8) 
Ζ 2 4 4 4 
ρcalc / g cm-3 2.283 2.213 1.805 2.251 
µ / mm-1 2.567 1.715 2.060 4.852 
Data / 
Parameters 
13463 / 611 11398 / 628 4403 / 227 4384 / 245 
Rint 0.0751 0.1161 0.0351 0.0252 
GOF 1.035 0.962 1.071 1.153 
R (>2σ(I)) R1a = 0.0524 
wR2 b= 0.1481 
R1 = 0.0659 
wR2 = 0.1485 
R1 = 0.0297 
wR2 = 0.0833 
R1 = 0.0224 
wR2 = 0.0645 
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∑ −
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Table 6.2 (cont.). 
 
 V6(Ale)4 V5(Ale)2 V5(Zol)2 V3(Zol)3 
Empirical 
formula 
C16H80N4Na6O60P8Rb2
V6 
C8H46N4O34P4Rb2
V5 
C10H42K1.5N6.5O34P4
V5 
C15H47N6Na3O37P6
V3 
Formula 
weight, g 
2151.1 1292.0 1234.7 1311.2 
Temperatur
e, K 
200 296 296 296 
Crystal 
system 
Orthorhombic Orthorhombic Orthorhombic Monoclinic 
Space group P212121 Pna21 P21212 P21/c 
a / Å 15.6504(7) 27.437(10) 14.357(6) 15.235(4) 
b / Å 20.8102(10) 15.5104(4) 30.538(13) 12.776(3) 
c / Å 23.9756(13) 9.9631(3) 9.420(4) 25.589(6) 
α / deg 90 90 90 90 
β / deg 90 90 90 104.256(6) 
γ / deg 90 90 90 90 
V / Å3 7808.6(7) 4239.5(2) 4130(3) 4827(2) 
Ζ 4 4 4 4 
ρcalc / g cm-3 1.830 2.024 1.986 1.804 
µ / mm-1 2.235 3.599 1.510 0.910 
Data / 
Parameters 
22745 / 902 12111 / 525 7280 / 554 6328 / 554 
Rint 0.0514 0.030 0.1060 0.047 
GOF 1.071 1.089 0.989 1.019 
R (>2σ(I)) R1 = 0.0902 
wR2 = 0.2598 
R1 = 0.0538 
wR2 = 0.1650 
R1 = 0.0595 
wR2 = 0.1533 
R1 = 0.0988 
wR2 = 0.2751 
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Figure 6.1 Ball and stick representation of the dodecanuclear polyoxomolybdates (a) 
Mo12(Ale)4 and (c) Mo12(AleC2) ; (b) view of the trinuclear unit constituting the Mo12 and Mo6 
POMs;  blue spheres = Mo, dark green spheres = P, grey sphere = Na, black spheres = C, light 
green spheres = N, red spheres = O; the arrows indicate the positions of the oxygen atoms which 
are connected to adjacent trimeric units. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
(a)                       (b) 
 
 
 
 
 
 
   (c) 
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Figure 6.2 Ball and stick representation of the hexanuclear anions in (a) Mo6(Sul)2 and (b) 
Mo6(Zol)2; (c) polyhedral representation common to the Mo6L2 (L = Ale, Sul, Zol) POM 
frameworks, blue spheres = Mo, yellow spheres = S, dark green spheres = P, black spheres = C, 
light green spheres = N, red spheres = O, green tetrahedral = PO3C, orange polyhedra = MoO6. 
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Figure 6.3 A and B conformations observed for the Mo6L2 compounds. 
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Figure 6.4 (a) Ball and stick representation of the Δ and Λ enantiomers of the mononuclear 
anions M(Ale)2 (M = Mo, W); (b) polyhedral representation; blue spheres = M, dark green 
spheres = P, black spheres = C, light green spheres = N, red spheres = O, yellow octahedra = 
MO6 (M = Mo, W), green tetrahedra = PO3C. 
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Figure 6.5 Ball and stick representation of the anions in (a) V6(Ale)4, the grey diamonds 
highlight the three parallel planes (see text), (b) V5(Ale)2, (c) V5(Zol)2 and (d) V3(Zol)2; cyan 
sphere = VIV, purple spheres = VV, dark green spheres = P, black spheres = C, light green spheres 
= N, red spheres = O. 
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Figure 6.6 Comparison of the geometry of the pentanuclear core present in V6(Ale)4, 
V5(Ale)2 and V5(Zol)2; the R chain of the BP ligands has been omitted for clarity; view of the 
coordination of two V5(Zol)2 complexes around a potassium ion and side view of V3(Zol)3. 
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Figure 6.7 Comparison of the experimental X-ray powder patterns (in black) and of the 
powder pattern calculated from the structure solved from single-crystal X-ray diffraction data (in 
red). 
  
Mo6(Sul)2 Mo6(Zol)2
Mo(Ale)2 W(Ale)2
V3(Zol)3 V6(Ale)4
V5(Zol)2 V5(Ale)2
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Figure 6.8 Synthetic pathways for the dodecanuclear Mo12(Ale)4 POM, the hexanuclear 
Mo6(Ale)2, Mo6(Sul)2, and Mo6(Zol)2 POMs, the mononuclear Mo(Ale)2 and W(Ale)2 POMs 
and the V6(Ale)4, V5(Ale)2, V5(Zol)2 and V3(Zol)3 polyoxovanadates. 
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Figure 6.9 (a) 31P NMR spectra of Mo6(Sul)2, Mo6(Zol)2 dissolved in D2O at room 
temperature; (b) 31P NMR spectrum of Mo(Ale)2 dissolved in D2O from 275 K to 350 K and of 
the same solution cooled down to 295 K after being heated at 350 K. 
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Figure 6.10 31P NMR spectrum of a solution of Mo(Ale)2 dissolved (a) in water (c = 2.5 10-3 
M) to which has been added free alendronate ligand ([Ale] = 7.5 10-3 M) at the same pH (6.5); 
(b) in physiological-like conditions (D2O, KD2PO4 buffer 100 mM, pH = 7.4, 120 mM NaCl, 
37°C). (c) Comparison of the 31P NMR spectrum of a solution of Mo(Ale)2 and W(Ale)2 
dissolved in water at room temperature. 
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